



Cite this: *Chem. Soc. Rev.*, 2021,
50, 1968

Biocatalytic routes to anti-viral agents and their synthetic intermediates

Sjoerd Slagman * and Wolf-Dieter Fessner *

With recent outbreaks of COVID-19 and Ebola, health and healthcare have once more shown to be heavily burdened by the lack of generally effective anti-viral therapies. Initial scientific ventures towards finding anti-viral agents are soon to be followed by challenges regarding their mass production. Biocatalysis offers mild, highly selective, and environmentally benign synthetic strategies for the production of pharmaceuticals in a sustainable fashion. Here we summarise biocatalytic methods that have been applied to the production of FDA-approved anti-viral drugs and their intermediates. Exemplary are the enzymatic asymmetric synthesis of amino acid components, the fermentative production of structurally complex intermediates of anti-influenza drugs and the fully enzymatic, large-scale synthesis of a potential block-buster HIV drug. With many enzyme classes being uncharted with regards to the synthesis of anti-viral agents, there is still a large unopened toolbox waiting to be unlocked. Additionally, by discussing biocatalytic strategies towards potential anti-viral agents against SARS-CoV-2, we hope to contribute to the development of novel synthetic routes to aid in the mass production of a future treatment of COVID-19.

Received 30th July 2020

DOI: 10.1039/d0cs00763c

rsc.li/chem-soc-rev

1. Introduction

Viral infections have a tremendous impact on society; recent outbreaks of COVID-19 (SARS-CoV-2) and the Ebola virus have

resulted in nearly 1 million casualties worldwide, a number still rising rapidly at the time of writing (September 2020).^{1,2} With currently over 30 million confirmed COVID-19 cases and numerous hospitalised, the capabilities of the healthcare sector are being stretched beyond limits.^{3,4} Let alone the burden on those that have no adequate access to medical professionals.^{5,6} Apart from the impact on our physical well-being, COVID-19-related

Institut für Organische Chemie und Biochemie, Technische Universität Darmstadt, Germany. E-mail: sjoerds slagman@gmail.com, fessner@tu-darmstadt.de



Sjoerd Slagman

and Dr M. Franssen. Prior, he finished his undergraduate education during which he was trained as synthetic organic chemist (University of Amsterdam, NL).

Sjoerd Slagman's main interest is biocatalytic method development, both in solution and at the solid/liquid interface. He currently holds a position as Post-Doc in the lab of prof. W.-D. Fessner at TU Darmstadt (DE) in which he focusses on the discovery and application of novel reductive aminases. He obtained his PhD from Wageningen University & Research (NL) where he studied laccase as surface modification tool in the lab of prof. H. Zuilhof



Wolf-Dieter Fessner

Professor of (Bio)Organic Chemistry at Technical University Darmstadt since 1998. His current research interest focuses on the discovery, engineering and application of enzymes from various classes for organic synthesis, with a special focus on asymmetric carbonylation, chiral aminoalcohol and oligosaccharide synthesis.

Wolf-Dieter Fessner studied chemistry and received his PhD in 1986 at Freiburg University followed by postdocs at Harvard University with George M. Whitesides and at University of Southern California with George A. Olah. Returning to Freiburg, he completed his Habilitation studying the potential of aldolases for diastereoselective organic synthesis. Following a position as Associate Professor at RWTH Aachen, he has been



lockdowns and quarantine-measures take their toll with regards to mental fitness and welfare.⁷

Viral outbreaks are not restricted to the present as numerous smallpox and cholera epidemics, the Spanish flu pandemic and more recently the onset of AIDS/HIV have shaped human life throughout history.^{8,9} With an estimated reservoir of 1.67 million unknown viruses in mammals and birds alone, viral infections are likely to be of continuous concern in the future too.^{10,11} In accordance to being struck by numerous pandemics, respective countermeasures also go way back. The word 'quarantine', for example, originates from the Venetian '*quarantena*', which designated the 40 days required for ships to be in isolation prior to allowing its passengers to go ashore during the plague epidemic.¹² The history of anti-viral drugs, however, spans only about 60 years. In 1963 the first anti-viral drug idoxuridine was FDA-approved for the treatment of herpes. A better understanding of viruses, and especially the emergence of retroviruses such as HIV, spurred the development of the field in the 80's. Up to date, approximately 100 anti-viral drugs have been approved by the FDA.

So far, no anti-viral drug has been proven to be effective for treating patients infected with COVID-19. With the proverbial clock ticking, research towards novel anti-viral agents and repurposing of known pharmaceuticals has sky-rocketed.^{13,14} A similarly big challenge awaits when a treatment is found, namely the large-scale production of the pharmaceutical agent. For this matter, access to a large synthetic toolbox, full of efficient and robust stereoselective technologies, is essential.¹⁵ These synthetic tools have to meet increasingly higher demands due to a rise in complexity of marketed drugs.^{16,17} While many of the initial anti-viral drugs were nucleoside analogues based on (deoxy)sugar building blocks from the chiral pool or simply non-chiral, novel anti-viral drugs are often more complex, multi-cyclic or macrocyclic, and possess multiple chiral centres that are difficult to install.^{18–20} To access such chiral centres, organic chemists commonly revert to transition metal catalysis which is, however, often burdened with highly sensitive chemical species, accumulation of toxic waste and non-optimal stereoselectivity. Synthesising molecules through fermentation or by employing (purified) enzymes on the other hand, usually proceeds with high (stereo)selectivity and allows for benign reaction conditions to be employed. The use of water as solvent, mild reaction conditions with regards to temperature and pH, and generation of mostly biodegradable waste make biotransformations particularly attractive.^{21–23} As such, biocatalysis thus not only offers an environmentally benign alternative to chemical synthesis, but also often proves to be the most economically viable choice.

In line with an increasing awareness of its potential, biocatalytic production of pharmaceuticals has become increasingly popular over the last decades.^{24–33} Additionally, in times of crisis and scarcity (of medicine) one requires tools to rapidly access the chemicals in need, a recent 90 day pressure test revealed biocatalysis to be excellently suited for achieving this.³⁴

To aid in the continuous development of biocatalytic tools for anti-viral agent synthesis and to hopefully also contribute to the rapid production of a treatment for COVID-19, we hereby present a comprehensive compilation of research on the

biocatalytic synthesis of anti-viral agents. After a brief introduction to the pharmacological targets of anti-viral drugs, the full breath of biocatalytic methods applied for accessing those drugs will be covered extensively. This includes an evaluation of the pertinent patent literature as well as industrial microbial production of starting materials. Both small scale academic ventures and industrial processes will be thoroughly discussed. This review largely covers FDA-approved drugs as to ensure that the highlighted biocatalytic pathways result in the effective production of active pharmaceutical agents. All drugs will be jointly discussed according to their structural similarity, which to a large degree is in agreement with a similarity in the addressed pharmacological target. Where possible, retrosynthetic analysis is applied to be able to pick-and-mix the mentioned biocatalytic syntheses of an intermediate with (chemical) routes to other intermediates of the drug of interest. The analysis of published literature on the topic is appended by an overview of biocatalytic strategies amenable towards the synthesis of promising agents against COVID-19. We will finalise with an outlook on the potential of novel biocatalytic methods that have not, or only scarcely, been employed to the synthesis of anti-viral agents. For the use of biocatalysis as drug discovery tool, the reader is referred to other outstanding works as this is considered to be outside the scope of this review.^{30,31}

2. Mechanism of action of anti-viral agents

A virus is an infectious particle that can only replicate inside the cells of a host organism. After infection, the host cell is forced to rapidly produce numerous copies of the virus to be released from the exhausted cell for subsequent infection of other cells. Anti-viral agents are designed to interrupt, or at least disturb, the viral life cycle. Several approaches to tackling viral infections have been adapted throughout the short history of anti-viral drug development. Most drugs have been targeted at the replication machinery of the viral genome. Exemplary are drugs that are incorporated in the viral DNA upon phosphorylation *in vivo*, preventing further DNA replication by DNA polymerase (Fig. 1A).¹⁹ Several (acyclic) nucleoside analogues such as brivudine, act in this fashion. Other (acyclic) nucleoside analogues, like didanosine and lamivudine, are phosphorylated *in vivo* to subsequently compete with natural deoxynucleotides for incorporation into the (viral) DNA. Chain elongation through reverse transcription can hereby be prevented. These drugs are referred to as nucleoside reverse transcriptase inhibitors (NRTIs, Fig. 1B). The hepatitis C virus (HCV) non-structural protein NS5B acts as RNA polymerase that can be inhibited by incorporation of the triphosphorylated form of a pro-drug such as sofosbuvir to terminate RNA chain elongation (Fig. 1C). Similarly, ribavirin inhibits RNA polymerisation of influenza viruses. NS5A, although not shown to be inherently enzymatically active, among others, modulates NS5B activity and is inhibited by drugs such as ledipasvir. Peptidomimetic protease inhibitors inhibit proteolytic cleavage of proteins that are essential to viral reproduction






Fig. 1 The viral life cycle upon host cell infestation including depiction of drug interaction sites: polymerase inhibitors (A), (nucleoside) reverse transcriptase inhibitors ((N)RTIs, B), RNA polymerase inhibitors including NS5A and NS5B inhibitors (C), protease inhibitors (D), integrase inhibitors (E), entry inhibitors (F) and neuraminidase inhibitors (G). ER: endoplasmic reticulum and HIV: human immunodeficiency virus. Adapted from De Clercq and Li (reproduced with permission).¹⁹


(Fig. 1D). HIV-1 protease inhibitors, for example, prevent cleavage of the precursor protein *gag* p55.³⁵ Integrase inhibitors prevent insertion of viral DNA into chromosomal DNA of the host cell (Fig. 1E). Entry inhibitors such as maraviroc block the virus from entering the host cell (Fig. 1F). The anti-influenza agents, oseltamivir, peramivir, zanamivir and laninamivir inhibit viral neuraminidase to prevent budding (release) of the virus from the host cell (Fig. 1G). Drugs interfering with viral uncoating or viral maturation have to this date not been FDA-approved or produced biocatalytically.

Anti-viral drug therapies are designed to reduce the virus replication rate and thus the total virus load in order to ameliorate symptoms caused by infection. The drug itself cannot destroy the virus to cure the disease, which requires involvement of the humoral immune system.³⁶ While there is an urgent need for new effective anti-viral drugs against COVID-19, the SARS-CoV-2 virus is likely to persist as a constant threat to mankind, even once vaccination will become possible.

3. FDA-approved anti-viral agents

3.1 Nucleoside analogues


3.1.1 2'-Deoxynucleosides. Most of the earliest anti-viral agents that have been approved by the FDA were nucleoside



Scheme 1 Schematic depiction of dual (A) or single (B) enzyme-catalysed transglycosylation towards the synthesis of nucleoside analogues. Enzymes have been coloured according to their enzyme commission number, e.g. transferases are represented by purple colouration. Shading is varied for subclasses; for example, phosphotransferases (EC 2.7) are shaded darker than transketolases (EC 2.2).

analogues. Many of the biocatalytic strategies for obtaining such nucleosides emerged already around 50 years ago. These include the use of 2'-deoxyribosyltransferases or the combined use of two phosphorylases, which in both cases results in glycosyltransfer (Scheme 1).^{37,38} The use of such enzymes for the synthesis of pharmaceutically relevant nucleosides is well established and has been elaborately reviewed.^{39–42} We will thus only address some (novel) enzymes and recent microbial technologies for obtaining anti-viral nucleosides.

Pivotal in the development of anti-viral drugs was the approval of idoxuridine, an iodinated derivative of 2'-deoxyuridine (**1**), in 1963.¹⁹ Idoxuridine is used for treating retinal herpes simplex virus (HSV) infections through its incorporation into viral DNA. Its structural analogues 2'-trifluorothymidine (trifluridine) and brivudine (Scheme 2) were approved for treating HSV infections in 1980 and 2000, respectively. While idoxuridine was initially prepared through iodination of **1**,⁴³ it can nowadays be obtained efficiently by biocatalytic means. By depriving either pyrimidine nucleoside phosphorylase (PyNP) or thymidine phosphorylase (TP) from an additional phosphate source, only transient phosphorylation of the nucleoside sugar unit is possible, allowing for transglycosylation with a suitable nucleobase.⁴⁴ By doing so, **1** could be converted to idoxuridine, trifluridine and brivudine using either of the immobilised enzymes. Immobilisation on a macro-sized matrix ensures facile isolation of the catalyst which enables its straightforward recycling. Alternatively, trifluridine could be obtained through the use of a 2'-deoxyribosyltransferase.⁴⁵




Scheme 2 Synthesis of anti-viral 2'-deoxynucleosides with thymidine phosphorylase (TP) or pyrimidine nucleoside phosphorylase (PyNP). For brevity and clarity, equilibrium arrows and cleaved/replaced components will usually only be displayed in reaction schemes when of importance for the mechanistic understanding.




3.1.2 Other simple furanose nucleosides. Vidarabine (9- β -D-arabinofuranosyladenine), was the second anti-viral agent to be approved for the treatment of herpes.⁴⁶ Like its 2'-deoxy-nucleoside counterparts, vidarabine has proven to be easily accessible through biocatalytic transglycosylation. Early examples of its biocatalytic synthesis include the use of various bacterial strains for the conversion of 9- β -D-arabinofuranosyluridine (**7**) to vidarabine (Scheme 3).⁴⁷ More recently, Ubiali and co-workers made use of several immobilised phosphorylases to synthesise this drug.^{48,49} These immobilised enzymes could also be applied for the synthesis of vidarabine in continuous flow on gram scale.⁵⁰

Fernández-Lucas and co-workers instead utilised immobilised 2'-deoxyribosyltransferases for the synthesis of vidarabine.⁵¹ This work was recently extended through the use of a highly stable and remarkably versatile purine nucleoside 2'-deoxyribosyltransferase (PDT) from *Trypanosoma brucei* for the synthesis of this drug.⁵² Mutagenesis through random or site-directed sequence variation allows for small modifications of an enzyme, resulting in alterations in its properties. Properties such as activity, selectivity and/or thermostability can hereby be tuned. In the case of this PDT enzyme, the valine in position 11 was replaced by alanine or serine (V11A or V11S), resulting in variants that showed an almost threefold increase in catalytic activity.

The second wave of FDA-approved anti-viral agents largely consisted of nucleoside analogues active against the human immunodeficiency virus (HIV). Didanosine (2',3'-dideoxyinosine), for example, acts on viral reverse transcriptase and competes with dATP to inhibit DNA synthesis.⁵³ The versatility of the PDT from *Trypanosoma brucei* was further highlighted by the fact that it could also convert 2',3'-dideoxyadenine to didanosine.⁵² Alternatively, this anti-viral nucleoside could be obtained by means of phosphorylase catalysis or the use of whole cells expressing such enzymes.^{48,54,55} Highly interesting with regards to didanosine synthesis is the full bioretrosynthetic pathway construction published by Birmingham and co-workers (Scheme 4).⁵⁶ Drawing inspiration from sugar and nucleoside metabolism, the group engineered three enzymes involved in converting 2',3'-dideoxyribose (**10**) to didanosine, namely ribokinase (RK), 1,5-phosphopentomutase (PPM) and purine nucleoside phosphorylase (PNP). Inhibition by the co-factor-related by-product ADP, however, limited the efficiency of the overall cascade. Inhibition could be suppressed by allowing for ATP recycling through addition of adenylate kinase (AK) and pyruvate kinase (PK, Scheme 4A). An unexpected bypass was found upon engineering RK, eliminating the need for PPM (Scheme 4B). Use of the shortened cascade resulted in a fiftyfold increase in didanosine production (milligram scale).



Scheme 3 Biocatalytic synthesis of vidarabine.




Scheme 4 Multi-enzymatic bioretrosynthetic pathway construction towards the synthesis of didanosine. Two routes have been engineered, either including 1,5-phosphopentomutase (PPM, A) or bypassing this enzyme (B). Arrows between ATP, ADP and AMP show likely routes of degradation.⁵⁶ RK: ribokinase, PNP: purine nucleoside phosphorylase, AK: adenylate kinase and PK: pyruvate kinase.


Two other HIV drugs, zidovudine and stavudine, were synthesised from the common nucleoside intermediate 5-methyluridine (**17**).^{57,58} Like the previously mentioned nucleoside analogues, **17** has been obtained through the use of isolated phosphorylases or whole cells overexpressing such enzymes (Scheme 5).^{59–62}

Arguably, hydrolases are the most commonly applied enzymes in the industrial synthesis of small-molecules.⁶³ This class comprises enzymes capable of cleaving bonds through attack of a water molecule. Dependent on the enzyme and the reaction conditions, the reverse reaction is also feasible. In this way, ester, organophosphate or amide bonds can either be broken or made. Many of these hydrolases, such as lipases for example, are highly regio-, chemo- and stereoselective. The latter allows for kinetic resolution of a racemic mixture resulting in the production of a single stereoisomer. As this feature comes with a very broad substrate scope, application of hydrolase enzymes will be thoroughly discussed throughout this work.

Regioselective de-acetylation with *Candida rugosa* lipase (CRL) allowed for the synthesis of 3-hydroxy-5-acetyl-thymidine (**21**) from the diacetate **20** in 90% yield (<1 g, Scheme 6).⁶⁴




Scheme 5 Biocatalytic synthesis of the nucleoside intermediate 5-methyluridine (**17**) as common intermediate towards the synthesis of stavudine and zidovudine.



Scheme 6 Regioselective de-acetylation of an intermediate (**20**) of zidovudine (**19**) with *Candida rugosa* lipase (CRL).⁶⁴





Scheme 7 Precipitation-driven purine nucleoside phosphorylase (PNP)-catalysed synthesis of ribavirin.⁷⁵

This intermediate could be chemically converted to zidovudine *via* a Mitsunobu double inversion protocol followed by deprotection.


Ribavirin is a nucleoside analogue composed of a ribose sugar and 1,2,4-triazolecarboxamide (23) as alternative nucleobase (Scheme 7). It is FDA-approved for a number of viral infections including those caused by the hepatitis C virus and the respiratory syncytial virus (RSV).⁶⁵ Its biocatalytic synthesis has been pursued extensively, allowing for a large toolbox of enzymes capable of converting a wide variety of nucleosides to ribavirin through transglycosylation.^{66–72} Recent examples include the use of immobilised bacteria for the synthesis of this drug.^{73,74}

An important feature of most enzymatic reactions is that they are reversible, which often limits formation of the desired product. Strategies for pushing the reaction equilibrium to the product side are highly important and will thus be discussed extensively using pertinent examples.

Ubiali and co-workers applied a two-pronged equilibrium shifting strategy towards the synthesis of ribavirin by using 7-methylguanosine iodide (22) as starting material (Scheme 7).⁷⁵ PNP from *Aeromonas hydrophila* did catalyse the transfer of 23 to 22, but not the reverse reaction as the formed nucleobase, 7-methylguanine (25), was not accepted by the enzyme. Due to its poor solubility, 7-methylguanine precipitated, further limiting the backwards reaction. This allowed for good (67%) conversion to the product ribavirin. Taribavirin, a pro-drug of ribavirin currently undergoing phase III clinical trials,⁷⁶ was likewise prepared by biocatalytic glycosyltransfer between inosine and 3-cyano-1,2,4-triazole using *Brevibacterium acetyllicum* ATCC 39311 followed by aminolysis at 20 g scale.⁷⁷

3.1.3 Complex furanose nucleosides. With time, increasingly complex anti-viral nucleosides have been developed and approved. The presence of additional substituents on the furanose core limits the ease by which such nucleosides can be synthesised through biocatalytic glycosyltransfer reactions. Sofosbuvir, for example, is a C6-phosphorylated furanose bearing a synthetically challenging 3'-quaternary carbon atom carrying a methyl and fluorine substituent. Sofosbuvir is a pro-drug, which, in its active nucleoside triphosphate form, acts on the non-structural protein NS5B and is used in combination with other drugs for treating hepatitis C.⁷⁸ The drug relies on the so-called Pro-Tide technology in which a masked phosphorylated nucleoside is supplied, rather than its parent nucleoside, allowing for rapid *in vivo* conversion to the active triphosphate form.⁷⁹

En route to sofosbuvir's nucleoside moiety, Cleary and co-workers employed highly versatile *Candida antarctica* lipase




Scheme 8 *Candida antarctica* lipase B (CAL-B)-catalysed resolution of the sofosbuvir aldol intermediate **28**.⁸⁰ LDA: lithium diisopropylamide and DMAP: *N,N*-dimethyl-4-aminopyridine.

B (CAL-B) to resolve a mixture of aldol products. By doing so, enantiomerically pure intermediate **28**⁸⁰ was obtained in the desired configuration by starting from 33 g of aldol product (Scheme 8).⁸¹ This intermediate was initially synthesised in enantiomerically enriched form through lithium diisopropylamide (LDA)-catalysed aldol addition of ethyl 2-fluoropropanoate (27) to (*R*)-glyceraldehyde acetonide (26). The latter can be accessed through oxidation of (*S*)-glycerol acetonide (32), which in turn, can be obtained by resolution of glycerol acetonide esters (31) using various free esterases or whole cells overexpressing such enzymes (Scheme 9).^{82–85}

Swiss-based HC-Pharma used CAL-B for a mild regioselective deacetylation of the C6-hydroxy group of the bis-acetylated nucleoside precursor of sofosbuvir. With the C4-acetate left untouched, this mono-acetate intermediate could be coupled to the phosphoramidate without competing reactivity.⁸⁶


The phosphoramidate moiety of sofosbuvir is chiral and only the (*S*)-configured enantiomer of the phosphoramidate drug is FDA-approved. Raushel and co-workers used an engineered *Pseudomonas diminuta* phosphotriesterase⁸⁷ for the kinetic resolution of **34** (Scheme 10). A G60A mutation allowed for almost 200-fold selectivity towards hydrolysis of (*R*)-**34**.⁸⁸ Coupling of (*S*)-**34** and the sugar derivative through nucleophilic substitution at the phosphorus centre led to the desired stereoinversion.⁸⁹

An illustrative example of the value of industrial biocatalytic anti-viral production is the recently published synthesis of islatravir by Merck (Scheme 11).⁹⁰ Islatravir is a reverse transcriptase translocation inhibitor currently in phase III clinical trials for the treatment of HIV. The team developed a telescoped two-step,




Scheme 9 Esterase-catalysed resolution of glycerol acetonide esters.





Scheme 10 Resolution of a Pro-Tide phosphoramidate intermediate of sofosbuvir with *Pseudomonas diminuta* phosphotriesterase (PTE).⁸⁸



Scheme 11 Fully enzymatic synthesis of islatravir as developed by Merck.⁹⁰ GOase: galactose oxidase, HRP: horseradish peroxidase, PanK: pantothenate kinase, AcK: acetate kinase, DERA: deoxyribose 5-phosphate aldolase, PPM: 1,5-phosphopentomutase, PNP: purine nucleoside phosphorylase and SP: sucrose phosphorylase.

five-enzyme approach for the synthesis **38** from 2-ethynylpropane-1,2,3-triol (**35**), which is followed by a one-pot cascade containing four enzymes to achieve the synthesis of islatravir from **38**.

Enzymes offer a clear advantage over 'traditional' catalysts here as they all operate under similar conditions (solvent, pH, and temperature) and show distinct non-competitive reactivities which allows their use in a one-pot cascade. The first step of the reaction sequence posed the biggest challenge as the selected galactose oxidase (GOase) from *Fusarium graminearum* (engineered F2 variant) had to undergo complete reversal of stereoselectivity in order to oxidise **35** to the (*R*)-enantiomer of **36**. This feat was eventually achieved through 12 rounds of evolution and a staggering 34 amino acid mutations, concomitantly providing an 11-fold increase in enzyme activity. Directed evolution of ATP-dependent pantothenate kinase (PanK) subsequently allowed for the phosphorylation of **36**. Employment of an acetate kinase (AcK) ensured regeneration of the co-factor ATP.

The subsequent four-enzyme cascade started with deoxyribose 5-phosphate aldolase (DERA)-catalysed formation of the aldol product **40** from **38** and acetaldehyde (**39**). Two rounds of directed evolution were sufficient for increasing the tolerance of DERA from *Shewanella halifaxensis* to 400 mM acetaldehyde. Aldol product **40** was converted to islatravir through the use of *E. coli* PPM and PNP. Directed evolution of these latter two enzymes resulted in a 70- and 350-fold increase in activity towards **40** and the fluorinated nucleobase **42**, respectively.


The equilibrium of the four-enzyme cascade was pushed to the product side by implementation of sucrose phosphorylase (SP) from *Alloscardovia omnicolens*, which consumed phosphate through the formation of glucose 1-phosphate (**47**).

Employment of this series of heavily engineered enzymes in just a two-staged process led to the isolation of islatravir in a high overall yield of 51%. This approach eliminates purification steps, recycles expensive co-factors, and couples favourable and unfavourable reactions. Stereochemical purity was amplified at every enzymatic step along the non-natural, nine-enzyme reaction sequence, and the final synthesis was both atom economical and cost effective.⁹¹

3.1.4 Non-furanose nucleosides. Like many of the drugs mentioned previously, non-furanose nucleoside analogues are acting as anti-metabolites. Some inhibit reverse transcriptase in the treatment of HIV, whereas others are approved against the hepatitis B virus (HBV). With the anti-viral agents, lamivudine and emtricitabine (Scheme 12A),⁹² the furanose core is replaced by a 1,3-oxathiolane ring. Because such nucleoside analogues are commonly no substrates for enzymes performing glycosyl-transfer reactions, different synthetic strategies are required for their preparation.


In an early approach towards lamivudine, Rayner and co-workers performed lipase-catalysed resolution (*Pseudomonas fluorescens*) on the acylated O,S-acetal **50**, allowing for spontaneous cyclisation upon acid-mediated deprotection (Scheme 12B).⁹³ Because the heterocyclic product **52** was synthesised as a mixture of diastereomers, their separation, upon coupling to the nucleobase, resulted in a low yield of diastereomerically pure lamivudine. In an alternative route, 5'-nucleotidase from snake venom was used to resolve lamivudine-5'-phosphate, requiring additional (enzymatic) dephosphorylation.⁹⁴ Final stage kinetic resolution of a racemic mixture of lamivudine using cytidine deaminase eliminated the need for its 5'-phosphate analogue.⁹⁵ The structurally related anti-viral agent, emtricitabine could be obtained in enantiopure form through pig liver esterase-catalysed resolution of its 5'-butanoate ester as shown by Schinazi and co-workers.⁹⁶

Various other resolution approaches to the enantiomerically pure protected 1,3-oxathiolane core have been reported since,



Scheme 12 Lamivudine and emtricitabine (A). Lipase-catalysed (*Pseudomonas fluorescens*; PFL) resolution of an acyclic lamivudine/emtricitabine intermediate (B).⁹³ Dynamic kinetic resolution to get to the protected lamivudine/emtricitabine core (C).⁹⁹ Base-catalysed interconversion of the acyclic thioether enantiomers as depicted above serves as a tentative mechanistic proposal by the authors of this work. STS: surfactant-treated subtilisin Carlsberg.






Scheme 13 Lactamase-catalysed resolution of Vince-lactam to obtain the corresponding (1*S*,4*R*)- γ -amino acid. This amino acid served as an intermediate towards abacavir and peramivir (*vide infra*).


however, all intrinsically restricted to 50% yield.^{97,98} These limitations could be lifted by employing the principle of dynamic kinetic resolution (DKR). DKR relies on *in situ* racemisation of the starting material and selective (enzymatic) conversion of one of the isomers to the desired product. Ramström and co-workers employed dynamic interconversion of a hemi-thioacetal (**53**) using triethylamine and subsequent stereoselective ring-closing using surfactant-treated subtilisin Carlsberg (STS, a protease from *Bacillus licheniformis*) to afford the protected 1,3-oxathiolane **54** in 89% yield (Scheme 12C).⁹⁹ Chemical Vorbrüggen coupling to the nucleobase and subsequent deprotection furnished lamivudine. By coupling STS-catalysed ring-closing to CAL-B-catalysed resolution, enantiopurity of the protected 1,3-oxathiolane intermediate could be further enhanced.¹⁰⁰

Abacavir is an anti-viral nucleoside analogue in which a cyclopentene unit constitutes the furanose mimic (Scheme 13).¹⁰¹ The drug is commonly being prepared from Vince-lactam (**55**) which acts as a versatile building block for a variety of pharmaceuticals.¹⁰² Stereoselective ring-opening of the racemic Vince-lactam can be achieved using either a (+)-lactamase followed by chemical hydrolysis of the remaining material or a (–)-lactamase leading directly to the desired (1*S*,4*R*)- γ -amino acid (1*S*,4*R*)-**56**. Over the past 30 years, numerous lactamases have been isolated and applied in the ring-opening of Vince-lactam.^{103–118} Resolution could, alternatively, be achieved using a variety of other enzymes including CAL-B and a non-haem chloroperoxidase from *Streptomyces viridochromogenes*.^{119–122} CAL-B resolution efficiency could be increased by making use of the activated *N*-hydroxymethyl Vince-lactam. In this way, Fülöp and co-workers realised enhanced reactivity and higher enantiomeric excess (ee) of the remaining (+)-lactam in comparison to CAL-B-catalysed resolution of the non-activated Vince-lactam.¹²³ Spontaneous cleavage of the activating group eliminated the need for chemical deprotection. The use of Savinase, a protease commonly employed in laundry detergents, allowed for stereoselective ring opening of *N*-protected Vince-lactams.¹²⁴ Upon (enzymatic) synthesis of protected (1*S*,4*R*)-**56**, Abacavir could be obtained through several chemical steps.¹²⁵

The versatility of CAL-B was further exemplified through the resolution of a structural isomer of Vince-lactam, 6-azabicyclo[3.2.0]hept-3-en-7-one (**58**, Scheme 14). This allowed for palladium-catalysed nucleobase (**60**) coupling after tosylation, leading up to the synthesis of abacavir.¹²⁶ Although much of the research described above has been conducted at laboratory scale, protease-catalysed



Scheme 14 Resolution of a β -lactam abacavir intermediate with *Candida antarctica* lipase B (CAL-B).¹²⁶




Scheme 15 Lipase-catalysed resolution of entecavir intermediates.

Vince-lactam ring-opening is nowadays performed on industrial scale, too.

Entecavir is an anti-HBV drug characterised by an unusual 4-methylenecyclopent-1-ene core, thus bearing a exocyclic terminal double bond.¹²⁷ Bristol Myers Squibb furnished entecavir through desymmetrisation of either di-acetate **62** or its parent diol **64** at multigram scale using a *Pseudomonas sp.* lipase (Scheme 15).¹²⁸ The formed complementary mono-acetates (1*R*,4*S*,5*R*)-**63** and (1*S*,4*R*,5*S*)-**63** could both be converted to Intermediate **65**.¹²⁹ Chemical synthesis subsequently provided entecavir. Desymmetrisation of **62** could also be achieved using electric eel acetylcholinesterase.¹³⁰ Although the esterase was slightly more selective towards the mono-acetate, use of bacterial enzymes is preferred due to a lack of efficient expression systems for animal-derived enzymes.

Alternative routes to entecavir as also explored by Bristol Myers Squibb proceeded through the Corey lactone **70**.¹²⁹ The latter has proven to be accessible through resolution of racemic bicyclo[3.2.0]hept-2-en-6-one (**67**) which could be selectively reduced to (*R*)-alcohol **68** using baker's yeast (Scheme 16). Re-oxidation to the ketone and subsequent chemical steps furnished **70**.¹³¹

Intermediate (3*aS*,6*aR*)-**69** could also be accessed directly from (–)-**67** through enzymatic Baeyer–Villiger oxidation using a double mutant (F255A/F443V) of (2,2,3-trimethyl-5-oxocyclopent-3-enyl)acetyl-CoA 1,5-monooxygenase (OTEMO) from *Pseudomonas*



Scheme 16 Synthesis of the Corey lactone **70** through stereoselective reduction of bicyclo[3.2.0]hept-2-en-6-one with baker's yeast.¹³¹



putida.¹³² Although the non-desired (3*aR*,6*aS*)-**69** has previously been generated from racemic **67** using Baeyer-Villiger oxidases, the OTEMO variant could not convert the racemic substrate with sufficient stereoselectivity.

3.2 Acyclic nucleoside analogues

3.2.1 Purine-based. Acyclic nucleoside anti-viral agents largely resemble their cyclic analogues as they can adopt a conformation that functionally resembles the native ring structure. A key example of such an acyclic nucleoside is anti-herpetic aciclovir (also called acyclovir), which could be described chemically as methoxyethanol-modified guanine and thereby mimics guanosine (Chart 1).¹³³ Their ability to mimic natural nucleosides also describes the pharmacological mode of action as these achiral nucleoside analogues get triphosphorylated *in vivo* and subsequently compete with deoxy-nucleoside triphosphates to inhibit viral DNA polymerases.

Valaciclovir is a pro-drug of aciclovir in which its hydroxy moiety is esterified with *L*-valinate (Chart 2).¹³⁴ This could be achieved mildly using a *Bacillus* protease.¹³⁵ Analogously, valganciclovir (Chart 2) is the *L*-valinate ester pro-drug of ganciclovir. Selective protease-catalysed mono-de-esterification of the di-*N*-Cbz-valine ester of ganciclovir afforded the mono-ester valganciclovir.¹³⁶

Although the active drugs themselves are non-chiral, enantiopure, isotopically labelled anti-herpetics famciclovir and penciclovir have been prepared enzymatically.¹³⁷ Lipase from *Candida cylindracea* was used to resolve racemic ¹³C-labelled methyl 4-(benzyloxy)-2-(hydroxymethyl)butanoate (*rac*-**75**) on small scale (Scheme 17). The remaining (*R*)-**75** and the formed (*S*)-**76** could subsequently be converted to either labelled (*R*)-famciclovir and (*R*)-penciclovir, or (*S*)-famciclovir and (*S*)-penciclovir, respectively. These isotopically labelled drugs could be of use to determine whether stereorecognition plays a role during *in vitro* phosphorylation.

Tenofovir (**85**) is a hydrolytically stable phosphonate that mimics mono-phosphorylated nucleosides, but suffers from low bioavailability upon oral administration due to its ionic charge.¹³⁸ In order for tenofovir to be employed as a drug, one requires masking of this ionic charge in the form of pro-drugs. Tenofovir disoproxil and tenofovir alafenamide are such pro-drugs which are used for treating HIV (Scheme 18).^{139,140}




Chart 1 Guanosine-mimicking anti-viral agent aciclovir.






Chart 2 Aciclovir pro-drugs valaciclovir and valganciclovir.



Scheme 17 Lipase-catalysed resolution of ¹³C-labelled (●) methyl 4-(benzyloxy)-2-(hydroxymethyl)butanoate towards the synthesis of radio-labelled penciclovir and famciclovir.¹³⁷




Scheme 18 *Candida antarctica* lipase B (CAL-B)-catalysed resolution of 1-(trityloxy)propan-2-ol towards the synthesis of (*R*)-propylene carbonate, which is an intermediate of tenofovir.¹⁴³

Tenofovir disoproxil is a diester, whereas tenofovir alafenamide makes use of the Pro-Tide technology discussed under sofosbuvir (Section 3.1.3).⁷⁹

Both tenofovir derivatives are commonly obtained by first synthesising tenofovir itself.^{141,142} Edlin and co-workers did so by using the pivotal building block (*R*)-propylene carbonate (**84**) to convey chirality.¹⁴¹ Using immobilised CAL-B (Novozym 435) to resolve 1-(trityloxy)propan-2-ol (**81**), **84** could be produced in gram scale in flow (Scheme 18).¹⁴³

As illustrated for famciclovir and penciclovir, radio-labelled pharmaceuticals are indispensable tools for studying pharmacological properties.¹⁴⁴ Using a ketoreductase (KRED), Rivera *et al.* synthesised perdeuterated and mono-tritium-labelled (*R*)-9-(2-hydroxypropyl)adenine (**87**) as tenofovir intermediates (**85**, Scheme 19A).¹⁴⁵ Deuterium-labelled [₆D]₆-**87** was produced through H/D exchange of its acidic protons. Additional labelling was subsequently achieved by enzymatic ketone reduction using the (*R*)-selective Codexis KRED P1B02 (> 99% ee for non-labelled **87**) *via* substrate-coupled co-factor recycling with 2-deutero-isopropanol





Scheme 19 Biocatalytic radiolabelling of tenofovir intermediates with deuterium (A) or tritium (B).¹⁴⁵ KRED: ketoreductase, GDH: glucose dehydrogenase.


(2-D-89) as the deuteride source (Scheme 19A). Loss of volatile acetone during the course of the reaction additionally pushed the reaction equilibrium to the product side.

Initially, the authors envisioned a similar approach for enzymatic tritium labelling but substantial amounts of acetone in the tritium-labelled isopropanol rendered this approach unsuccessful. Instead, glucose dehydrogenase and 1-tritio-glucose (1-T-90) were employed to generate the required NADPT (Scheme 19B). The released gluconolactone (91) spontaneously hydrolysed to gluconic acid (92), further driving the reaction.

This is just one example of a (multi-)enzymatic co-factor recycling cascade. Unlike co-factors such as PLP or FAD, nicotinamide co-factors such as NAD(P)H are not tightly bound to the enzyme. Stoichiometric use of co-factors such as NAD(P)H beyond the multimilligram scale is not economically viable, thus requiring co-factor recycling *in situ*. Commonly, when using isolated enzymes, an artificial recycling cascade such as the one described above is employed to regenerate NAD(P)H back from NAD(P)⁺ using either formate/formate dehydrogenase or glucose/glucose dehydrogenase. When using whole cell biocatalysis, the living organism ensures recycling of the co-factor. Several recycling strategies will be discussed throughout this review.

3.2.2 Pyrimidine-based. While all acyclic nucleosides mentioned so far consist of a purine nucleobase, cidofovir is the only FDA-approved anti-viral acyclic nucleoside analogue bearing a pyrimidine nucleobase (cytosine).¹⁴⁶ Cidofovir is synthesised from (*R*)-glycidol ((*R*)-94), which could be produced biocatalytically.¹⁴⁷ The majority of these biocatalytic approaches involve resolution.

Minamiura and co-workers resolved 3-chloro-1,2-propanediol (*rac*-93) using *Pseudomonas sp.*, which selectively consumed the (*S*)-enantiomer (Scheme 20A).^{148,149} Treatment with base afforded (*R*)-glycidol with excellent ee. Resolution of 3-chloro-1,2-propanediol or acetylated analogues thereof could also be achieved with a variety of other biocatalysts including glycerol kinases and lipases, although the latter required sequential resolutions to achieve satisfactory enantiopurity.^{150,151}



Scheme 20 Resolution of 3-chloro-1,2-propanediol upon consumption of the (*S*)-enantiomer by *Pseudomonas sp.* followed by conversion to (*R*)-glycidol as a precursor to cidofovir (A).¹⁴⁸ Chloroperoxidase-catalysed synthesis of either (*R*)-3-chloro-1,2-propanediol or (*R*)-glycidol, dependent on the presence or absence of chloride ions (B).¹⁵⁷ IL: ionic liquid.

Duine *et al.* employed quinoxaemoproteins from a variety of sources for direct resolution of glycidol.^{152,153} These enzymes selectively oxidised (*S*)-glycidol to glycidic acid, however, only with poor enantioselectivity. Resolution of the butyrate ester of glycidol by lipase from *Rhizopus oryzae* proved to be more effective, resulting in >99% ee for (*R*)-glycidol, although highly dependent on the solvent and method of enzyme immobilisation.¹⁵⁴ It is worth mentioning that some commercial enzyme formulations consist of a mixture of enzymes. Fernandez-Lafuente and co-workers used such a mixture, porcine pancreas lipase (PPL), to resolve the butyrate ester of glycidol and managed to prepare (*R*)-glycidol with 96% ee under optimal conditions.¹⁵⁵ Interestingly, the use of a lipase-like enzyme named 25L, a specific isolate from this mixture, resulted in a significant stereoselectivity improvement (>99% ee).¹⁵⁶

In a complementary approach, Zhai and co-workers employed the chloroperoxidase from *Caldariomyces fumago* for functionalisation of allyl alcohol (96) in ionic liquids.¹⁵⁷ While the enzyme selectively produced (*R*)-3-chloro-1,2-propanediol ((*R*)-93) in the presence of a chlorine source, omission of the latter led to the formation of (*R*)-glycidol ((*R*)-94), (Scheme 20B). Both products could be obtained with excellent ee. This modular approach thus allowed for the production of two highly functionalised enantiopure C3-building blocks from simple achiral starting material.

3.3 Peptide mimics

Since the FDA-approval of saquinavir (Chart 3) in 1995, around a dozen peptidomimetic protease inhibitors have been authorised as anti-viral agents.^{19,158} These drugs structurally resemble small peptides and thus require amino acids as key building blocks. Because biocatalytic production of (non-)proteinogenic amino acids is generally well established and has been thoroughly reviewed, the subject will not be addressed here.¹⁵⁹ Where of interest, biocatalytic production of synthetically challenging unnatural amino acids will be discussed.





Chart 3 Protease inhibitor saquinavir; the first FDA-approved anti-viral peptide mimic.




3.3.1 Unnatural amino acids. A key unnatural amino acid that has proven to be a privileged building block for a large number of anti-viral pharmaceuticals is *L*-*tert*-leucine (**100**). HIV protease inhibitors atazanavir,¹⁶⁰ boceprevir¹⁶¹ and telaprevir¹⁶² contain this amino acid. Its synthesis, however, remained cumbersome for several decades.¹⁶³

After various marginally successful attempts at resolution of (protected) *L*-*tert*-leucine, Turner and co-workers developed an interesting DKR approach in which racemic *tert*-leucine was resolved from its rapidly interconverting (*R*-) and (*S*-) enantiomeric oxazolone derivatives (**98**, Scheme 21).¹⁶⁴ *Mucor miehei* lipase (MML) selectively catalysed ring-opening of the (*S*-) enantiomer in the presence of butanol and triethylamine (NEt₃). Subsequent two-step chemoenzymatic deprotection afforded *L*-*tert*-leucine (**100**) with >99% ee in 94% yield. More recently, kinetic resolution of *N*-phenylacetyl- and *N*-acetyl-protected *L*-*tert*-leucine was achieved using *Kluyvera citrophila* penicillin G acylase and *Mycobacterium sp.* JX009, respectively.^{165,166}

Although dynamic kinetic resolution is elegant, single step asymmetric synthesis is a more attractive strategy. Wandrey and co-workers at Degussa were successful in employing a *Bacillus cereus* leucine dehydrogenase (LeuDH) in the synthesis of *L*-*tert*-leucine from trimethylpyruvate (**101**, Scheme 22).¹⁶⁷ Recycling of the polymer-bound co-factor was enabled through the use of formate dehydrogenase. The use of a membrane reactor allowed for retention of both high-molecular mass co-factor and enzyme but permitted formed product to pass. By doing so, space-time yields of 638 g (L d)⁻¹ could be achieved from a continuously operated process for several months. Later, the use of whole cells overexpressing both enzymes eliminated the need for addition of external co-factor and proved to be equally efficient in producing *L*-*tert*-leucine with >99% ee.¹⁶⁸ Recent developments include the use of LeuDHs from other organisms and replacement of formate dehydrogenase-catalysed co-factor recycling by the more efficient glucose dehydrogenase system.^{169–173} Directed evolution of the LeuDH from *L. aphaericus* resulted in a two-fold increase in specific activity as compared to



Scheme 21 Dynamic kinetic resolution through base-catalysed isomerisation of *L*-*tert*-leucine-based oxazolone enantiomers and stereoselective ring-opening with *Mucor miehei* lipase (MML).¹⁶⁴



Scheme 22 Enzymatic synthesis of *L*-*tert*-leucine with Leucine dehydrogenase (LeuDH) and co-factor recycling with formate dehydrogenase (FDH).


the wild-type enzyme, which was met with a concomitant increase in space-time yield from 666 to 1170 g (L d)⁻¹.¹⁷⁴

Complementary to the use of LeuDH, several transaminases were also found capable of converting trimethylpyruvate (**101**) to *L*-*tert*-leucine (**100**). Transaminases (also called aminotransferases) catalyse the transfer of an amine group from a donor to an amine acceptor, which is a ketone or aldehyde. Most transaminases will accept α -amino acids as substrate (α -transaminases), but several can additionally convert primary amines not bearing an α -carboxylic acid moiety (ω -transaminases, sometimes also called aminotransaminases).

Similar to most (enzymatic) reactions, transaminase-catalysed reductive amination is reversible. This intrinsic equilibrium situation requires the use of an external driving force in order to favour product formation. Several approaches to shift the equilibrium for the synthesis of *L*-*tert*-leucine have been proposed. Fotheringham *et al.* employed an *E. coli* branched-chain amino acid aminotransferase (BCAT) to convert trimethylpyruvate to *L*-*tert*-leucine using glutamic acid (**102**) as the amine donor (Scheme 23).¹⁷⁵ The formed side product, α -ketoglutarate (**103**), could be converted back to glutamic acid using a *Bacillus subtilis* ornithine aminotransferase. Ornithine aminotransferase requires ornithine (**104**) as amine donor and converts it to glutamate- γ -semialdehyde (**105**). The latter is susceptible to spontaneous, virtually irreversible, cyclisation, thereby resulting in 73% yield as compared to 31% in the absence of the recycling cascade.


In a similar approach, Gefflaut and co-workers replaced ornithine aminotransferase with *Thermosinus carboxydvorans* Nor1 α -transaminase which was capable of employing glutamine as amine donor.¹⁷⁶ The resulting α -ketoacid spontaneously cyclised, again shifting the reaction equilibrium to the product side. In an alternative approach, the authors employed *Mega-sphaera elsdenii* DSM20460 α -transaminase as this enzyme was shown to accept both trimethylpyruvate and glutamine as substrates. By doing so, the use of a single enzyme thus catalysed the formation of product and it ensured a favourable shift of the reaction equilibrium towards product formation. Alternative equilibrium shifting approaches involved transaminase-catalysed amine donor regeneration coupled to pyruvate decarboxylase or the use of an amino acid dehydrogenase for amine donor regeneration coupled to alcohol dehydrogenase-catalysed co-factor recycling at the expense of isopropanol.^{177,178}

Using an enzymatic fuel cell, chemical energy can be converted to electrical energy. In an intriguing proof-of-concept study involving



Scheme 23 Synthesis of *L*-*tert*-leucine using a branched-chain amino acid aminotransferase (BCAT) and amine donor recycling/equilibrium shifting with ornithine aminotransferase (OAT).¹⁷⁵





Scheme 24 Enzymatic fuel cell-based synthesis of *L*-*tert*-leucine.¹⁷⁹ SHI: soluble [NiFe] hydrogenase I, Nit: nitrogenase, DI: diaphorase and LeuDH: leucine dehydrogenase.

integration of enzymatic electrocatalysis in the enzymatic fuel cell, Minter and co-workers were able to generate high added-value chemicals such as *L*-*tert*-leucine (**100**) from largely elementary starting materials (Scheme 24).¹⁷⁹ In the anodic chamber, *Pyrococcus furiosus* soluble [NiFe] hydrogenase I (SHI) reduced methyl viologen (MV²⁺, **107²⁺**) to MV^{•+} (**107^{•+}**) via oxidation of hydrogen gas to protons. The protons migrated over the semi-permeable membrane to the cathodic chamber. Re-oxidation of MV^{•+} at the anode resulted in the production of electrons, enabling reduction of MV²⁺ at the cathode. Nitrogen gas was subsequently converted to ammonia at the expense of MV^{•+} using a nitrogenase. The presence of ammonia finally allowed LeuDH to convert trimethylpyruvate (**101**) to *L*-*tert*-leucine (**100**). *In situ* NADH co-factor recycling was achieved by oxidation of MV^{•+} using a diaphorase from *Geobacillus stearothermophilus*.

Whereas most anti-viral peptidomimetic drugs are designed to combat HIV, telaprevir and boceprevir are used against the hepatitis C virus. From a biocatalytic perspective, telaprevir provides for a particularly interesting synthetic target. When retrosynthetically disassembled, one can envision its synthesis from six building blocks, which include three unnatural amino acids (Chart 4).^{23,180,181} One is the amino acid *L*-*tert*-leucine (**100**) discussed above and the other two are *L*-cyclohexylglycine (**110**) and the bicyclic proline analogue **111**.

Remarkably, Sorm and co-workers reported the resolution of *N*-acetyl-*L*-cyclohexylglycine using hog renal acylase I as early as 1966.¹⁸² More recently, Holla and co-workers described the resolution of racemic *N*-acetyl-*L*-cyclohexylglycine using a microbial acylase (*Aspergillus sp.*).¹⁸³ Various other *N*-protected *L*-cyclohexylglycine derivatives could be resolved using, for example, penicillin G acylase.¹⁸³ Although enzymatic resolution is most





Chart 4 Retrosynthetic analysis of telaprevir.

commonly achieved using acylases or lipases, other biocatalysts have been shown to be effective, too. Lin and Wang applied *Rhodococcus sp.* AJ270 cells to resolve numerous α -amino nitriles resulting in the formation of a wide variety of (unnatural) amino acids including *L*-cyclohexylglycine.¹⁸⁴ An (*S*)-selective amidase and a non-stereoselective nitrile hydratase were shown to catalyse this microbial transformation. Again, kinetic resolution being limited to 50% yield makes asymmetric synthesis of the amino acid a more attractive approach. Such a synthesis was achieved by a team from Asymchem through enzymatic reductive amination of pro-chiral 2-cyclohexyl-2-oxoacetate using a LeuDH from *Bacillus sphaericus*.¹⁸⁵

The third unnatural amino acid building block of telaprevir is the bicyclic proline analogue **111**. Turner and co-workers employed desymmetrisation of commercially available **114** using a monoamine oxidase (MAO) variant to yield the corresponding $^1\Delta$ -pyrroline (**115**, Scheme 25A).¹⁸⁶ MAO catalyses the oxidative deamination of amines to ketones and aldehydes. The employed fungal MAO-N D5 from *Aspergillus niger*, however, is a more versatile engineered variant that also catalyses reductive amination and oxidation of cyclic amines, for example.¹⁸⁷ Hydrocyanation of **115**, followed by nitrile hydrolysis subsequently furnished **111**. In collaboration with the group of Orru, an Ugi-type 3-component reaction was developed for the synthesis of various prolyl peptides by starting from a carboxylic acid component, a nitrile component and a cyclic imine.¹⁸⁸ This approach was ultimately employed for the synthesis of telaprevir through the use of an elegant late stage 3-component coupling involving **116**, **117** and **115**, thereby eliminating the need to access amino acid **111** separately (Scheme 25B).¹⁸⁹


The MAO-N D5 variant used in the synthesis of **115** had been employed in the millimolar range, which would not be viable on industrial scale. A collaboration between Merck and Codexis resulted in the engineering of a highly active MAO-N variant capable of resisting temperatures up to 50 °C and allowing substrate concentrations above 1 M.¹⁹⁰

Similar to telaprevir, boceprevir could be built up from an unnatural bicyclic proline analogue (**120**, Scheme 26). Use of the Merck/Codexis MAO-N variant resulted in oxidation of **118** with high yield and ee. *In situ* capture of the corresponding $^1\Delta$ -pyrroline **119** using sodium bisulfite and subsequent chemical transformations led to an efficient synthesis of the methyl ester of **120** (**120-Me**) in 56% overall yield and >99% ee.



Scheme 25 Oxidation of *cis*-3-aza-bicyclo[3.3.0]octane (**114**) by monoamine oxidase variant D5 (MAO-N D5) and subsequent chemical synthesis to the corresponding amino acid **111** (A).¹⁸⁶ Late stage Ugi-type 3-component reaction towards the synthesis of telaprevir (B).¹⁸⁹





Scheme 26 Monoamine oxidase (MAO-N) variant-catalysed synthesis of boceprevir intermediate.¹⁹⁰

3.3.2 Tetra-substituted core with C3 backbone. As mentioned previously, there is a high degree of similarity among peptidomimetic anti-viral agents. Saquinavir,¹⁹¹ darunavir,¹⁹² amprenavir,¹⁹³ fosamprenavir¹⁹⁴ and atazanavir, for example, all share the same (3*S*)-1,3-diamino-4-phenylbutan-2-ol (DAPB) core with either (*R*)- or (*S*)-configuration at the 2-position (Chart 5). This core element mimics the transition state formed upon amide attack by the HIV protease, with the central hydroxyl group binding to the catalytic aspartate residues for high inhibitor affinity.¹⁹⁵

A team at Roche approached the synthesis of saquinavir from several directions.¹⁹⁶ Retrosynthetically, saquinavir was disconnected as such that its building blocks could be assembled largely through simple amide coupling (Scheme 27A). In one of these approaches, the final disconnection involves nucleophilic attack of the decahydroisoquinoline building block **125** on the protected aminodiol **124** resulting in the formation of the DAPB core.

Sugiura and co-workers employed desymmetrisation of a bis-acetylated tosyl aziridine (**127**) using *Pseudomonas sp.* lipase for the synthesis of its mono-acetylated counterpart **128** (Scheme 27B).¹⁹⁷ Several subsequent chemical steps led to the formation of protected 3-aminobutane-1,2,4-triol (ABT, **129**), a key building block of nelfinavir (*vide infra*).¹⁹⁸ **129** could subsequently be converted to the desired protected aminodiol **130**. As protection of **130** is analogous to that of **124**, this could serve as building block for saquinavir too.

Due to concerns regarding the stability of the azido-protected (2*S*,3*S*)-3-amino-4-phenylbutane-1,2-diol derivative **124**, Roche abandoned this route.¹⁹⁶ Instead, replacing the sulphate protected diol by an epoxide was considered favourable to facilitate the subsequent coupling step.

Chemoenzymatic synthesis of chiral epoxide **133** (PG = Boc) was initially explored at multigram scale by Bristol Myers Squibb (Scheme 28).¹⁹⁹ Microbial reduction of **131** by *Streptomyces nodosus* SC 13149 resulted in the formation of chlorohydrin (2*R*)-**132** with excellent enantio- and diastereomeric purity, which,






Chart 5 (3*S*)-1,3-diamino-4-phenylbutan-2-ol (DAPB) core of saquinavir, darunavir, (Fos)amprenavir and atazanavir.



Scheme 27 Retrosynthetic analysis of saquinavir (A). Lipase-catalysed desymmetrisation of a tosylated aziridine intermediate towards protected 3-aminobutane-1,2,4-triol (ABT) and protected (2*S*,3*S*)-3-amino-4-phenylbutane-1,2-diol (B).¹⁹⁸




Scheme 28 Stereoselective biocatalytic reduction towards the construction of the (3*S*)-1,3-diamino-4-phenylbutan-2-ol (DAPB) core of saquinavir, darunavir, (Fos)amprenavir and atazanavir. For readability and continuity, atoms have been numbered as to match numbering for 1,3-diamino-4-phenylbutan-2-ol (DAPB).

upon treatment with base, would afford (2*R*)-**133**. As a follow-up of this work, Bristol Myers Squibb investigated several *Rhodococcus* strains for the production of (2*R*)-**132** and employed the building block in the synthesis of atazanavir.²⁰⁰ Subjecting **131** to reduction by a ketoreductase from *Ralstonia sp.* led to the interesting observation that the enzyme's stereoselectivity could be reversed by switching the *N*-protecting group.²⁰¹ Use of Boc-protected **131** resulted in the formation of (2*R*)-**132**, whereas the use of its Cbz-protected counterpart resulted in the formation of (2*S*)-**132**. Recently, Shao *et al.* subjected a short-chain dehydrogenase from *Novosphingobium aromaticivorans* to multiple rounds of mutagenesis to obtain a variant (G141V/I195L) that was approximately four times more active against **131** than the wild-type enzyme.²⁰²

The central scaffold of nelfinavir differs from DAPB in that the phenyl moiety is replaced by a thiophenol.²⁰³ As with DAPB, the nelfinavir core could be accessed through the thiophenol equivalent of **131**,²⁰⁴ which in turn allowed for KRED catalysis to furnish the corresponding (2*R*)-chlorohydrin as reported by Pace and co-workers.²⁰⁵ It was shown that, as for the synthesis of **131** from *L*-phenylalanine, *S*-phenyl-*L*-cysteine could serve as starting material for the corresponding α -chloroketone.^{204,205} Although several patented procedures are available for the biocatalytic synthesis of the non-proteinogenic amino acid *S*-phenyl-*L*-cysteine, at the time productivity did not exceed laboratory scale. Mitsui Toatsu Chemicals, however, developed a scalable procedure






Scheme 29 Fermentation with wild-type and engineered *E. coli* for the production of L-cysteine and S-phenyl-L-cysteine.²⁰⁷ SAT: serine acetyltransferase and OASS: O-acetylserine sulfhydrylase.


using tryptophan synthase-producing *E. coli* to convert L-serine and thiophenol to S-phenyl-L-cysteine.²⁰⁶

By re-engineering the cysteine biosynthetic pathway in *Escherichia coli*, Maier developed a strain capable of producing a large variety of unnatural amino acids including S-phenyl-L-cysteine (**137**, Scheme 29).²⁰⁷ The wild-type microbial strain converted glucose (**90**) to serine (**134**) and thereafter to O-acetylserine (**135**) using serine acetyltransferase (SAT). With sulfide as the nucleophile, the enzyme O-acetylserine sulfhydrylase subsequently converted O-acetylserine to cysteine (**136**). O-Acetylserine sulfhydrylase was shown to also accept other nucleophiles instead of sulfide to produce unnatural amino acids in low yield. The low yield was attributed to inhibition of SAT by cysteine, which thereby limited the overall concentration of O-acetylserine. Screening of several SAT variants led to the discovery of an enzyme that was less susceptible to inhibition by cysteine while retaining 50% activity (SAT^{fbr}). Implementation of the gene encoding for SAT^{fbr} allowed for effective microbial production of S-phenyl-L-cysteine (**137**) using thiophenol as nucleophile (72% yield from O-acetylserine).

However, both the high costs of S-phenyl-L-cysteine and the possibility to access the arylthioether through late-stage substitution make other synthetic strategies more attractive. Most routes instead involve the use of protected 3-aminobutane-1,2,4-triol (ABT, **138**, Scheme 30).^{208–210} Suitably protected equivalents of ABT could be obtained efficiently through biocatalytic resolution. Faure and co-workers employed either single-step or two-step lipase-catalysed resolution of N-protected ABT to obtain (2S,3R)-**144** from **143** (Scheme 31A). Improved enantiomeric purity was observed for the two-step-resolution approach (>99% vs. <98%).²¹¹ Noto and co-workers analogously used



Scheme 30 Synthesis of nelfinavir from suitably protected 3-aminobutane-1,2,4-triol (ABT) as described by Uchida *et al.* (I),²⁰⁸ Cho and co-workers (II)²⁰⁹ and Borer *et al.*²¹⁰




Scheme 31 Resolution of protected ABT derivatives **143** (A)²¹¹ and **145/146** (B).²¹² PPL: porcine pancreas lipase, PFL: Amano AK lipase (*P. fluorescens*), BCL: Amano PS lipase (*Burkholderia cepacia*) and BCL-C II: BCL immobilised on ceramic instead of diatomite.

immobilised Amano PS lipase (a *Burkholderia cepacia* (BCL) preparation) to resolve dioxepanes **145** and **146** at laboratory scale (Scheme 31B).²¹²

Bare ABT **138** itself also provides for an attractive target for biocatalytic production due to its high solubility and the presence of two adjacent chiral centres in a small molecule. Lye and co-workers developed a two-step enzymatic cascade for the synthesis of ABT.²¹³ Transketolase catalyses the interconversion of two phosphorylated C2–C5 ketoses/aldoses. Several transketolase types, however, can also accept non-phosphorylated sugar derivatives. *E. coli* transketolase was used to synthesise L-erythrulose (**148**) from glycolaldehyde (**147**) and hydroxypyruvate (**149**) by carbonylation (Scheme 32A). Decarboxylative coupling of an α -ketoacid such as hydroxypyruvate results in the (irreversible) formation of CO₂, which provides a strong driving force for product formation. An ω -transaminase from *Pseudomonas aeruginosa* was used to transfer the amine moiety from (S)- α -methylbenzylamine ((S)-**150**) to the intermediate L-erythrulose. A laboratory scale two-step, one-pot cascade reaction was enabled by overexpressing the endogenous transketolase and the transaminase in *E. coli*.

Although constituting a very attractive cascade, no enantiomeric and/or diastereomeric purity was reported, the transaminase




Scheme 32 Two-step enzymatic synthesis of 3-aminobutane-1,2,4-triol (A)²¹³ and inclusion of *in situ* hydroxypyruvate formation/amine donor recycling (B).²¹⁶ TK: transketolase, ThDP: thiamine diphosphate, TA: transaminase and PLP = pyridoxal phosphate.




reaction was in equilibrium, (*S*)- α -methylbenzylamine proved an inconvenient amine donor and hydroxypyruvate is chemically unstable.²¹⁴ By switching to a highly versatile ω -transaminase from *Chromobacterium violaceum* capable of employing isopropylamine as simple donor, formation of volatile acetone pushed the reaction equilibrium in favour of product formation and side reactions could be suppressed. This optimised cascade resulted in the formation of (2*R*,3*S*)-**138** as a single stereoisomer (>95% ee).²¹⁵ Addition of a second α -transaminase enzyme from *Deinococcus geothermalis* DSM11300 allowed for the *in situ* generation of hydroxypyruvate from L-serine (**134**), which enabled continuous dosing of this labile intermediate.²¹⁶

By using a single transaminase from *Rhodobacter sphaeroides* ATCC17025 (TA^{RS}) with specificity for both L-erythrose (**148**) and L-serine, simultaneous generation of hydroxypyruvate (**149**) and ABT led to a simplified semi closed-loop cascade (Scheme 32B). Although the required initial formation of hydroxypyruvate was ensured as TA^{RS} also utilised glycolaldehyde as an amine acceptor, significant amination of this substrate led to a limitation of the overall ABT yield to a maximum of 9%. As the complex reaction system requires careful adjustments, further process optimisation is being pursued extensively.^{217–219}

3.3.3 Indinavir. Differing from the core structure of the anti-viral protease inhibitors discussed above, indinavir is comprised of an elongated C₅-rather than a C₃-backbone (Scheme 33).²²⁰ Whereas biocatalytic access to this core element has not been heavily pursued, biocatalytic access to its (1*S*,2*R*)-1-amino-2-indanol capping fragment ((1*S*,2*R*)-**155**) has been investigated all the more. Access to this chiral amino alcohol was achieved through hydrolytic enzymatic resolution of a variety of precursors (Scheme 33).^{221–223} Kim and co-workers employed a *Pseudomonas* lipase from Amano to resolve α -acetoxyindanone (**153**) and subsequently performed chemical reductive amination to provide (2*R*)-1-amino-2-indanol ((2*R*)-**155**, Scheme 34).²²⁴ Resolution of the second stereocentre



Scheme 34 Four-step route to (1*S*,2*R*)-amino-2-indanol including lipase and transaminase (TA)-catalysed resolution.²²⁴




Scheme 35 Oxidation of indene by *P. putida* towards the synthesis of (1*S*,2*R*)-1-amino-2-indanol.^{226,227}

was achieved using an ω -transaminase from *Vibrio fluvialis* JS17 (96% de). Addition of γ -cyclodextrin was suggested to result in selective binding of the desired (1*S*,2*R*)-1-amino-2-indanol ((2*S*,2*R*)-**155**) preventing its deamination as the absence of this additive resulted in only 35% de at 45% conversion.

Earlier attempts at resolving intermediates of (1*S*,2*R*)-1-amino-2-indanol involved the use of *Pseudomonas putida* to achieve dihydroxylation of indene (**161**, Scheme 35).^{226,227} As the reaction initially yielded both enantiomers of *cis*-indane-1,2-diol (**157**), dihydroxylation was suggested to be catalysed by an insufficiently stereoselective toluene dioxygenase. With extended reaction duration, enantiomeric excess increased to >90% in favour of (1*S*,2*R*)-**157**, however. Based on the concomitant formation of α -hydroxyindanone (**154**), the authors suggested the presence of a *cis*-glycol dehydrogenase that exclusively oxidised (1*R*,2*S*)-**157**. Alternatively, (1*S*,2*R*)-Indane-1,2-diol could be accessed by reduction of indane-1,2-dione using *Trichosporon cutaneum* MY1506.²²⁸ Synthesis of the target (1*S*,2*R*)-1-amino-2-indanol from (1*S*,2*R*)-indane-1,2-diol could be achieved using a Ritter reaction.²²⁹


Indinavir's piperazine fragment could also be accessed biocatalytically. Hydrolysis of racemic piperazine-2-carboxamide using an amidase from *Klebsiella terrigena* DSM 9174 afforded (*S*)-piperazine-2-carboxylic acid in 99% ee, albeit in low yield (22%).²³⁰

3.3.4 (Fos)amprenavir. In addition to sharing the DAPB core, amprenavir and its phosphate ester pro-drug fosamprenavir both possess a (*S*)-3-hydroxytetrahydrofuran fragment (Scheme 36A). Although its structure is rather simple, stereoselective biocatalytic synthesis of (*S*)-3-hydroxytetrahydrofuran ((*S*)-**164**) has only been achieved recently. The very small size difference of the ring fragments on opposing sides of the secondary alcohol requires chiral differentiation of the ether *versus* the alkane moiety based on polarity differences. This renders **164** particularly difficult to resolve (Scheme 36B).



Scheme 33 Synthesis of (1*S*,2*R*)-1-amino-2-indanol via biocatalytic resolution as described by Ozgul *et al.* (I),²²¹ Nohira *et al.* (II),²²² and Afonso and co-workers (III),²²³ and the synthesis of indinavir from this intermediate as described by Zhong and co-workers (IV).²²⁵ BCL: Amano PS lipase (*Burkholderia cepacia*), IL: ionic liquid and CAL-B: *Candida antarctica* lipase B.






Scheme 36 Structures of amprenavir and fosamprenavir (A). 3-Hydroxytetrahydrofuran including plain of symmetry indicating the near absent difference in size of the left- and right-hand ring fragments (B). Fumarase-catalysed hydration of fumarate, subsequent protection, reduction to the 2-protected (S)-1,2,4-butanetriol and acid-mediated deprotection/cyclisation to yield (S)-3-hydroxytetrahydrofuran (C). PG: protecting group.

Whereas screening of over 100 hydrolytic enzymes by Bornscheuer *et al.* resulted in the discovery of candidates capable of resolving three other challenging substrates, resolution of acetylated (S)-3-hydroxytetrahydrofuran remained elusive.²³¹ Engineering of a *Bacillus stearothermophilus* esterase, however, effected a more than two-fold increase in stereoselectivity (E-factor 4.3 to 10.4).²³² Although a significant improvement, this remains insufficient for practical applications.

Reetz and co-workers instead focused on biocatalytic reduction of pro-chiral oxolan-3-one. Initially, reduction with *Thermoethanolicus brockii* alcohol dehydrogenase afforded (R)-3-hydroxytetrahydrofuran with only 23% ee. Directed evolution of this highly stable enzyme was pursued in order to reverse and improve its stereoselectivity. The triple mutant I86V/W110L/L294Q proved most effective as it was able to fully convert oxolan-3-one with 94% ee in favour of the (S)-enantiomer.²³³

The groups of Wynberg and Izawa showed that (S)-3-hydroxytetrahydrofuran could be prepared from the hydroxy-protected acyclic precursor L-malate dialkyl ester (**168**).^{234,235} The latter was synthesised from L-malic acid (**166**), which is commercially produced by fermentation on industrial scale through fumarase-catalysed hydration of fumarate (**165**, Scheme 36C).²³⁶ L-Malic acid can also be prepared from the racemate through kinetic resolution.²³⁷

The chemical synthesis of (S)-3-hydroxytetrahydrofuran proceeded through protected (S)-1,2,4-butanetriol (**169-PG**). As shown by Chung and co-workers, production of 1,2,4-butanetriol could also be achieved from renewable resources through the use of an engineered *E. coli* strain capable of fermenting xylose (Scheme 37).²³⁸ Introduction of heterologous genes encoding for *Caulobacter crescentus* xylose dehydrogenase (XDH) allowed for the oxidation of xylose (**170**) to xylonic acid (**171**). C3-dehydration by *E. coli*'s native D-xylonic acid dehydratase (DHT) followed by decarboxylation with benzoylformate decarboxylase (mdlC) from *Pseudomonas putida* afforded 3,4-dihydroxybutanal (**173**). The latter could be reduced to 1,2,4-butanetriol (**169**) using native KREDs. Disruption of the genes encoding for 2-keto-3-deoxy-D-xylonate aldolase (kdxA) and the enzymes responsible for xylose isomerisation




Scheme 37 Production of (S)-1,2,4-butanetriol through fermentation of xylose with engineered *E. coli*.²³⁸ XDH: xylose dehydrogenase, DHT: D-xylonic acid dehydratase, mdlC: benzoylformate decarboxylase, xylA/xylB: xylose isomerisation enzymes, kdxA: 2-keto-3-deoxy-D-xylonate aldolase and KRED: ketoreductase.

(xylA and xylB) resulted in an additional improvement of the cascade to yield 1,2,4-butanetriol in 0.88 g L⁻¹ (13% overall yield). In comparison, a two-step, two-microbe system for the production of (S)-**169** as reported by Frost and co-workers (initial production of **171** with XDH from *P. fragi*), proved to be more efficient (1.6 g L⁻¹, 18% overall yield and >99% ee).²³⁹ Through re-engineering of the malate pathway, glucose could also be used as carbon-source for the production of 1,2,4-butanetriol, albeit in titres of only 55 mg L⁻¹.²⁴⁰ Alternatively, resolution of racemic 1,2,4-butanetriol provided access to both enantiomers.¹⁵⁰


3.3.5 Darunavir. Similar to (Fos)amprenavir, darunavir bears a tetrahydrofuran-derived fragment; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol or in short 3-hydroxy-bis-tetrahydrofuran (3-OH-bis-THF; (3R,3aS,6aR)-**176**, Scheme 38). Resolution of an enantiomeric mixture of acetylated **176** could be achieved using various lipases (Scheme 38).^{241–243} The mixture of **176** enantiomers could also be resolved through enzymatic acetylation.^{241,244,245} BCL was additionally proven to be capable of resolving a diastereomeric mixture of **176**.²⁴⁶

Several multi-step, one-pot procedures that include lipase resolution have been published for the synthesis of 3-OH-bis-THF. Itoh and co-workers devised a strategy involving organocatalytic cycloaddition of glycolaldehyde (**147**) and 1,2-dihydrofuran (**179**) to obtain 3-OH-bis-THF as a mixture of diastereomers.²⁴⁷ The latter was subsequently resolved using BCL (Scheme 39A). Around the same time, Opatz *et al.* reported a three-step, one-pot telescoping approach to (3R,3aS,6aR)-**176**,²⁴⁸ making use of a stereoselective [2+2]-photocycloaddition between furan (**181**) and Cbz-protected glycolaldehyde (**182**) to afford the bicyclic oxetane



Scheme 38 Enzymatic resolution of (acetylated) 3-OH-bis-THF with lipase.





Scheme 39 Two-step, one-pot organocatalytic cyclisation followed by lipase-catalysed resolution (A)²⁴⁷ and three-step, one-pot photocatalytic cyclisation, followed by deprotection and lipase-catalysed resolution (B)²⁴⁸ for the synthesis of 3-OH-bis-THF. BCL: Amano PS lipase (*Burkholderia cepacia*), STUC: Schreiner's thiourea catalyst and PPL: porcine pancreas lipase.

183 (Scheme 39B). Hydrogenative deprotection resulted in the spontaneous rearrangement of ring-strained **184** to yield *trans*-**176**. The latter was subsequently resolved using porcine pancreas lipase (PPL) and propionic anhydride as acylating agent. PPL showed enhanced enantioselectivity as compared to *Pseudomonas fluorescens* lipase and CAL-B, although preferentially for the undesired acylated product. Interestingly, switching from acetic anhydride to propionic anhydride resulted in an increase of ee from 93% to >99%. The use of propionic anhydride also shortened reaction times by 24 h as compared to other donors.

3.4 Bis-cyclopropyl-based protease inhibitors

Among the anti-viral agents classified as peptide mimics, the bis-cyclopropyl-based drugs form a defined sub-class of protease inhibitors for combating the hepatitis C virus. Again, a large degree of structural similarity is observed among these agents. All share a cyclopropylsulfonamide linked to a (1*R*,2*S*)-1-amino-cyclopropanecarboxylic acid (ACCA) moiety flanked by a hydroxyproline derivative or analogue thereof. An additional common feature is that most are macrocyclic, except for asunaprevir and vaniprevir (Chart 6).

3.4.1 L-Hydroxyproline. As with the other peptidomimetic drugs discussed above, the bis-cyclopropyl-based protease inhibitors can for a large part be constructed from amino acid components. For most of the bis-cyclopropyl-based protease inhibitors, *trans*-4-hydroxy-L-proline (L-hydroxyproline) constitutes the central core to which all other fragments are connected. The non-canonical amino





Chart 6 Common structure of bicyclopropyl-based protease inhibitors.




Scheme 40 Hydroxylation of L-proline with proline 4-hydroxylase (P4H).

acid L-hydroxyproline accounts for 4% of all amino acids incorporated in animal tissue, but unlike the canonical amino acids it is synthesised through post-translational hydroxylation of L-proline. Ozaki and co-workers have shown that microbial proline 4-hydroxylases (P4Hs) are excellent biocatalysts for synthesising L-hydroxyproline ((2*S*,4*R*)-**186**) *ex vivo* (Scheme 40).^{249–251} P4H contains an enzyme-bound oxo-iron species that enables conversion of L-proline to L-hydroxyproline at the expense of α -ketoglutarate (**103**). The resulting Fe(III) species are inhibitory but can be reduced back to Fe(II) in the presence of ascorbate. The enzyme could also be used for synthesising the six-membered ring analogue of L-hydroxyproline, pipercolic acid.²⁵² Introduction of the P4H encoding gene from *Dactylosporangium sp.* into a proline-producing, isoleucine-bradytroph *Corynebacterium glutamicum* allowed for the efficient production of L-hydroxyproline.²⁵³ Strict control over the L-isoleucine concentration was essential as high concentrations of this amino acid minimised L-proline production, while low concentrations resulted in minimal growth of the organism. Use of a bradytroph, a strain that grows slowly in the absence of a certain metabolite (in this case L-isoleucine) due to a limiting defect in its metabolic pathway, resulted in controlled L-isoleucine production. By allowing cell-growth in minimal medium containing a carefully tuned ratio of glucose to L-isoleucine (46:1), 7.1 g L⁻¹ of L-hydroxyproline could be produced from glucose.

Clapés and co-workers recently developed a *de novo* chemo-enzymatic approach towards hydroxyproline by starting from simple building blocks.²⁵⁴ Aldol addition of pyruvate (**175**) to Cbz-protected 2-aminoacetaldehyde (**188**) catalysed by 2-keto-3-deoxy-L-rhamnonate aldolase (YfaU) was followed by treatment of the condensation product with palladium on carbon. The latter resulted in amine deprotection, spontaneous cyclisation and subsequent reductive amination to yield hydroxyproline as a mixture of stereoisomers (*cis*-**186**, 40% de, Scheme 41). YfaU-catalysed carbonylation did not occur stereoselectively, likely due to the achiral nature of the protected 2-aminoacetaldehyde and the equilibrium nature of the conversion favouring thermodynamic over kinetic control.

In a similar approach, Franssen *et al.* used 2-keto-3-deoxygluconate aldolase from *Sulfolobus acidocaldarius* to condense



Scheme 41 Condensation of N-Cbz-protected 2-aminoacetaldehyde and pyruvate catalysed by 2-keto-3-deoxy-L-rhamnonate aldolase (YfaU) followed by deprotection/cyclisation to obtain racemic hydroxyproline.²⁵⁴




2-azidoacetaldehyde and pyruvate in a stereoselective fashion.²⁵⁵ Zinc-catalysed deprotection and reduction resulted in the generation of hydroxyproline as a mixture of diastereomers in which the undesired (4*S*)-isomer prevailed. Hydroxylation of L-proline is thus the preferred route to the desired (2*S*,4*R*)-hydroxyproline isomer.

3.4.2 L-tert-Leucine. The bicyclopropyl-based protease inhibitors grazoprevir,²⁵⁶ glecaprevir,²⁵⁷ voxilaprevir,²⁵⁸ asunaprevir²⁵⁹ and vaniprevir²⁶⁰ contain L-tert-leucine as a synthetic building block. For the biocatalytic synthesis of this unnatural amino acid, the reader is referred to Section 3.3.1.

3.4.3 (1*R*,2*S*)-1-aminocyclopropanecarboxylic acid derivatives. Vaniprevir contains a cyclopropane-based amino acid fragment identical to the one also found in coronatine (Chart 6); an active natural product formed by plant pathogenic microbes. Due to its origin, the building block is named coronamic acid, but this amino acid, as well as its unsaturated vinyl-analogue, are more commonly referred to by their systematic names; (1*R*,2*S*)-1-amino-2-ethylcyclopropanecarboxylic acid (ethyl-ACCA) and (1*R*,2*S*)-1-amino-2-vinylcyclopropanecarboxylic acid (vinyl-ACCA), respectively. Grazoprevir and asunaprevir both contain vinyl-ACCA, whereas simeprevir²⁶¹ and paritaprevir²⁶² require its incorporation to allow for macrocyclisation through ring-closing metathesis.²⁶³

The synthesis of vinyl-ACCA as outlined by Boehringer Ingelheim in 2005 is regarded as the gold standard for the production of this compound (Scheme 42A).²⁶⁴ Their synthetic strategy involved resolution of the *N*-Boc-protected vinyl-ACCA methyl ester (*cis*-**190**) by Alcalase 2.4L (a *Bacillus licheniformis* protease formulation). Although applicable on large scale, two consecutive resolution steps were required in order to reach 99% ee for the desired remaining isomer (1*R*,2*S*)-**190**, resulting in a complex, time-consuming approach. In an independent study, resolution of the *N*-Boc protected vinyl-ACCA ethyl ester with *Sphingomonas aquatilis* whole cells afforded the remaining (1*R*,2*S*)-configured ester with 88% ee.²⁶⁵ Strikingly, resolution of unprotected racemic vinyl-ACCA was claimed to result in a reversal of selectivity; the formed (1*R*,2*S*)-configured ester was isolated in 99.6% ee.

Kroll and co-workers protected racemic vinyl-ACCA as its trifluoromethyl-substituted azlactone (**192**, Scheme 42B).²⁶⁶ Interconversion of both enantiomers of **192**, which was proposed to be enabled through an unusual [3,3]-sigmatropic




Scheme 42 Resolution of the *N*-Boc-protected amino-2-vinylcyclopropanecarboxylic acid (vinyl-ACCA) methyl ester with Alcalase 2.4L (a *Bacillus licheniformis* protease (BLP) formulation) (A).²⁶⁴ Dynamic kinetic resolution with Amano PS lipase (*Burkholderia cepacia*, BCL) to obtain protected vinyl-ACCA (B).²⁶⁶

oxadivinylycyclopropane rearrangement, allowed for dynamic kinetic resolution through lipase-catalysed ethanolsis. Unfortunately, using BCL for hydrolysis of the desired stereoisomer resulted in only 75% ee and 96% yield after 18 days. Ethyl-ACCA, a vaniprevir fragment, could be obtained through reduction of vinyl-ACCA.^{267,268}

Glecaprevir and voxilaprevir both contain a difluoromethyl-ACCA fragment. A team at Abbvie developed a synthetic route to glecaprevir in which difluoromethyl-ACCA was derived from vinyl-ACCA *via* multi-step chemical conversion.²⁶⁹ As the yield was moderate and the synthesis required a complicated work-up procedure, this process proved not to be viable on large scale. The authors disclosed that alternative synthetic procedures had been developed.²⁷⁰ One of these included the preparation of enantiomerically enriched difluoromethyl-ACCA through two consecutive enzymatic resolution steps (Scheme 43).²⁷¹ Dipropyl 2-(difluoromethyl)cyclopropane-1,1-dicarboxylate (*rac*-**194**) would first be subjected to resolution with *Thermomyces lanuginosus* lipase (AH45) to isolate the desired (*R*)-enantiomer (*R*)-**194** (Scheme 43). Subsequent desymmetrisation with an esterase from either *Bacillus subtilis* (*yvaK*) or *Bacillus stearothermophilus* (*BsteE*), followed by Curtius rearrangement and hydrolysis afforded *N*-Boc-protected difluoromethyl-ACCA (**196**).


3.4.4 L-6-Heptenylglycine – paritaprevir. The final unnatural amino acid to be discussed with regards to peptidomimetic anti-viral agents is L-6-heptenylglycine ((*S*)-2-amino-8-nonenic acid). After peptide coupling of vinyl-ACCA (**199**), L-hydroxyproline ((2*S*,4*R*)-**186**) and L-6-heptenylglycine (**198**), ring-closing metathesis of the two terminal olefins allowed for the synthesis of paritaprevir (Scheme 44A).²⁶³ Resolution of the *N*-acetyl-protected racemate with acylase I afforded L-6-heptenylglycine with >99% ee on large scale.²⁷² Alternatively, the corresponding *N*-Boc-protected precursor could be resolved by subjecting its ethyl ester to protease-catalysed hydrolysis.²⁷³

Dutch life-sciences company DSM developed a dynamic kinetic resolution process comprising of three enzymes, which required L-6-heptenylglycine to be prepared as its hydantoin derivative (**200**).²⁷⁴ An L-selective hydantoinase from *Arthrobacter aurescens* (HyuH) ensured enantioselective ring-opening and the L-carbamoylase from *Bacillus stearothermophilus* (HyuQ) subsequently cleaved the resulting urea moiety (Scheme 44B). Rapid interconversion of both hydantoin enantiomers was enabled by a hydantoin racemase from *Agrobacterium radiobacter* (HyuA). In a complementary approach, Japanese Kaneka applied a *N*-acylamino acid racemase (AaaR)-catalysed



Scheme 43 Two-step enzymatic resolution of a difluoromethyl-ACCA intermediate.²⁷¹ AH45: *Thermomyces lanuginosus* lipase, *yvaK*: *Bacillus subtilis* esterase and *BsteE*: *Bacillus stearothermophilus* esterase.






Scheme 44 Retrosynthetic analysis of paritaprevir (A). Enzymatic dynamic kinetic resolution for the synthesis of L-6-heptenylglycine through its hydantoin (B)²⁷⁴ or its *N*-succinate (C).²⁷⁵ HyuA: hydantoin racemase from *Agrobacterium radiobacter*, HyuH: L-hydantoinase from *Arthrobacter aurescens*, HyuQ: L-carbamoylase from *Bacillus stearothermophilus*, aaaR: *N*-acylamino acid racemase and quant. conv.: quantitative conversion.


interconversion of racemic *N*-succinyl 6-heptenylglycine (**202**), followed by kinetically controlled enantioselective amide cleavage by L-succinylase to furnish the desired enantiopure amino acid (**198**, Scheme 44C).²⁷⁵

Finally, a team at Merck developed an efficient four-step asymmetric synthesis of L-6-heptenylglycine *via* 2-oxonon-8-enoic acid (**204**) which in turn was obtained through Grignard chemistry (Scheme 45).²⁷⁶ Use of a leucine dehydrogenase from Codexis converted the ketoacid **204** to L-6-heptenylglycine (**198**) with >99% ee. Subsequent Boc protection and isolation of **205** as its dicyclohexylamine salt allowed for an overall yield of 60% starting from 7-bromoheptene (**203**), thereby clearly outcompeting non-dynamic resolution approaches as such strategies would result in a maximum theoretical yield of 50%.

3.4.5 Simeprevir. While most bis-cyclopropyl-based protease inhibitors are built around a L-hydroxyproline core, simeprevir is constructed around its carbocyclic analogue. The presence of an additional chiral centre at the site for macrocyclisation provides for a considerable synthetic challenge. A team at Janssen Pharmaceuticals explored various routes to obtain either (4*S*)- or (4*R*)-**209** (Scheme 46), which both would allow for stereoselective construction of the anti-viral agent simeprevir. The two routes that were explored beyond analytical scale started by



Scheme 45 Concise synthesis of 2-oxonon-8-enoic acid and subsequent reductive amination catalysed by a leucine dehydrogenase (LeuDH).²⁷⁶ GDH: glucose dehydrogenase and DEO: diethyl oxalate.



Scheme 46 Chemoenzymatic synthesis of simeprevir precursors as proposed by Janssen Pharmaceuticals.²⁷⁷ CAL-B: *Candida antarctica* lipase B, CDI: carbonyldiimidazole, KRED: ketoreductase, quant.: quantitative yield, GDH: glucose dehydrogenase and EEDQ: *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.

lipase catalysed desymmetrisation of dimethyl *trans*-4-oxocyclopentane-1,2-dicarboxylate (**206**) using CAL-B to obtain **207** in 37% yield and 94% ee (Scheme 46).²⁷⁷ Diverging from there, route A involved chemical amide coupling with *N*-methylhex-5-enylamine (**212**) followed by ketone reduction with a commercially available KRED to obtain (4*R*)-**209**, whereas route B followed the reverse order of events using another KRED enzyme in order to obtain (4*S*)-**209**. The (*R*)-selective KRED used in the first case proved to be more stereoselective (98.5 vs. 94% de), likely due to stereodiscrimination being facilitated by the presence of the bulky aliphatic amide, and thus route A was selected for scale-up to multikilogram scale. A Hoffmann-La Roche study had previously shown that stereoselective reduction of **207** using an (*R*)-selective Codexis KRED, instead of the (*S*)-selective KRED employed by Janssen Pharmaceuticals, was equally viable (94% yield, >93% ee).²⁷⁸

3.4.6 Grazoprevir and glecaprevir. Both macrocyclic grazoprevir and glecaprevir can be retrosynthetically disassembled in such a way that three out of six of their building blocks are non-canonical amino acids that could be conveniently obtained through biocatalysis as discussed above. Additionally, both anti-viral agents required incorporation of either (1*R*,2*R*)-2-(allyloxy)cyclopentanol (**218**) or the analogous (1*R*,2*R*)-2-(pent-4-ynyl)cyclopropanol (**219**, Chart 7).^{269,279,280}

Controlled hydrolytic resolution of cyclopentane-1,2-diyl diacetate (**222**) with BCL, *O*-alkylation with allyl bromide and subsequent deprotection afforded **218** in 14% overall yield and 96% ee (Scheme 47A).²⁷⁹ However, running regioselective lipase-catalysed resolution up to complete mono-deacetylation is challenging, thus often requiring termination of the reaction at the stage of sub-optimal conversion. The same Abbvie team that optimised the synthesis of difluoromethyl-ACCA also managed to improve the synthesis of (1*R*,2*R*)-2-(allyloxy)cyclopentanol.²⁶⁹ Ring-opening of cyclopentene oxide (**224**) with allyl alcohol,








Chart 7 Retrosynthetic analysis of glecaprevir and grazoprevir.



Scheme 47 Two complementary chemoenzymatic routes for the synthesis of (1*R*,2*R*)-2-(allyloxy)cyclopentanol by enzymatic resolution, effected either initially (A) or as the final step (B).²⁶⁹ BCL: Amano PS lipase (*Burkholderia cepacia*), CAL-B: *Candida antarctica* lipase B and DIPEA: *N,N*-diisopropyl-*N*-ethylamine.

acetylation and subsequent resolution with CAL-B allowed for isolation of the target molecule in 32% overall yield and >99% ee at pilot scale (Scheme 47B).

Multikilogram scale resolution of 2-(pent-4-ynyl)cyclopropyl acetate (**226**) with CAL-B as performed by Merck afforded the grazoprevir intermediate (1*R*,2*R*)-2-(pent-4-ynyl)cyclopropanol (**219**) with 92% ee (Scheme 48A).²⁸¹ As asymmetric synthesis would, however, be the preferred synthetic strategy, Merck also investigated biocatalytic cyclopropanation towards this fragment.²⁸² The team envisioned recently discovered new-to-nature carbene transfer onto activated alkenes catalysed by haemoproteins to achieve cyclopropanation. Use of the non-activated 5-chloropentene (**228**), however, proved to be challenging, but a mutant of Hells' Gate globin I (HGG) from *Methylophilium infernorum* was found to catalyse the desired reaction. Four rounds of directed evolution were required to obtain the Q50V/L54A/F43V/N45S mutant, which was sufficiently active and showed



Scheme 48 Synthesis of (1*R*,2*R*)-2-(pent-4-ynyl)cyclopropanol through enzymatic resolution (A)²⁸¹ or enzymatic asymmetric synthesis by carbene transfer (B)²⁸² followed by several chemical steps (I).²⁸¹ CAL-B: *Candida antarctica* lipase B, TFAA: trifluoroacetic anhydride and HGG: Hells' Gate globin I.

reasonable stereoselectivity (Scheme 48B). Preparative scale proof-of-concept cyclopropanation performed on **227** and **228** led to only 16% yield and 75% ee (99:1 *trans*-selectivity). Several chemical steps are thereafter needed to complete the synthesis of (1*R*,2*R*)-2-(pent-4-ynyl)cyclopropanol (**219**).²⁸¹ The promising nature of biocatalytic carbene transfer will be further discussed in chapter 5.

3.5 Fused multicyclic integrase inhibitors

In 2007, raltegravir was the first of several structurally related integrase inhibitors to be approved for combating HIV.²⁸³ Raltegravir is built up from three (hetero)cyclic fragments connected by short flexible linkers. The latest additions to this class of anti-viral agents are elvitegravir, dolutegravir and bictegravir, which instead are rigid fused multicycles. Additionally, all three of these integrase inhibitors contain an amino alcohol fragment that could be synthesised biocatalytically (Chart 8).

The amino alcohol moiety of elvitegravir, *L*-valinol, was produced on ton scale through reduction of *L*-valine.²⁸⁴ Several exemplary biocatalytic strategies have been developed that allowed for its synthesis from achiral starting material, however. Kroutil and co-workers discovered four transaminases capable of converting hydroxy-3-methyl-2-butanone (**233**) to *L*-valinol (**234**) using either isopropylamine or *D*-alanine as amine donor (Scheme 49A).²⁸⁵ More recently, a transaminase from *Mycobacterium vanbaalenii* was shown to catalyse this transformation, however, requiring the less sustainable aromatic (*R*)- α -methylbenzylamine ((*R*)-**150**) as amine donor.²⁸⁶ An interesting small scale cascading approach was taken by co-expressing the latter enzyme with an epoxide hydrolase and two alcohol dehydrogenases (ADHs) to allow for the conversion of epoxides to amino alcohols (Scheme 49B).²⁸⁷ Complete hydrolysis of racemic 2-isopropylloxirane (**236**) was achieved with a *Sphingomonas sp.* HXN-200 epoxide hydrolase. Subsequent oxidation of the resulting (*R*)- and (*S*)-**237** required the use of two ADHs with complementary (*R*)- and (*S*)-selectivity, namely 2,3-butanediol dehydrogenase from *Bacillus subtilis* and polyol dehydrogenase from *Gluconobacter oxydans*, respectively. The hydroxy-3-methyl-2-butanone product (**233**) was finally converted to *L*-valinol (**234**) by enantioselective transamination, which liberated acetophenone (**151**) as side-product. Its reduction





Chart 8 Structures of the fused multicyclic integrase inhibitors elvitegravir, dolutegravir and bictegravir.






Scheme 49 Transaminase (TA)-catalysed synthesis of L-valinol (A)²⁸⁵ and incorporation of a transaminase in a multi-enzymatic cascade for the synthesis of L-valinol from 2-isopropylloxirane (B).²⁸⁷ EH: epoxide hydrolase and ADH: alcohol dehydrogenase.^a Conversion to product.


by the ADHs allowed for closed-loop recycling of co-factor NAD⁺. In the search for complementary reductive amination biocatalysts, several *Lysinibacillus fusiformis* LeuDH variants²⁸⁸ were shown capable of also converting α -hydroxyketones to produce, among others, L-valinol with up to 96% ee.²⁸⁹

Also dolutegravir's (R)-3-aminobutanol building block can be accessed through reduction of the corresponding acid or its ester. The latter has been prepared through hydrolytic resolution with lipase or aminopeptidase, for example.^{290–293}

More interesting, however, is its asymmetric synthesis from readily available ethyl 3-oxobutanoate (239). Kroutil *et al.* have used an (R)-selective transaminase from *Arthrobacter sp.* (ATA-117) to synthesise ethyl (R)-3-aminobutanoate ((R)-240-Et) with 98% yield and 98% ee from 239 (Scheme 50).²⁹⁴ The use of D-alanine (D-235) as amine donor allowed coupling to a lactate dehydrogenase to convert the resulting pyruvate (175) to lactate (242) to shift the equilibrium to the product side. The same team also reported on several other transaminases capable of catalysing this transformation, including ArRmut11.²⁹⁵ The latter is a mutant of ATA-117 jointly developed by Merck and Codexis to perform late stage biocatalytic reductive amination towards the synthesis of the anti-diabetic sitagliptin.²⁹⁶ The vast majority of transaminases are (S)-selective, tolerate only a single large substituent on a ketone substrate and are specific for amino acid-based amine donors. In contrast, ArRmut11 is highly (R)-selective, accepts bulky substrates and can employ isopropylamine as amine donor. Its extensive engineering by directed evolution is considered to be one of the hallmarks of biocatalytic drug production.



Scheme 50 Transaminase (ATA-117)-catalysed synthesis of (R)-3-aminobutanoate.²⁹⁴ GDH: glucose dehydrogenase and LDH: lactate dehydrogenase.



Scheme 51 Mutation of a highly specific Aspartase to a Lyase capable of converting crotonic acid to (R)-3-aminobutanoic acid.²⁹⁹

By making use of a transaminase from *Actinobacteria sp.*, 4-hydroxy-2-butanone could be converted to (R)-3-aminobutanol directly, eliminating the need for additional carboxyl reduction.²⁹⁷ In order to further optimise (R)-3-aminobutanol production, Wei and co-workers mutated *Aspergillus terreus* transaminase to obtain the H55A/G126F/S215P triple mutant, which showed a 10-fold increase in $k_{\text{cat}} \cdot K_{\text{M}}^{-1}$ and improved thermostability as compared to the wild-type.²⁹⁸


In an alternative approach to (R)-3-aminobutanoic acid (240), Wu, Janssen and co-workers performed biocatalytic hydroamination of crotonic acid (244).²⁹⁹ *Bacillus sp.* YM55-1 aspartase was shown to be solely capable of catalysing the deamination of aspartate (243) to fumarate (165, Scheme 51). Screening of thousands of its mutants for expanded substrate scope proved to only be marginally successful.^{300,301} Therefore, the team engaged in a *in silico* modelling study to pin-point possible mutations that would likely support conversion of the target substrates. For the production of (R)-3-aminobutanoic acid, a small “smart library” of 34 enzyme variants was constructed, which, upon expression, resulted in 14 active enzymes. Use of the quadruple mutant B19 (T187C/M321I/K324L/N326A) allowed for the synthesis of (R)-3-aminobutanoic acid from crotonic acid with 92% yield and 99% ee on kilogram scale.

The third fused multicyclic integrase inhibitor to be discussed is bictegravir, which contains a (1R,3S)-3-aminocyclopentanol fragment that could be obtained through resolution. Resolution by transesterification with pancreatin or *Pseudomonas* lipase afforded the N-protected 4-aminocyclopent-2-en-1-yl acetate in the desired configuration (248/249, Scheme 52).^{302,303} In a complementary fashion, 4-acetamidocyclopent-2-en-1-yl acetate (247) could be resolved through chemoselective hydrolysis of its ester functionality with electric eel acetylcholinesterase.³⁰² Olefin reduction and deprotection would subsequently afford (1R,3S)-3-aminocyclopentanol (250).

3.6 Anti-influenza amino sugar derivatives

The first drug to be approved for treating influenza was achiral amantadine (adamantylamine).³⁰⁴ However, because most influenza viruses became resistant against this agent, it is no longer recommended for treatment of the common flu. The same holds for the analogous rimantadine (1-(adamantany)ethanamine). With the FDA-approval of the structurally more complex neuraminidase inhibitors oseltamivir and zanamivir in 1999, the number of anti-viral agents available for treating influenza has been doubled.³⁰⁵ Most influenza A and B viruses are currently still susceptible to these agents. Viral neuraminidase is involved in budding of the virus from its host cell upon hydrolysis of N-acetylneuraminic acid (Neu5Ac, 252), a process that proceeds through a boat-shaped





Scheme 52 Enzymatic kinetic resolution catalysed by electric eel acetylcholinesterase, *Pseudomonas* sp. lipase (PSL)³⁰² or pancreatin (PC)³⁰³ in the production of (1*R*,3*S*)-3-aminocyclopentanol, which serves as an intermediate in the synthesis of bictegavir.




Chart 9 Neu5Ac and the intermediate structure of the sialosyl cation upon dehydration by (viral) neuraminidase (A). Anti-influenza neuraminidase inhibitors indicating their functioning as transition state mimics (B).³⁰⁷


sialosyl cation intermediate (253, Chart 9).³⁰⁶ Modern-day neuraminidase inhibitors such as oseltamivir (254), zanamivir (255) and peramivir (256), act as mimics of this sialosyl cation.³⁰⁷

3.6.1 Oseltamivir. The anti-influenza drug oseltamivir contains three contiguous chiral centres which renders its synthesis challenging, but well-suited for applying biocatalytic methods. Because oseltamivir shows a high degree of similarity to shikimic acid, the first scalable route to oseltamivir started from this natural product.^{308,309} The demand for shikimic acid rose sharply upon oseltamivir approval, thus requiring additional sources besides its isolation from star anis.^{310,311} Naturally, *E. coli* does not accumulate shikimic acid, but rather uses it as an intermediate towards the synthesis of aromatic amino acids. In a pioneering multi-pronged metabolic re-engineering approach, Frost and co-workers managed to develop an *E. coli* strain capable of accumulating shikimic acid.³¹² Coupling of two products from the glycolysis pathway, phosphoenol pyruvate (PEP, 257) and erythrose 4-phosphate (E4P, 258) could be achieved with 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase (aroF, Scheme 53A). However, as wild-type aroF was susceptible to inhibition by aromatic amino acids, it was replaced by a mutant isozyme (aroF^{FBR}) that was less prone to inhibition. Insertion of an additional aroB gene that encoded for 3-dehydroquininate synthase (DHQS) ensured that the rate-limiting formation of 3-dehydroquinic acid (DHQ, 261) from 3-deoxy-D-arabino-heptulosonic acid 7-phosphate (DAHP, 259) was of lesser influence on the

rate of the entire cascade. DHQ was subsequently converted to 3-dehydroshikimic acid (DHS, 262) by 3-dehydroquininate dehydratase (DHT) which was thereafter reduced to shikimic acid (263) by overexpressed shikimate dehydrogenase (SDH). SDH could also reduce DHQ, resulting in the undesired formation of quinic acid (265). Its formation could, however, be suppressed by increasing the influx of glucose (90) in the fed-batch fermenter. Additional disruption of the *E. coli* aroK and aroL genes restricted 3O-phosphorylation of shikimic acid and led to 20.2 g L⁻¹ shikimic acid. Quinic acid contamination was sufficiently low to allow for purification of shikimic acid through crystallisation.


Active equilibration of the formed shikimic acid to quinic acid limited purity of the non-isolated product. The yield of shikimic acid could be optimised by, among others, carefully controlling the amount of glucose in the medium.³¹³ Through optimisation of the glycolysis pathway, PEP production could be maximised, which thereby allowed for further optimisation of shikimic acid production up to 87 g L⁻¹ and 36% yield from glucose.³¹⁴ The by-product quinic acid could also serve as a source of shikimic acid through strategic application of several *Gluconobacter oxydans* enzymes.³¹⁵ Metabolic engineering aspects for further optimisation of microbial shikimic acid production continue to arouse attention.^{316–319}

Oseltamivir (254) could, alternatively, be synthesised from aminoshikimic acid (267, Scheme 53B),³²⁰ which in turn can be produced through fermentation employing either a single engineered microbe or two microbes in tandem.³²¹



Scheme 53 Production of the oseltamivir (see insert) intermediate shikimic acid through fermentation with an engineered *E. coli* strain (A).³¹² Production of aminoshikimic acid through fermentation with either multiple strains or a single bacterium (B).³²¹ PEP: phosphor-enol pyruvate, E4P: erythrose-4-phosphate, aroF^{FBR}: 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase mutant, DAHP: 3-deoxy-D-arabino-heptulosonic acid 7-phosphate, DHQS: 3-dehydroquininate synthase, DHQ: 3-dehydroquinic acid, SDH: shikimate dehydrogenase, DHT: 3-dehydroquininate dehydratase, DHS: 3-dehydroshikimic acid, aroK/aroL: shikimate phosphorylation enzymes and S3P: shikimic acid 3-phosphate.






Scheme 54 Oxidative fermentation of bromobenzene and ethyl benzoate catalysed by microbes expressing toluene dioxygenases (TDOs).


Oxidation of bromobenzene (268) or ethyl benzoate (269) catalysed by organisms expressing toluene dioxygenases (TDOs) led to the formation of the corresponding *cis*-diols (Scheme 54).^{322–325} Either of both diols has been employed as starting material for the synthesis of oseltamivir.^{324–327}

As for many of the molecules discussed throughout this work, enzymatic resolution/desymmetrisation has proven to be an effective tool for generating optically active oseltamivir intermediates too.^{328–330} The most intriguing example of which has been reported by Wirz and co-workers as it involves stereoselective hydrolysis of a densely functionalised intermediate (Scheme 55).³²⁸ The synthesis started from 2,6-dimethoxyphenol (272) which was chemically converted to 273. Ruthenium-catalysed all-*cis*-hydrogenation of 273 followed by demethylation afforded 275. Subsequent pig liver esterase (PLE)-catalysed desymmetrisation resulted in the mono-acid 276 in 98% yield and excellent enantiopurity (>96% ee). Subsequent chemical steps furnished oseltamivir as its phosphate salt.

3.6.2 Zanamivir and laninamivir octanoate. As with oseltamivir, zanamivir has initially been synthesised by starting from a natural product, that is, the sialic acid *N*-acetylneuraminic acid (Neu5Ac or NANA).³³¹ A modified version of this route has since been employed on industrial scale.³³² Neu5Ac can be isolated from edible bird's nests and has been produced through fermentation of cheap carbon sources such as glucose and glycerol.^{333–335} Industrially relevant titres of 39 g L⁻¹ have previously been reported for this transformation. More common, however, is the formation of Neu5Ac (280) by enzymatic aldol addition of pyruvate (175) to *N*-acetylmannosamine (ManNAc, 279) using neuraminic acid (Neu5Ac) aldolase (also referred to as Neu5Ac lyase; Scheme 56).^{336–340} Epimerisation of the economically more desirable *N*-acetylglucosamine (GlcNAc, 278) with base or an epimerase enzyme allowed for the *in situ* production of ManNAc.^{341–348} Pyruvate could also be generated *in situ* from lactate using lactic acid oxidase (LOX).³⁴⁹



Scheme 55 Chemoenzymatic route towards oseltamivir as developed by Wirz and co-workers. TMSI: iodo(trimethyl)silane and PLE: pig liver esterase.³²⁸




Scheme 56 (Chemo)enzymatic synthesis of *N*-acetylneuraminic acid (Neu5Ac). GlcNAc: *N*-acetylglucosamine and ManNAc: *N*-acetylmannosamine.

The pro-drug laninamivir octanoate (277) is an analogue of zanamivir that has been approved for the treatment of influenza in Japan.³⁵⁰ It differs from zanamivir in that the hydroxy group in the 7-position is methylated and its 9-hydroxy group is esterified to the corresponding octanoate ester. Analogous to the synthesis of zanamivir, a Neu5Ac aldolase-catalysed addition of pyruvate to 4-OMe-ManNAc afforded the 7-OMe-Neu5Ac intermediate required for the synthesis of laninamivir.³⁵¹

3.6.3 Peramivir. The densely functionalised cyclopentane-based influenza drug peramivir (256, Chart 9) has been synthesised chemically from (1*S*,4*R*)-4-aminocyclopent-2-enecarboxylic acid.³⁵² The latter could in turn be obtained through lactamase-catalysed resolution of Vince-lactam as described for abacavir (Section 3.1.4).

3.7 Miscellaneous compounds

3.7.1 Ledipasvir. Ledipasvir belongs to a group of non-structural protein 5 inhibitors (NS5A) employed against the hepatitis C virus,³⁵³ all of which bear a central rigid, largely aromatic, scaffold flanked on two sides by methyl carbamate-capped dipeptide mimics. The peptidic parts of ledipasvir (281) contain a spirocyclic proline analogue on one side and a bridged bicyclic proline analogue on the other (Scheme 57). Indeed, both unnatural amino acids have been employed in the synthesis of ledipasvir by Gilead Sciences.³⁵³ Alkyl esters of both the *N*-Boc-protected spirocyclic (282) and bridged bicyclic (284) proline derivatives could be resolved with CAL-B and PPL, respectively (Scheme 57).^{354,355}




Scheme 57 Structure of ledipasvir (A). Enzymatic resolution of *N*-Boc-protected esters of the ledipasvir proline derivatives (B).^{354,355} CAL-B: *Candida antarctica* lipase B and PPL: porcine pancreas lipase.



3.7.2 Maraviroc. The HIV drug maraviroc blocks the interaction between the chemokine receptor type 5 and envelope glycoprotein GP120.³⁵⁶ A Pfizer team described the synthesis of maraviroc from β -phenylalanine *via* the correspondingly reduced aldehyde and alcohol derivatives.³⁵⁷ The amino acid β -phenylalanine constitutes a particularly interesting target for biocatalytic production.

Resolution of the corresponding ester or amide has been achieved using various enzymes.^{358–362} Many lipases are known to show enhanced activity on the interface of water and an immiscible co-solvent. Gröger *et al.* exploited this feature by employing BCL to resolve the β -phenylalanine butyl ester in “mini-emulsions” generated through ultrasonication.³⁶³ This technique allowed for substrate concentrations to exceed 3 M, while still maintaining excellent ee (>99%) and high conversion. Concomitant *in situ* racemisation, as developed by Bäckvall and co-workers, allowed for DKR of the β -phenylalanine ethyl ester (**286**) with CAL-A with 89% or 96% ee using a ruthenium or palladium catalyst, respectively (Scheme 58A).^{364,365} Although amides are usually not substrates for lipases, Fülöp and co-workers achieved highly stereoselective resolution of strained 4-phenylazetididin-2-one (**289**) at elevated temperatures to furnish the pure (*S*)- β -lactam (*S*)-**289** as a precursor to the desired *L*- β -phenylalanine (*L*-**290**, Scheme 58B).³⁶⁶

Janssen and co-workers developed a mutated phenylalanine aminomutase (PAM) capable of enantioselectively converting *D*- β -phenylalanine to *L*-phenylalanine (**292**), which could thus be employed to resolve racemic β -phenylalanine.³⁶⁷ Quasi-irreversible conversion of *L*-phenylalanine to cinnamic acid (**293**) by phenylalanine ammonia lyase (PAL) provided for the driving force and allowed for facile isolation of the *L*- β -phenylalanine product (*L*-**290**, Scheme 58C). The large structural similarity between PAM and PAL drove the research team to engineer another PAM mutant (R92S) that showed additional



Scheme 58 Enzymatic resolution of β -phenylalanine (derivatives). Dynamic kinetic resolution of the β -phenylalanine ethyl ester with *Candida antarctica* lipase A (CAL-A, A),^{364,365} resolution of 4-phenylazetididin-2-one with *Candida antarctica* lipase B (CAL-B, B),³⁶⁶ and bienzymatic resolution of β -phenylalanine with a phenylalanine aminomutase (PAM) mutant and phenylalanine ammonia lyase (PAL, C).³⁶⁷ ^aConversion to product.

PAL activity,³⁶⁸ which allowed for the resolution of racemic β -phenylalanine by direct deamination of *D*- β -phenylalanine (48% yield, >97% ee).

The aspartase that had been mutated to a lyase capable of producing (*R*)-3-aminobutanoic acid (Section 3.5, Scheme 51) could also be mutated as such that it would catalyse the hydroamination of cinnamic acid to form *L*- β -phenylalanine (>99% ee).²⁹⁹ However, conversion did not exceed 50% due to the unfavourable reaction equilibrium.


L- β -Phenylalanine could also be produced directly by transamination of 3-oxo-3-phenylpropanoic acid (**295**), which did prove to be a rather chemically unstable substrate. Such limitations could, however, be partially offset through lipase-catalysed *in situ* saponification of ethyl 3-oxo-phenylpropanoate (**294**, Scheme 59).³⁶⁹ In the presence of an (*S*)-transaminase from *E. aerosaccus* the β -oxoacid was subsequently converted to *L*-**290** at the expense of 3-aminobutyric acid (**240**) as the amine donor (82% conversion to product, >99% ee). (*S*)-transaminases from *Sphaerobacter thermophilus*,^{370,371} *Polaromonas sp.*³⁷² and a β -amino acid dehydrogenase from *Candidatus cloacamonas acidaminovorans* have also been proven capable of catalysing said transformation.³⁷³ Replacing lipases with nitrilases in the cascade conversion allowed for the use of 3-oxo-3-phenylpropanenitrile as alternative starting material.^{370,372,373} In those cases where isolated yields have been reported for the lipase- or nitrilase-transaminase cascade, however, the amount of isolated material from these small scale experiments remains low.

In order to circumvent the use of the unstable β -oxoacid, Rudat and co-workers employed a mutated transaminase to convert the corresponding ethyl ester, but the enantiopure *L*- β -phenylalanine ethyl ester could only be isolated in 9% yield.³⁷⁴

(*S*)-3-Amino-3-phenylpropanol can also be converted to maraviroc upon conversion of the alcohol to a good leaving group.³⁵⁷ Resolution of various protected 3-amino-3-phenylpropanol derivatives could be achieved using either lipase or penicillin G acylase.^{375,376}


3.7.3 Podophyllotoxin. Podophyllotoxin (podofilox) is a plant natural product that is used for the treatment of warts caused by infection with the human papilloma virus (HPV).³⁷⁷ Among the several synthetic routes towards this drug, Maeng and co-workers applied PPL-catalysed desymmetrisation of the bridged tricyclic diacetate **297** to achieve the desired stereoconfiguration (Scheme 60A).³⁷⁸ Most of the reported chemical routes, however, are rather lengthy, limiting their utility.

Elucidation of the biosynthetic route to podophyllotoxin in 2015 revealed a 2-oxoglutarate-dependent dioxygenase (2-ODD) that catalysed the crucial cyclisation of yatein to deoxy-



Scheme 59 *In situ* de-esterification with lipase and subsequent transaminase (TA)-catalysed synthesis of *L*- β -phenylalanine.³⁶⁹ ^aConversion to product.






Scheme 60 Desymmetrisation of a podophyllotoxin intermediate with porcine pancreas lipase (PPL, A).³⁷⁸ Two concurrent routes to podophyllotoxin based on (hydroxy)-yatein cyclisation with the 2-oxoglutarate-dependent dioxygenase from *Podofyllum hexandrum* (2-ODD-PH, B and C).^{380,381} ^aBased on recovered starting material.


podophyllotoxin.³⁷⁹ Recently, both Fuchs *et al.* and Renata *et al.* have independently employed the dioxygenase from *Podofyllum hexandrum* (2-ODD-PH) to achieve the synthesis of podophyllotoxin itself.^{380,381} Multigram scale resolution of racemic hydroxy-yatein (**300**) through selective conversion of (–)-hydroxy-yatein to epipodophyllotoxin (*epi*-**299**) using 2-ODD-PH had been shown by Fuchs and co-workers (Scheme 60B). Subsequent chemical steps furnished podophyllotoxin (**299**) in 32% overall yield. The synthesis by Renata and co-workers involved chemical synthesis of (–)-yatein (**301**), its 2-ODD-PH-catalysed conversion to deoxy-podophyllotoxin (**302**), subsequent chemical oxidation and stereoselective reduction to podophyllotoxin (28% overall yield, Scheme 60C). These chemoenzymatic routes could thereby compete with the most efficient chemical syntheses.³⁸²

3.7.4 Tipranavir. The anti-HIV drug tipranavir is a protease inhibitor that was approved by the FDA in 2005.³⁸³ Its chiral building block (*S*)-1-(3-nitrophenyl)propanol ((*S*)-**303**) could be obtained through resolution by transesterification with BCL (Scheme 61).³⁸⁴

3.7.5 Efavirenz. Efavirenz is a non-nucleoside reverse transcriptase inhibitor used for the treatment of HIV.³⁸⁵ Its synthesis involves



Scheme 61 Kinetic resolution of the tipranavir intermediate 1-(3-nitrophenyl)propanol with *Burkholderia cepacia* Amano PS lipase (BCL).³⁸⁴




Scheme 62 Synthesis of (1*R*,2*S*)-phenyl-2-(pyrrolidinyl)propanol through reduction with a ketoreductase (KRED) and its implementation as chirality inducer in the synthesis of an efavirenz intermediate.^{386,387} GDH: glucose dehydrogenase and PMB: *p*-methoxybenzyl.

acetylide (**309**) addition to a ketone precursor (**308**) to result in the formation of a chiral quaternary centre (Scheme 62).³⁸⁶ Enantioselectivity is induced through addition of lithium (1*R*,2*S*)-phenyl-2-(pyrrolidinyl)propanolate (**307-Li**). A recent patent disclosed the pilot scale synthesis of **307-H** through stereoselective KRED-catalysed reduction of the corresponding ketone (**306**).³⁸⁷ Co-factor recycling was enabled through the use of isopropanol as sacrificial co-substrate or by addition of glucose/glucose dehydrogenase.


3.7.6 Nevirapine. Like efavirenz, nevirapine is a non-nucleoside reverse transcriptase inhibitor used as anti-HIV drug. Nevirapine is achiral and synthesised from 2-chloronicotinic acid (**314**).³⁸⁸ Preparation of the latter has been achieved by whole cell-catalysed conversion of 2-chloronicotinonitrile (**312**) based on nitrile hydratase activity, or by separate amidase-catalysed hydrolysis of the intermediate 2-chloronicotinamide (**313**, Scheme 63).^{389,390} Both processes, however, are of limited utility as the costs of both **312** and **313** are higher than that of the product **314**.

3.7.7 Docosanol. The fatty alcohol docosanol (**323**, Scheme 64) has been approved as an over-the-counter drug for topical treatment of HSV in 2000.³⁹¹ David and co-workers enabled docosanol production in *S. cerevisiae* (yeast) through engineering of its fatty acid metabolism.³⁹² Overexpression of a mutated acetyl coenzyme A (acetyl-CoA) carboxylase (Acc1)³⁹³ and introduction of an additional (mycobacterial) fatty acid synthase (FAS) system, the FAS I system from *M. vaccae*, were the key engineered elements (Scheme 64). FAS is a multimeric enzyme that catalyses the formation of long-chain fatty acids from acetyl-CoA (**316**) and malonyl-CoA (**317**). Heterologous expression of *M. vaccae* FAS I in *S. cerevisiae* merely led to C₂₆, rather than C₂₂ fatty acid



Scheme 63 Biocatalytic synthesis of the nevirapine intermediate 2-chloronicotinic acid.^{389,390}





Scheme 64 Docosanone production through fermentation with heavily engineered microbes.³⁹² Acc1: acetyl-CoA carboxylase, FAS: fatty acid synthase, Elo1-3: elongase 1-3 and FAR: fatty acid reductase.

accumulation, however. Disruption of native elongase Elo3 (β -ketoacyl-CoA synthase) and overexpression of Elo1 and Elo2 was required to realise selective formation of C_{22} fatty acids. Docosanone (323) was subsequently synthesised through reduction of the C_{22} fatty acid by implementation of an *Arabidopsis thaliana* fatty acid reductase. Fatty acid reductase overexpression, however, led to inhibited cell-growth. The latter could be compensated through dynamic control of gene expression, which resulted in a docosanone production of 84 mg L^{-1} .

4. Biocatalytic production of potential SARS-CoV-2 anti-viral agents

The immense impact and current lack of an effective cure for COVID-19 has led to numerous global ventures aimed at repurposing (anti-viral) small-molecule drugs for the treatment of this SARS-CoV-2-induced disease.^{394,395} The sheer size of the COVID-19 pandemic with the need for treatment of millions of patients requires significant scale-up of the potential anti-viral agents of interest. Economical scale-up of such drug candidates has only been the topic of a limited number of studies.³⁹⁴

Emergence of new forms of influenza such as the highly pathogenic and life-threatening avian influenza virus H5N1 has already identified critical supply issues for the only orally effective drug oseltamivir.³⁹⁶ Bottlenecks in its synthesis were caused by the limited availability of the required natural feed-stock chemicals (quinic acid or shikimic acid; see Section 3.6.1, Scheme 53), potentially hazardous intermediates, and demanding purification steps. Scarcity of the drug thereby spurred the development of several novel synthetic routes with improved scalability.^{397,398} Notwithstanding the need for bulk supply of starting materials, biocatalysis might offer a sustainable solution to the scalable mass production of pharmaceuticals, as emphasised throughout this manuscript. Crucial factors regarding the effectiveness of biocatalysis include the high selectivity of enzymes and the self-replicating nature of biological systems used for their production.

Here we would like to highlight some biocatalytic opportunities and strategies towards the synthesis of anti-viral agents against SARS-CoV-2 that underwent, or are currently undergoing, phase III clinical trials. As no definitive conclusion can yet be drawn

regarding the effect of any such agents, we have chosen a diversity-oriented approach, focussing on various targets that would highlight the potential of biocatalysis. Inclusion in this panel should not be regarded as proof of treatment effectiveness.

4.1 Remdesivir

Gilead's remdesivir had been shown active against the RNA virus Ebola and is currently considered to be one of the most promising drugs for treating patients infected with SARS-CoV-2, which too is an RNA virus.³⁹⁹ Remdesivir is an investigational drug that has not been FDA-approved but it is the first medicine against COVID-19 to be recommended for authorisation in the EU as of late June 2020.⁴⁰⁰ It is also authorised in the United States under an Emergency Use Authorization (EUA) for the treatment of patients with severe COVID-19.⁴⁰¹ Resembling AMP, it is a nucleotide pro-drug that has the major benefit of being resistant to proofreading exonucleases occurring in coronaviruses, thus evading the repair mechanism for preservation of its anti-viral activity.⁴⁰²


Apart from the heteroaromatic moiety mimicking the nucleobase, remdesivir (327) is made up from a sugar and chiral phosphoramidate building block. Remdesivir has been synthesised by starting from perbenzylated ribonolactone (*D*-ribo-1,4-lactone (326), Scheme 65).⁴⁰³ Ribonolactone can be obtained through enzymatic oxidation of ribose with *Agaricus meleagris* pyranose dehydrogenase.⁴⁰⁴ *Yarrowia lipolytica* short-chain dehydrogenase also proved capable of oxidising 5-*O*-trityl-*D*-ribose.⁴⁰⁵

Remdesivir bears a Pro-Tide ligand allowing for improved bioavailability. It was shown that the related Pro-Tide ligand of sofosbuvir could be enzymatically resolved to obtain the desired (*S*)-enantiomer.⁸⁹ Appreciating that the remdesivir phosphoramidate only differs from its sofosbuvir counterpart through the presence of a slightly elongated ester fragment (2-ethylbutyl vs. isopropyl alanine ester), makes it highly likely that this fragment could be obtained through enzymatic resolution as well.

A critical step in the synthesis of remdesivir is the installation of the cyanide group at the pseudo-anomeric centre. Currently, adequate biocatalytic methods for installing the chiral quaternary centre are lacking. Novel C–C bond forming enzymes are required to catalyse the desired transformation, since neither the enzymes involved in the biosynthesis of *C*-nucleosides,⁴⁰⁶ nor known oxynitrilases match the requirements.⁴⁰⁷


4.2 (Hydroxy)chloroquine

The anti-malarials chloroquine (328) and hydroxychloroquine (329) (Scheme 66A) had been speculated to be potential anti-viral agents against SARS-CoV-2 soon after the outbreak of



Scheme 65 Gilead developed the synthesis of remdesivir from Ribonolactone.^{399,403}





Scheme 66 Structures of chloroquine and hydroxychloroquine (A). Resolution of N^1,N^1 -diethylpentane-1,4-diamine catalysed by *Candida antarctica* lipase B (CAL-B) and dodecanoic acid as acyl donor (B).⁴¹² Kinetic resolution (KR) and dynamic kinetic resolution (DKR) of N^1,N^1 -diethylpentane-1,4-diamine to produce the corresponding (*R*)-amide (C).⁴¹⁴

the virus.⁴⁰⁸ However, their efficiency and potential have not remained undisputed.⁴⁰⁹

Because both anti-malarial agents are used as racemates, they have as such also been tested in racemic form during COVID-19 trials. However, it is unknown whether both enantiomers can act as active pharmaceutical ingredient. It has been proposed to repurpose these drugs *via* a chiral switch strategy, thus either as enantiopure (*R*)- or (*S*)- (hydroxy)chloroquine.^{410,411}

Gil and co-workers have shown that the diamine fragment of chloroquine, N^1,N^1 -diethylpentane-1,4-diamine (**330**), could rapidly be resolved with immobilised CAL-B (Novozym 435, Scheme 66B) and dodecanoic acid (**318**) as acyl donor.⁴¹² Both the remaining (*S*)-amine (*S*)-**330** and the formed (*R*)-amide **331** were isolated with > 99% ee at small scale. The unique stability features of CAL-B were highlighted once more as resolution was best performed at 80 °C. The same group also managed to perform dynamic kinetic resolution through thiyl radical-mediated racemisation to produce the (*R*)-amide **333** (resolution with CAL-B, Scheme 66C).^{413,414} As thiyl radical formation was performed photocatalytically, DKR reaction times could easily be tuned by turning irradiation on and off. By employing a three-step, one-pot procedure, starting with initial (non-dynamic) kinetic resolution, the (*R*)-amide could be isolated in 62% yield and 90% ee. Although this DKR procedure was shown to be efficient for the formation of other (*R*)-amides, DKR of N^1,N^1 -diethylpentane-1,4-diamine (**330**) proved to be less efficient as compared to conventional CAL-B-catalysed resolution. Biocatalytic reductive amination catalysed by transaminases or recently discovered reductive aminases (*vide infra*) would allow for the use of a non-chiral ketone as starting material and might result in enhanced stereoselectivity, even at room temperature.

4.3 Azithromycin

Azithromycin is an FDA-approved anti-bacterial macrolide that, commonly in combination with hydroxychloroquine, has gone through various clinical trials in order to establish its




Chart 10 Bioretrosynthetic analysis of azithromycin.

effectiveness in combating COVID-19.^{408,409,415} This semisynthetic drug (**335**) is obtained from erythromycin A (**336**) through chemical oxime formation, Beckmann rearrangement and *N*-methylation (Chart 10).⁴¹⁶ Erythromycin A, also used as antibiotic, is in turn commonly produced through fermentation.^{417,418} Strains that have proven capable of naturally accumulating erythromycin A, such as *Streptomyces coelicolor* and *Streptomyces lividans* do so in small amounts only. Transfer of gene clusters from these strains to optimised overexpressing strains (*S. erythraea*) led to an approximate 50-fold increase in titres for erythromycin analogues.⁴¹⁹

The azithromycin precursor erythromycin is commonly isolated as a mixture of the congeners A–C. Because erythromycin A purity is essential for effective azithromycin production, minimising the production of the congeners B and C is crucial. Accumulation of erythromycin B and C could be almost completely abolished through regulation of the *EryK* and *EryG* genes, coding for a P450 hydroxylase and an (*S*)-adenosylmethionine-dependent *O*-methyltransferase, respectively.⁴²⁰


A crucial intermediate towards the biosynthesis of erythromycin A is the polyketide 6-deoxyerythronolide B (**337**, Chart 10). This non-glycosylated precursor could either be obtained through the use of metabolically engineered microorganisms or isolated enzymes.^{421,422} While 6-deoxyerythronolide B could be produced efficiently (> 1 g L⁻¹) in an *E. coli* host,^{423,424} erythromycin production using this bacterium has proven to be much less effective (< 0.1 g L⁻¹).^{425,426}

4.4 Dexamethasone

Very recently (mid 2020), the corticosteroid dexamethasone received considerable attention. In preliminary studies the use of the drug resulted in a reduction of the COVID-19 mortality rate for patients on mechanical ventilation by about one third.⁴²⁷ This result is not based on anti-viral activity but on the potent anti-inflammatory effects of the steroid. Patients with severe COVID-19 can develop a systemic inflammatory response that can lead to lung injury and multisystem organ dysfunction, and it has been proposed that dexamethasone might prevent or mitigate these deleterious effects.

Production of this drug starts from other steroid precursors and commonly involves biocatalysis, as is typical for the steroid field, which often requires regio- and stereospecific functionalisation at unreactive aliphatic positions.^{428,429} Although detailed procedures are scarce, early stage microbial dehydrogenation of





Scheme 67 Chemoenzymatic synthesis of dexamethasone from steroid precursors.

341 and subsequent chemical steps have allowed for the production of Dexamethasone (**340**, Scheme 67).⁴³⁰ Late stage microbial dehydrogenation at the Δ^1 -position and deacetylation of **338** afforded **339**,⁴³¹ which, upon HF-mediated epoxide ring-opening⁴³² also led to dexamethasone. Deacetylation of dexamethasone acetate has been achieved with *Penicillium decumbens* ATCC 10436, albeit in only 5% yield.⁴³³

4.5 Darunavir and TMC-310911

The peptidomimetic anti-viral agent darunavir has already been discussed above related to its FDA-approval for the treatment of HIV infections (Sections 3.3.2 and 3.3.5). TMC-310911 (also called ASC-09) is an analogue of darunavir developed by Johnson & Johnson, which was intended for the treatment of HIV. The latter is now also being trialled for treating SARS-CoV-2-infected patients (Chart 11).⁴³⁴ Thus, all biocatalytic strategies towards the chiral building blocks of darunavir also apply to TMC-310911. Both the biocatalytic synthesis of its (2*S*,3*S*)-1,3-diamino-4-phenylbutan-2-ol (DAPB) core as well as resolution approaches towards 3-OH-bis-THF have been extensively researched.

4.6 Danoprevir

Danoprevir is a bis-cyclopropyl-based protease inhibitor that is currently being considered for treating SARS-CoV-2 infections (Chart 12).⁴³⁵ As discussed previously for its structural analogue paritaprevir, all amino acid components from which danoprevir's macrocyclic fragment is built-up, could be obtained through biocatalysis (see Section 3.4). This includes, for example, proline 4-hydroxylase-catalysed hydroxylation of to obtain L-hydroxyproline and the synthesis of L-6-heptenylglycine with leucine dehydrogenase. Several approaches towards the enzymatic resolution of (1*R*,2*S*)-




Chart 11 Darunavir and TMC-310911 with the (2*S*,3*S*)-1,3-diamino-4-phenylbutan-2-ol (DAPB) core and the 3-OH-bis-THF capping ligand highlighted in blue.




Chart 12 Danoprevir with its unnatural amino acid fragments highlighted; L-6-heptenylglycine and (1*R*,2*S*)-amino-2-vinylcyclopropanecarboxylic acid (vinyl-ACCA) in blue and L-hydroxyproline in red.

amino-2-vinylcyclopropanecarboxylic acid (vinyl-ACCA) have additionally been developed.


4.7 Ruxolitinib

Faster clinical improvement was observed in COVID-19 patients treated with ruxolitinib (**349**), although quantitative evidence for the effect of this drug is yet lacking.^{436,437} The (*S*)-3-cyclopentyl-3-hydroxypropanenitrile precursor (**346**) could be obtained biocatalytically. Enzymatic reduction of 3-cyclopentyl-3-oxopropanenitrile (**345**) with a yeast short-chain dehydrogenase (YMR226C) resulted in the formation of the hydroxylated fragment in 89% yield and >99% ee (Scheme 68). Subsequent coupling with 4-bromo-1*H*-pyrazole (**347**) under Mitsunobu conditions allowed for the desired reversal of stereochemistry.⁴³⁸

5. Emerging enzyme classes – challenges and opportunities in the synthesis of anti-viral agents

As shown through the examples discussed above, biocatalysis has evidently matured into an essential tool for modern, cost effective manufacturing of (chiral) anti-viral agents and their intermediates. There is, however, still a huge untapped potential as numerous enzymes, and their corresponding activities, have yet to be explored to match the available reaction scope of chemical conversions. Additionally, the synthesis of only a limited number of industrially relevant molecules have been pursued by means of enzyme catalysis, leaving the vast majority of demanding molecular architectures still to be investigated.

The renewable nature of enzyme catalysts not only brings significant benefits from an environmental perspective but also stabilises catalyst costs.⁴³⁹ Although biocatalysis thus provides



Scheme 68 Chemoenzymatic synthesis of a ruxolitinib intermediate with a yeast short-chain dehydrogenase.⁴³⁸



considerable merits as a complementary technology to 'traditional' synthesis/catalysis, it is subject to certain limitations and challenges, too. While numerous vendors nowadays provide various off-the-shelf chemical catalysts, the number of catalogued enzymes of a certain type can be rather narrow or absent. A few enzyme classes such as lipases or KREDs are well established. There are, however, still gaps in the biocatalytic toolbox, although many recently discovered enzyme classes are being rapidly developed in both academia and industry.³³

Of particular significance are nucleoside analogues and peptidomimetics as these types of anti-viral agents directly interfere with unique stages of the viral replication cycle (Fig. 1). By discussing specific requirements of these drug structures as well as the technologies for making and coupling suitable synthetic intermediates, this chapter serves as an outlook into the future needs of biocatalytic anti-viral drug development, highlighting the potential of novel or engineered enzymes.


The importance of nucleoside analogues in treating viral infections lies in their versatility. These drugs typically target viral replication at stages A to C (Fig. 1), where they mimic the natural substrates by variation of both the nucleobase and the sugar core components.

While enzymatic approaches towards several nucleoside sugar moieties have been developed throughout recent years, biocatalytic nucleobase synthesis has only been marginally explored. Currently, synthesis of nucleobase analogues mostly relies on conventional cyclocondensation reactions using various simple building blocks.^{440–442} Recent studies showed that biocatalytic synthesis of simple unsaturated/aromatic *N*-heterocycles can be achieved using transaminases and imine reductases.^{443,444} In the future, such enzymatic conversions might also become applicable for the synthesis of analogues of purines and pyrimidines.

Functionalisation of the nucleobase is often required in order for the nucleoside analogue to show improved affinity/selectivity (*i.e.* islatravir and abacavir). Biocatalytic alternatives to metal-catalysed functionalisation strategies might be of value here, too. Currently, several enzymes have already been shown to be capable of functionalising *N*-heterocycles such as tryptophan and indole, for example.^{445–447} The importance of other enzymatic (late-stage) C–H functionalisation will be elaborated on in more detail towards the end of this chapter.

Similarly, decoration of the nucleoside's sugar core is often required in order for the drug to selectively inhibit viral protein targets. Examples of nucleoside analogues bearing such additional functional groups are sofosbuvir, remdesivir and islatravir, which contain fluoro, cyano or alkynyl branching, respectively. Biocatalytic access to such non-natural structural elements requires novel enzymes with innovative reactivity and tolerance for unusual substrates.

The synthesis of Sofosbuvir's fluorinated sugar core through chemical aldol addition, as discussed previously, provides an excellent example for highlighting the potential of enzyme catalysis upon prospective protein engineering. Sofosbuvir's sugar fragment has been prepared through a lithium diisopropylamide (LDA)-promoted aldol addition of ethyl 2-fluoropropanoate (27) to (*R*)-glyceraldehyde acetonide (26).⁸⁰ However, this reaction



Scheme 69 Lithium diisopropylamide (LDA)-catalysed aldol addition towards the sofosbuvir intermediate (*2R,3R*)-**28** as developed by HC-Pharma (A).⁸⁰ Enzymatic aldol reaction of (*R*)-glyceraldehyde and fluoro-pyruvic acid as developed by Chang *et al.*⁴⁴⁸ SwHpcH1: *Sphingomonas wittichii* aldolase and EcHpcH: *E. coli* aldolase.

resulted in a mixture of stereoisomers that required additional resolution and down-stream purification in order to isolate (*2R,3R*)-**28** in pure form (Scheme 69A). This type of transformation would thus likely profit from the use of a biocatalyst as these often provide excellent stereoselectivity. Chang and co-workers have recently reported on the aldolase-catalysed addition of fluoro-pyruvic acid (**352**) to unprotected (*R*)-glyceraldehyde (**351**). Treatment of the resulting aldol product with hydrogen peroxide resulted in the formation of carboxylic acid **353**, which is structurally similar to **28** (Scheme 69B).⁴⁴⁸ Use of either an aldolase from *Sphingomonas wittichii* (SwHpcH1) or *E. coli* (EcHpcH) resulted in quantitative conversion of starting material with a strong preference towards the anti-product. By mutating the leucine in position 212 to phenylalanine, EcHpcH was made to favour formation of the desired (*3R*)-product, albeit at the expense of enzyme activity.

Clearly, significant further development is needed to arrive at the sugar core of sofosbuvir, including enzyme engineering to adapt for fluorinated oxobutanoate as nucleophile. Nonetheless, the use of an enzyme-catalysed reaction to furnish sofosbuvir's sugar core would be a more sustainable alternative to harsh wasteful chemical aldol addition. Indeed, aldolases are of particular synthetic value as they allow for the stereoselective construction of complex molecular architectures through C–C bond formation as exemplified by the stereospecific construction of islatravir's and zanamivir's central frameworks from simple building blocks.

In order to attain the correct oxidation state of the aldose moiety in sofosbuvir, the resultant fluorocarboxylic acid intermediate (analogous to **353**) would need to be reduced to a fluoroaldehyde. Aldehyde functionalities are sensitive and readily oxidise to carboxylic acids, which is why selective oxidation or reduction to an aldehyde species can be challenging to control. The ability of enzymes to perform orthogonal reactions in water allows for *in situ* generation of (labile) intermediates to enable cascade reactions.⁴⁴⁹ Carboxylic acid reductases are a class of enzymes that only recently emerged as biocatalytic tools that can catalyse the selective reduction of a wide variety of carboxylic acids to aldehydes.⁴⁵⁰



Not only the biocatalytic synthesis of the heavily decorated sugar fragments themselves has been proven to be challenging, their enzymatic coupling to the nucleobase is often highly demanding, too. The ethynyl group on islatravir's core, for example, hampered biocatalytic coupling efficiency considerably. The latter only could be effected upon significant engineering of the involved enzymes.⁹⁰ As discussed above, potential biocatalytic synthesis of remdesivir would likely pose even bigger challenges due to the presence of an additional cyano substituent that renders the nucleobase linkage non-glycosidic. Natural glycosyltransferases and phosphorylases are incapable of coupling such non-natural components, which would require significant engineering of existing biocatalysts or the discovery of novel enzymes for this purpose.

Peptidomimetic drugs are the second largest class of anti-viral agents. These drugs act as protease and integrase inhibitors and thereby suppress viral replication (Fig. 1D/E). Their main building blocks are amino acids of which several are non-canonical. Notable examples are bulky amino acids such as *L*-*tert*-leucine, *L*-6-heptenylglycine and *L*-cyclohexylglycine. The latter are accessible in enantiomerically pure form through various well established biocatalytic resolution or deracemisation approaches. In addition, the biocatalytic asymmetric synthesis of amino acids from pro-chiral ketones is becoming more and more routine (*vide supra*) using, e.g., leucine dehydrogenases or transaminases.

Over the past five years reductive aminases have been developed as another class of enzymes capable of performing cofactor-driven reductive aminations between an amine and a carbonyl component.⁴⁵¹ Reductive aminases are a sub-class of imine reductases that catalyse both sequential steps of imine formation and reduction. Even though these enzymes are only a very recent addition to the biocatalysis toolbox, first processes are already employed on industrial scale.^{452,453}

Despite the multitude of available methods applied to the biocatalytic synthesis of non-canonical amino acids the preparation of (*S*)-2-amino-4-morpholinobutanoic acid, which is a cobicistat building block, is lacking. Cobicistat (**354**, Chart 13A) is part of several multi-drug formulations, but not an anti-viral agent itself. It acts as an inhibitor of liver enzymes that are responsible for eliminating the active drug by metabolising it for clearance. The net result of cobicistat combinations is an increase in the effective drug concentration, which thus allows for lower dosaging.⁴⁵⁴ The morpholine containing unit is commonly prepared through oxidation of *L*-homoserine (or a peptidomimetic fragment containing this amino acid) to the corresponding aldehyde and subsequent reductive amination





Chart 13 Structures of cobicistat with its morpholine-based amino acid highlighted in blue (A) and (*1R,2S*)-1-aminocyclopropanecarboxylic acid (ACCA) derivatives (B).

with morpholine.⁴⁵⁵ The use of any of the described biocatalytic transamination/reductive amination strategies for the synthesis of, for example, (*S*)-2-amino-4-morpholinobutanoic acid and ruxolitinib (Scheme 68) would be of considerable interest.

Other amino acids, for example those bearing an α -quaternary centre, cannot be accessed through reductive amination or transamination. Their direct biocatalytic synthesis would thus require different enzymes. Exemplary is the bis-cyclopropyl-based protease inhibitors' distinctive ACCA-moiety (Chart 13B) which is currently obtained through wasteful enzymatic kinetic resolution. Enzymatic cyclopropanation has briefly been touched upon regarding a marginally successful synthesis of the grazoprevir intermediate (*1R,2R*)-2-(pent-4-ynyl)cyclopropanol (Section 3.4.6). The scope of cytochrome P411-mediated (carbene transfer) reactions, however, is far bigger than mere cyclopropanation of such scarcely functionalised substrates.^{456–458} Synthesis of ACCA by cytochrome-catalysed cyclopropanation would potentially allow for its single step synthesis from achiral starting material. The promising nature of these enzymes will be highlighted once more towards the end of this chapter.

The (*2S,3S,5S*)-2,5-diamino-1,6-diphenylhexan-3-ol building block (**361**) is the central core of ritonavir and lopinavir (Kaletra), an anti-HIV combination drug that is currently also trialled against SARS-CoV-2 (Scheme 70).^{459,460} Rudolph and co-workers have developed one of the shortest chemical routes towards **361** by combining asymmetric aldol addition to α -amino aldehyde **359** and reductive amination.⁴⁶¹ Whereas the degree of chiral induction had not been reported, reductive amination of similar test substrates resulted in 86% de, at best. With the possible integration of *in situ* aldehyde generation, stereoselective aldol addition and transamination, the potential enzymatic synthesis of **361** might provide for an excellent showcase of biocatalysis. Although yet a pipe dream, recent protein engineering initiatives have already shown that enzymatic transamination of similarly bulky substrates is possible.^{296,462}

Coupling of biocatalytically generated amino acid (analogues) through enzymatic amide bond formation would mean yet another advancement in the sustainable nature of biocatalytic anti-viral drug production. Currently, coupling is generally



Scheme 70 Ritonavir and lopinavir, the active pharmaceutical ingredients of Kaletra (A). Chemical synthesis of (*2S,3S,5S*)-2,5-diamino-1,6-diphenylhexan-3-ol as developed by Rudolph and co-workers (B).⁴⁶¹ PMP: *para*-methoxyphenyl and CAN: cerium ammonium nitrate.



achieved using (harsh) chemical methods.^{463,464} This not only holds for amide bonds between amino acid fragments but also for those present in integrase inhibitors such as dolutegravir and bictegravir. Hydrolases are a well-established class of enzymes capable of catalysing kinetically controlled amide forming reactions.^{465–467} More recently, the use of ATP-dependent enzymes for the formation of amide bonds has garnered considerable attention, too. Exemplary is the use of amide bond synthetase McbA for the synthesis of the monoamine oxidase A inhibitor moclobemide.⁴⁶⁸ The amidation could even be performed at near stoichiometric amounts of amine. The potential, but also the challenges, of biocatalytic amide bond formation have recently been reviewed by Petchey and Grogan.⁴⁶⁹ For examples of biocatalytic amidation reactions on industrial scale the reader is referred to a recent review by Dorr and Fuerst.⁴⁷⁰

Although not discussed previously, a common chemical route to the synthesis of darunavir's capping fragment 3-OH-bis-THF ((3*R*,3*aS*,6*aR*)-176) involves the (*in situ*) formation of 3,4-dihydroxy-2-(2-hydroxyethyl)butanal (**364**) or suitable derivatives thereof (Scheme 71). Application of acidic conditions trigger spontaneous double cyclisation to furnish 3-OH-bis-THF. Non-stereoselective synthesis of protected analogues of **364** required additional (enzymatic) resolution or down-stream purification of 3-OH-bis-THF.⁴⁷¹ Complementary to a complex stereoselective chemical synthesis of the desired (2*S*,3*R*)-**364**,^{472–474} an enzymatic aldol addition would pose an interesting short synthetic strategy. With various examples discussed throughout this manuscript, biocatalytic carbonylation has clearly been shown to be a powerful tool capable of rapidly accessing the complex architectures present in both anti-viral nucleoside analogues and peptidomimetics.

The value of biocatalytic C–H functionalisation at a late stage in the synthesis route deserves specific attention as it allows the use of simple (non-activated) non-functionalised starting materials. Exemplary are flavin-dependent halogenases which catalyse site-selective C–H halogenation of aromatic compounds. They offer potential synthetic utility through preparative-scale halogenation of building blocks, sequential halogenation/cross-coupling or late-stage product functionalisation.⁴⁷⁵ Throughout the last years numerous enzymes have been discovered/developed to achieve oxyfunctionalisation, such as novel peroxygenases.^{476,477} Cytochrome P450 enzymes, which possess the unique ability of activating inert sp³-hybridised C–H bonds, offer an attractive synthetic tool for both regioselective oxyfunctionalisation as well as late-stage scaffold diversification.^{478,479} Although P450-catalysed processes have often been deemed unsuited for industrial scale-up, recent developments by Innosyn/DSM have led to the production of 4-hydroxy- α -isophorone on kilogram

scale.⁴⁸⁰ Catalytic anti-Markovnikov oxidation of alkene feedstocks by engineered cytochrome P450 enzymes could simplify synthetic routes to many important molecules and solve a long-standing challenge in chemistry.⁴⁸¹ Beyond the use of α -ketoglutarate-dependent non-haem iron oxygenases/hydroxylases such as those employed in the synthesis of L-hydroxyproline and podophyllotoxin, the use of related halogenases for C–H functionalisation has been rapidly developed over the last years.⁴⁸²


Apart from challenges regarding the specific chemistries discussed above, other limitations towards the wide-spread implementation of biocatalysis involve process-related parameters. One of the key advantages of biocatalysts is their activity in water. The use of aqueous solvent systems does, however, impede the use of hydrophobic substrates, a limitation that can partially be relieved by the use of co-solvents or emulsions.³⁶³ However, in conjunction with extreme pH and elevated temperatures, the use of co-solvents is likely to result in a loss of enzyme activity. A viable remedy is to employ naturally (thermo)stable enzymes from extremophilic organisms that live in harsh environments. Such enzymes are commonly also stable against organic co-solvents.^{483–486}

Despite the challenges, the adoption of biocatalysis in the pharmaceutical industry continues to expand as a result of an increased ability of engineering such enzymes to meet the demands of ideal industrial process conditions. In order to become compatible with the time pressure related to pharmaceutical process development, dramatic increases in the speed of protein engineering are needed to reduce the lead times for biocatalytic process optimisation.⁴⁸⁷ Conventional experiments for generating proteins with improved properties by directed evolution are iterative, lengthy and costly. Novel ultrahigh-throughput microfluidic screening technologies⁴⁸⁸ can dramatically accelerate the discovery of superior biocatalysts against the desired criteria from a single round of genetic randomisation.⁴⁸⁹

Further acceleration is likely to be gained by applying machine learning technologies and artificial intelligence.^{488,490} Indeed, the augmented ability of tailoring enzyme function by *in vitro* evolution (enhancing specific activity, substrate scope, stereoselectivity, tolerance to high co-solvent/substrate/reagent/product loading, long-term kinetic and thermal stability) or even inventing entirely new-to-nature activities that match chemical precedence has enormous potential for future pharmaceutical process development.⁴⁹¹

6. Conclusions

The outbreak of COVID-19 has once more emphasised the impact of viral infections on human health and healthcare. Research towards the development and repurposing of anti-viral agents has sky-rocketed concomitantly. Upon finding an effective drug, mass production of this agent will prove to be the next challenge. This comprehensive overview reveals that biocatalytic synthesis of anti-viral agents is much more widespread than apparent from earlier surveys on the topic; altogether over 60% of all FDA-approved anti-viral agents (or intermediates thereof) are accessible through biocatalysis. As such, this key



Scheme 71 Formal synthesis of (2*S*,3*R*)-3,4-dihydroxy-2-(2-hydroxyethyl)butanal, followed by cyclisation towards the darunavir intermediate 3-OH-bis-THF.



enabling technology has a bright prospect of being a crucial sustainability factor in the synthesis of future COVID-19 drugs.

The structural diversity among anti-viral drug molecules is evidently matched well by a broad range of biocatalytic strategies that have been applied to make them. While enzymatic kinetic resolution is still used frequently, ingenious strategies for direct asymmetric synthesis clearly dominate recent developments to obtain enantiomerically pure anti-viral agents. Microbial engineering furthermore enabled numerous effective fermentative procedures. More and more of these synthetic strategies have been scaled up from academic ventures to industrial processes.³³ Generally, the field made a transition from single step hydrolytic transformations to the development of efficient complex reaction cascades *in vitro*.⁴⁹² The recent development of an entirely non-natural enzymatic reaction sequence for the synthesis of islatravir is, in our opinion, an absolute masterwork that heralds a paradigm shift in the synthesis of complex chiral small molecule drugs by exploiting the potential of synthetic biology.^{90,91} This seems to suggest that there is (almost) no limit to what can be achieved through dedicated biocatalysis.

Although the number of biocatalytically accessible molecules is rising due a continuous enlargement of the enzymatic toolbox, the process of achieving this remains challenging. There are still a large number of enzyme classes and their corresponding transformations that are underrepresented in the class of anti-viral pharmaceuticals, or that have not yet been applied at all. Reasons might stem from a limited early development stage of novel enzyme types or a lack of enzyme activity matching the desired substrate structures. Protein engineering, and especially rapid screening for improved protein variants, is currently one of the largest bottlenecks towards the routine application of novel enzymes. Lifting such limitations is a crucial step in the further development of the field of biocatalysis. Because of our limited understanding of the protein folding problem and related structure–activity–function relationships, research at the forefront of the science is involving artificial intelligence by machine-learning approaches jointly with ultra-high-throughput screening platforms to accelerate enzyme discovery and engineering.⁴⁹¹

Perhaps the largest limitation towards a more profound implementation of biotechnological processes is not a practical one, but rather the result of a lack of incorporation of biocatalytic methods into the synthetic chemistry curriculum. To be able to realise the benefits of biocatalysis, students need to be familiarised with the synthetic potential of biocatalytic methods, and they should be taught early on how these can be interfaced with chemical routes. Biocatalysis and 'traditional' synthetic chemistry are not two separate philosophies,²³ and more and more scientists from both fields are actively involved in research efforts to integrate the two in view of the enormous opportunities for novel creative solutions and IP generation.

Given the demand from a continuously rising number of chiral (anti-viral) drugs, the impact of biocatalysis on industrial pharmaceutical synthesis will likely experience a similar growth. As the market is currently going through a transition imposed by the COVID-19 pandemic, scientists around the globe are urged to seize the momentum by implementing these novel biocatalytic

technologies in order to sustainably revolutionise pharmaceutical production. We strongly believe that a crisis such as the one caused by COVID-19 will also open up golden opportunities for those considering biocatalytic synthesis in the search for the proverbial silver bullet against this, and future, viral diseases.

Conflicts of interest

Within the framework of the Tralaminol project the authors co-operate with BASF SE, which is involved in the production of anti-viral intermediates discussed in this work. However, the authors did not consult with BASF staff on this topic.

Acknowledgements

This work was supported by The German Federal Ministry of Education and Research (BMBF) under Grant Agreement No 031B0595 and the initiative ERA CoBioTech. ERA CoBioTech has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No 722361.

References

- 1 WHO Coronavirus Disease (COVID-19) Dashboard, <https://covid19.who.int/>, accessed 22/09, 2020.
- 2 Ebola situation reports: Democratic Republic of the Congo, World Health Organization, 2019.
- 3 S. M. Moghadas, A. Shoukat, M. C. Fitzpatrick, C. R. Wells, P. Sah, A. Pandey, J. D. Sachs, Z. Wang, L. A. Meyers, B. H. Singer and A. P. Galvani, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 9122–9126.
- 4 E. J. Emanuel, G. Persad, R. Upshur, B. Thome, M. Parker, A. Glickman, C. Zhang, C. Boyle, M. Smith and J. P. Phillips, *N. Engl. J. Med.*, 2020, **382**, 2049–2055.
- 5 J. Hopman, B. Allegranzi and S. Mehtar, *JAMA, J. Am. Med. Assoc.*, 2020, **323**, 1549–1550.
- 6 M. Gilbert, G. Pullano, F. Pinotti, E. Valdano, C. Poletto, P.-Y. Boëlle, E. D'Ortenzio, Y. Yazdanpanah, S. P. Eholie, M. Altmann, B. Gutierrez, M. U. G. Kraemer and V. Colizza, *Lancet*, 2020, **395**, 871–877.
- 7 B. Pfefferbaum and C. S. North, *N. Engl. J. Med.*, 2020, **383**, 510–512.
- 8 B. A. Cunha, *Infect. Dis. Clin.*, 2004, **18**, 141–155.
- 9 M. H. Merson, J. O'Malley, D. Serwadda and C. Apisuk, *Lancet*, 2008, **372**, 475–488.
- 10 D. Carroll, P. Daszak, N. D. Wolfe, G. F. Gao, C. M. Morel, S. Morzaria, A. Pablos-Méndez, O. Tomori and J. A. K. Mazet, *Science*, 2018, **359**, 872–874.
- 11 S. J. Anthony, J. H. Epstein, K. A. Murray, I. Navarrete-Macias, C. M. Zambrana-Torrel, A. Solovyov, R. Ojeda-Flores, N. C. Arrigo, A. Islam, S. Ali Khan, P. Hosseini, T. L. Bogich, K. J. Olival, M. D. Sanchez-Leon, W. B. Karesh, T. Goldstein, S. P. Luby, S. S. Morse, J. A. K. Mazet, P. Daszak and W. I. Lipkin, *mBio*, 2013, **4**, e00598.



- 12 R. Henry, *Emerging Infect. Dis.*, 2013, **19**, 263.
- 13 J. M. Sanders, M. L. Monogue, T. Z. Jodlowski and J. B. Cutrell, *JAMA, J. Am. Med. Assoc.*, 2020, **323**, 1824–1836.
- 14 L. Dong, S. Hu and J. Gao, *Drug Discoveries Ther.*, 2020, **14**, 58–60.
- 15 M. A. Hardy, B. A. Wright, J. L. Bachman, T. B. Boit, H. M. S. Haley, R. R. Knapp, R. F. Lusi, T. Okada, V. Tona, N. K. Garg and R. Sarpong, *ACS Cent. Sci.*, 2020, **6**, 1017–1030.
- 16 O. Méndez-Lucio and J. L. Medina-Franco, *Drug Discovery Today*, 2017, **22**, 120–126.
- 17 M. M. Hann, A. R. Leach and G. Harper, *J. Chem. Inf. Comput. Sci.*, 2001, **41**, 856–864.
- 18 R. M. Gulick, *Top. Antivir. Med.*, 2018, **25**, 127–132.
- 19 E. De Clercq and G. Li, *Clin. Microbiol. Rev.*, 2016, **29**, 695–747.
- 20 S. Chaudhuri, J. A. Symons and J. Deval, *Antiviral Res.*, 2018, **155**, 76–88.
- 21 J. M. Woodley, *Appl. Microbiol. Biotechnol.*, 2019, **103**, 4733–4739.
- 22 R. A. Sheldon and J. M. Woodley, *Chem. Rev.*, 2018, **118**, 801–838.
- 23 N. J. Turner and L. Humphreys, *Biocatalysis in organic synthesis: The retrosynthesis approach*, Royal Society of Chemistry, London, 2018.
- 24 J. M. Woodley, *Trends Biotechnol.*, 2008, **26**, 321–327.
- 25 D. J. Pollard and J. M. Woodley, *Trends Biotechnol.*, 2007, **25**, 66–73.
- 26 R. N. Patel, *Bioorg. Med. Chem.*, 2018, **26**, 1252–1274.
- 27 P. Grunwald, *Pharmaceutical Biocatalysis: Chemoenzymatic Synthesis of Active Pharmaceutical Ingredients*, CRC Press, Boca Raton, 2019.
- 28 K. Rosenthal and S. Lütz, *Curr. Opin. Green Sustainable Chem.*, 2018, **11**, 58–64.
- 29 D. L. Hughes, *Org. Process Res. Dev.*, 2018, **22**, 1063–1080.
- 30 A. Fryszkowska and P. N. Devine, *Curr. Opin. Chem. Biol.*, 2020, **55**, 151–160.
- 31 P. N. Devine, R. M. Howard, R. Kumar, M. P. Thompson, M. D. Truppo and N. J. Turner, *Nat. Rev. Chem.*, 2018, **2**, 409–421.
- 32 Y. Wang, Y. Cao, Y. Li, J. Jin, J. Li and H. Song, *Tetrahedron: Asymmetry*, 2017, **28**, 745–757.
- 33 S. Wu, R. Snajdrova, J. C. Moore, K. Baldenius and U. T. Bornscheuer, *Angew. Chem., Int. Ed.*, 2020, **59**, 2–34.
- 34 A. Casini, F.-Y. Chang, R. Eluere, A. M. King, E. M. Young, Q. M. Dudley, A. Karim, K. Pratt, C. Bristol, A. Forget, A. Ghodasara, R. Warden-Rothman, R. Gan, A. Cristofaro, A. E. Borujeni, M.-H. Ryu, J. Li, Y.-C. Kwon, H. Wang, E. Tatsis, C. Rodriguez-Lopez, S. O'Connor, M. H. Medema, M. A. Fischbach, M. C. Jewett, C. Voigt and D. B. Gordon, *J. Am. Chem. Soc.*, 2018, **140**, 4302–4316.
- 35 E. O. Freed, *Virology*, 1998, **251**, 1–15.
- 36 A. Kapoor and S. Raju, *Illustrated medical pharmacology*, JP Medical Ltd, New Delhi, 1st edn, 2013.
- 37 J. Holguin, R. Cardinaud and C. A. Salemink, *Eur. J. Biochem.*, 1975, **54**, 515–520.
- 38 T. A. Krenitsky, G. W. Koszalka and J. V. Tuttle, *Biochemistry*, 1981, **20**, 3615–3621.
- 39 J. F. Lucas and M.-J. C. Rius, *Enzymatic and Chemical Synthesis of Nucleic Acid Derivatives*, John Wiley & Sons, Hoboken, 2019.
- 40 E. S. Lewkowicz and A. M. Iribarren, *Curr. Pharm. Des.*, 2017, **23**, 6851–6878.
- 41 J. Fernández-Lucas, *Appl. Microbiol. Biotechnol.*, 2015, **99**, 4615–4627.
- 42 M. Ferrero and V. Gotor, *Chem. Rev.*, 2000, **100**, 4319–4348.
- 43 W. H. Prusoff, *Biochim. Biophys. Acta*, 1959, **32**, 295–296.
- 44 I. Serra, T. Bavaro, D. A. Cecchini, S. Daly, A. M. Albertini, M. Terreni and D. Ubiali, *J. Mol. Catal. B: Enzym.*, 2013, **95**, 16–22.
- 45 A. Fresco-Taboada, I. Serra, J. Fernández-Lucas, C. Acebal, M. Arroyo, M. Terreni and I. De la Mata, *Molecules*, 2014, **19**, 11231–11249.
- 46 R. Whitley, C. Alford, F. Hess and R. Buchanan, *Drugs*, 1980, **20**, 267–282.
- 47 T. Utagawa, H. Morisawa, F. Yoshinaga, A. Yamazaki, K. Mitsugi and Y. Hirose, *Agric. Biol. Chem.*, 1985, **49**, 1053–1058.
- 48 I. Serra, D. Ubiali, J. Piškur, S. Christoffersen, E. S. Lewkowicz, A. M. Iribarren, A. M. Albertini and M. Terreni, *ChemPlusChem*, 2013, **78**, 157–165.
- 49 I. Serra, S. Daly, A. R. Alcantara, D. Bianchi, M. Terreni and D. Ubiali, *RSC Adv.*, 2015, **5**, 23569–23577.
- 50 L. Tamborini, C. Previtali, F. Annunziata, T. Bavaro, M. Terreni, E. Calleri, F. Rinaldi, A. Pinto, G. Speranza, D. Ubiali and P. Conti, *Molecules*, 2020, **25**, 1223.
- 51 J. Fernández-Lucas, R. Harris, I. Mata-Casar, A. Heras, I. de la Mata and M. Arroyo, *J. Ind. Microbiol. Biotechnol.*, 2013, **40**, 955–966.
- 52 E. Pérez, P. A. Sánchez-Murcia, J. Jordaan, M. D. Blanco, J. M. Mancheño, F. Gago and J. Fernández-Lucas, *ChemCatChem*, 2018, **10**, 4406–4416.
- 53 C. M. Perry and S. Noble, *Drugs*, 1999, **58**, 1099–1135.
- 54 S. Christoffersen, I. Serra, M. Terreni and J. Piškur, *Nucleosides, Nucleotides Nucleic Acids*, 2010, **29**, 445–448.
- 55 M. Nobile, M. Terreni, E. Lewkowicz and A. M. Iribarren, *Biocatal. Biotransform.*, 2010, **28**, 395–402.
- 56 W. R. Birmingham, C. A. Starbird, T. D. Panosian, D. P. Nannemann, T. M. Iverson and B. O. Bachmann, *Nat. Chem. Biol.*, 2014, **10**, 392–399.
- 57 B.-C. Chen, S. L. Quinlan and J. Gregory Reid, *Tetrahedron Lett.*, 1995, **36**, 7961–7964.
- 58 R. H. Spector, B.-C. Chen and S. L. Quinlan, *US Pat.*, US5608049A, 1997.
- 59 N. Hori, M. Watanabe, Y. Yamazaki and Y. Mikami, *Agric. Biol. Chem.*, 1989, **53**, 197–202.
- 60 M. Ishii, H. Shirae and K. Yokozeki, *Agric. Biol. Chem.*, 1989, **53**, 3209–3218.
- 61 N. Hori, M. Watanabe, K. Sunagawa, K. Uehara and Y. Mikami, *J. Biotechnol.*, 1991, **17**, 121–131.
- 62 D. F. Visser, K. J. Rashamuse, F. Hennessy, G. E. R. Gordon, P. J. Van Zyl, K. Mathiba, M. L. Bode and D. Brady, *Biocatal. Biotransform.*, 2010, **28**, 245–253.
- 63 M.-S. Daniel, L.-I. María and G.-F. Vicente, *Curr. Org. Chem.*, 2016, **20**, 1186–1203.



- 64 C. Callaghan, M. Redmond, R. C. Alnoch, C. Mateo, M. Filice and J. M. Palomo, *ChemCatChem*, 2017, **9**, 2536–2543.
- 65 E. Thomas, M. G. Ghany and T. J. Liang, *Antiviral Chem. Chemother.*, 2012, **23**, 1–12.
- 66 H. Shirae, K. Yokozeki and K. Kubota, *Agric. Biol. Chem.*, 1988, **52**, 1499–1504.
- 67 H. Shirae, K. Yokozeki and K. Kubota, *Agric. Biol. Chem.*, 1988, **52**, 1233–1237.
- 68 H. Shirae, K. Yokozeki, M. Uchiyama and K. Kubota, *Agric. Biol. Chem.*, 1988, **52**, 1777–1783.
- 69 H. Shirae and K. Yokozeki, *Agric. Biol. Chem.*, 1991, **55**, 1849–1857.
- 70 H. Shirae, K. Yokozeki and K. Kubota, *Agric. Biol. Chem.*, 1991, **55**, 605–607.
- 71 V. N. Barai, A. I. Zinchenko, L. A. Eroshevskaya, E. N. Kalinichenko, T. I. Kulak and I. A. Mikhailopulo, *Helv. Chim. Acta*, 2002, **85**, 1901–1908.
- 72 I. D. Konstantinova, N. A. Leont'eva, G. A. Galegov, O. I. Ryzhova, D. V. Chuvikovskii, K. V. Antonov, R. S. Esipov, S. A. Taran, K. N. Verevkina, S. A. Feofanov and A. I. Miroshnikov, *Russ. J. Bioorg. Chem.*, 2004, **30**, 553–560.
- 73 E. C. De Benedetti, C. W. Rivero and J. A. Trelles, *J. Mol. Catal. B: Enzym.*, 2015, **121**, 90–95.
- 74 C. W. Rivero, E. C. De Benedetti, M. E. Lozano and J. A. Trelles, *Process Biochem.*, 2015, **50**, 935–940.
- 75 M. Rabuffetti, T. Bavaro, R. Semproli, G. Cattaneo, M. Massone, C. F. Morelli, G. Speranza and D. Ubiali, *Catalysts*, 2019, **9**, 355.
- 76 F. Poordad, E. Lawitz, M. L. Shiffman, T. Hassanein, A. J. Muir, B. R. Bacon, J. Heise, D. Halliman, E. Chun and J. Hammond, *Hepatology*, 2010, **52**, 1208–1215.
- 77 H. Ren, L. Lu, M. Zheng, R. Ou, X. Lin, G. Huang and Y. Ning, *PRC Pat.*, CN102978264A, 2013.
- 78 I. Gentile, A. E. Maraolo, A. R. Buonomo, E. Zappulo and G. Borgia, *Exp. Opin. Drug Discovery*, 2015, **10**, 1363–1377.
- 79 D. Cahard, C. McGuigan and J. Balzarini, *Mini-Rev. Med. Chem.*, 2004, **4**, 371–381.
- 80 P. Zhang, H. Iding, M. Cedilote, S. Brunner, T. Williamson and T. P. Cleary, *Tetrahedron: Asymmetry*, 2009, **20**, 305–312.
- 81 P. Wang, B.-K. Chun, S. Rachakonda, J. Du, N. Khan, J. Shi, W. Stec, D. Cleary, B. S. Ross and M. J. Sofia, *J. Org. Chem.*, 2009, **74**, 6819–6824.
- 82 F. Molinari, O. Brenna, M. Valenti and F. Aragozzini, *Enzyme Microb. Technol.*, 1996, **19**, 551–556.
- 83 M. J. Dröge, R. Bos and W. J. Quax, *Eur. J. Biochem.*, 2001, **268**, 3332–3338.
- 84 D. Romano, F. Falcioni, D. Mora, F. Molinari, A. Buthe and M. Ansorge-Schumacher, *Tetrahedron: Asymmetry*, 2005, **16**, 841–845.
- 85 L. F. Godinho, C. R. Reis, P. G. Tepper, G. J. Poelarends and W. J. Quax, *Appl. Environ. Microbiol.*, 2011, **77**, 6094–6099.
- 86 M. Gaboardi, G. Pallanza, M. Baratella, G. Castaldi and M. Castaldi, *World Pat.*, WO2017144423A1, 2017.
- 87 C. Roodveldt and D. S. Tawfik, *Protein Eng., Des. Sel.*, 2005, **18**, 51–58.
- 88 D. F. Xiang, A. N. Bigley, E. Desormeaux, T. Narindoshvili and F. M. Raushel, *Biochemistry*, 2019, **58**, 3204–3211.
- 89 B. S. Ross, P. Ganapati Reddy, H.-R. Zhang, S. Rachakonda and M. J. Sofia, *J. Org. Chem.*, 2011, **76**, 8311–8319.
- 90 M. A. Huffman, A. Fryszkowska, O. Alvizo, M. Borra-Garske, K. R. Campos, K. A. Canada, P. N. Devine, D. Duan, J. H. Forstater, S. T. Grosser, H. M. Halsey, G. J. Hughes, J. Jo, L. A. Joyce, J. N. Kolev, J. Liang, K. M. Maloney, B. F. Mann, N. M. Marshall, M. McLaughlin, J. C. Moore, G. S. Murphy, C. C. Nawrat, J. Nazor, S. Novick, N. R. Patel, A. Rodriguez-Granillo, S. A. Robaire, E. C. Sherer, M. D. Truppo, A. M. Whittaker, D. Verma, L. Xiao, Y. Xu and H. Yang, *Science*, 2019, **366**, 1255–1259.
- 91 E. O'Reilly and J. Ryan, *Science*, 2019, **366**, 1199–1200.
- 92 C. Orkin, J. M. Llibre, S. Gallien, A. Antinori, G. M. N. Behrens and A. Carr, *HIV Med.*, 2018, **19**, 18–32.
- 93 J. Milton, S. Brand, M. F. Jones and C. M. Rayner, *Tetrahedron Lett.*, 1995, **36**, 6961–6964.
- 94 R. Storer, I. R. Clemens, B. Lamont, S. A. Noble, C. Williamson and B. Belleau, *Nucleosides Nucleotides*, 1993, **12**, 225–236.
- 95 M. Mahmoudian, B. S. Baines, C. S. Drake, R. S. Hale, P. Jones, J. E. Piercey, D. S. Montgomery, I. J. Purvis, R. Storer, M. J. Dawson and G. C. Lawrence, *Enzyme Microb. Technol.*, 1993, **15**, 749–755.
- 96 L. K. Hoong, L. E. Strange, D. C. Liotta, G. W. Koszalka, C. L. Burns and R. F. Schinazi, *J. Org. Chem.*, 1992, **57**, 5563–5565.
- 97 R. P. C. Cousins, M. Mahmoudian and P. M. Youds, *Tetrahedron: Asymmetry*, 1995, **6**, 393–396.
- 98 Y. Chen, X. Zhang, G. Zheng and S. Gao, *Process Biochem.*, 2019, **81**, 77–84.
- 99 L. Hu, F. Schaufelberger, Y. Zhang and O. Ramström, *Chem. Commun.*, 2013, **49**, 10376–10378.
- 100 Y. Ren, L. Hu and O. Ramström, *Mol. Catal.*, 2019, **468**, 52–56.
- 101 P. S. Hervey and C. M. Perry, *Drugs*, 2000, **60**, 447–479.
- 102 R. Singh and R. Vince, *Chem. Rev.*, 2012, **112**, 4642–4686.
- 103 S. J. C. Taylor, R. McCague, R. Wisdom, C. Lee, K. Dickson, G. Ruecroft, F. O'Brien, J. Littlechild, J. Bevan, S. M. Roberts and C. T. Evans, *Tetrahedron: Asymmetry*, 1993, **4**, 1117–1128.
- 104 X. Qin, J. Wang and G. Zheng, *Appl. Biochem. Biotechnol.*, 2010, **162**, 2345–2354.
- 105 S. Zhu, C. Gong, D. Song, S. Gao and G. Zheng, *Appl. Environ. Microbiol.*, 2012, **78**, 7492–7495.
- 106 Z. Assaf, E. Eger, Z. Vitnik, W. M. F. Fabian, D. Ribitsch, G. M. Guebitz, K. Faber and M. Hall, *ChemCatChem*, 2014, **6**, 2517–2521.
- 107 J. Wang, G. Zhao, Z. Zhang, Q. Liang, C. Min and S. Wu, *Appl. Microbiol. Biotechnol.*, 2014, **98**, 6991–7001.
- 108 J. Wang, J. Zhu, C. Min and S. Wu, *BMC Biotechnol.*, 2014, **14**, 40.
- 109 S. Gao, S. Zhu, R. Huang, Y. Lu and G. Zheng, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 3878–3881.
- 110 L. Ren, S. Zhu, Y. Shi, S. Gao and G. Zheng, *Appl. Biochem. Biotechnol.*, 2015, **176**, 170–184.



- 111 J. Wang, J. Zhu and S. Wu, *Appl. Microbiol. Biotechnol.*, 2015, **99**, 4691–4700.
- 112 T.-Y. Xue, G.-C. Xu, R.-Z. Han and Y. Ni, *Appl. Biochem. Biotechnol.*, 2015, **176**, 1687–1699.
- 113 S. Gao, R. Huang, S. Zhu, H. Li and G. Zheng, *Appl. Microbiol. Biotechnol.*, 2016, **100**, 9543–9553.
- 114 S. Zhu, R. Huang, S. Gao, X. Li and G. Zheng, *J. Biosci. Bioeng.*, 2016, **121**, 484–490.
- 115 Y. Su, S. Gao, H. Li and G. Zheng, *Process Biochem.*, 2018, **72**, 96–104.
- 116 M. Yang, Q. Gao, S. Wu, J. Wang and G. Zheng, *Biotechnol. Lett.*, 2012, **34**, 275–279.
- 117 S. Zhu, L. Ren, S. Yu, C. Gong, D. Song and G. Zheng, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 4899–4902.
- 118 Y. Sun, H. Zhao, J. Wang, J. Zhu and S. Wu, *Appl. Microbiol. Biotechnol.*, 2015, **99**, 7559–7568.
- 119 H. S. Toogood, R. C. Brown, K. Line, P. A. Keene, S. J. C. Taylor, R. McCague and J. A. Littlechild, *Tetrahedron*, 2004, **60**, 711–716.
- 120 J.-G. Yin, Y. Gong, X.-Y. Zhang, G.-W. Zheng and J.-H. Xu, *Catal. Sci. Technol.*, 2016, **6**, 6305–6310.
- 121 E. Forro and F. Fuloep, *Eur. J. Org. Chem.*, 2008, 5263–5268.
- 122 L. L. Torres, A. Schliessmann, M. Schmidt, N. Silva-Martin, J. A. Hermoso, J. Berenguer, U. T. Bornscheuer and A. Hidalgo, *Org. Biomol. Chem.*, 2012, **10**, 3388–3392.
- 123 Z. Galla, E. Forro and F. Fuloep, *Tetrahedron: Asymmetry*, 2016, **27**, 729–731.
- 124 M. Mahmoudian, A. Lowdon, M. Jones, M. Dawson and C. Wallis, *Tetrahedron: Asymmetry*, 1999, **10**, 1201–1206.
- 125 S. M. Daluge, M. T. Martin, B. R. Sickles and D. A. Livingston, *Nucleosides, Nucleotides Nucleic Acids*, 2000, **19**, 297–327.
- 126 G. A. Boyle, C. D. Edlin, Y. Li, D. C. Liotta, G. L. Morgans and C. C. Musonda, *Org. Biomol. Chem.*, 2012, **10**, 1870–1876.
- 127 T. Shaw and S. Locarnini, *Exp. Rev. Anti-Infect. Ther.*, 2004, **2**, 853–871.
- 128 R. N. Patel, A. Banerjee, Y. R. Pendri, J. Liang, C.-P. Chen and R. Mueller, *Tetrahedron: Asymmetry*, 2006, **17**, 175–178.
- 129 Y. R. Pendri, C.-P. H. Chen, S. S. Patel, J. M. Evans, J. Liang, D. R. Kronenthal, G. L. Powers, S. J. Prasad, J. T. Bien and Z. Shi, *World Pat.*, WO2004052310, 2006.
- 130 D. A. Griffith and S. J. Danishefsky, *J. Am. Chem. Soc.*, 1996, **118**, 9526–9538.
- 131 I. J. S. Fairlamb, J. M. Dickinson, R. O'Connor, S. Higson, L. Grieveson and V. Marin, *Bioorg. Med. Chem.*, 2002, **10**, 2641–2656.
- 132 K. Balke, M. Bäumgen and U. T. Bornscheuer, *ChemBioChem*, 2017, **18**, 1627–1638.
- 133 A. J. Wagstaff, D. Faulds and K. L. Goa, *Drugs*, 1994, **47**, 153–205.
- 134 D. Ormrod, L. J. Scott and C. M. Perry, *Drugs*, 2000, **59**, 839–863.
- 135 K. McClean, C. Preston, D. Spence, P. W. Sutton and J. Whittall, *Tetrahedron Lett.*, 2011, **52**, 215–218.
- 136 M. K. Sethi, S. R. Bhandya, R. Shukla, A. Kumar, N. Maddur, V. S. N. J. Mittapalli, V. S. Rawat and R. K. Yerramalla, *J. Mol. Catal. B: Enzym.*, 2014, **108**, 77–81.
- 137 J. T. Sime, R. D. Barnes, S. W. Elson, R. L. Jarvest and K. J. O'Toole, *J. Chem. Soc., Perkin Trans. 1*, 1992, 1653–1658, DOI: 10.1039/P19920001653.
- 138 C. Callebaut, G. Stepan, Y. Tian and M. D. Miller, *Antimicrob. Agents Chemother.*, 2015, **59**, 5909–5916.
- 139 B. P. Kearney, J. F. Flaherty and J. Shah, *Clin. Pharmacokinet.*, 2004, **43**, 595–612.
- 140 A. S. Ray, M. W. Fordyce and M. J. Hitchcock, *Antiviral Res.*, 2016, **125**, 63–70.
- 141 D. L. Riley, D. R. Walwyn and C. D. Edlin, *Org. Process Res. Dev.*, 2016, **20**, 742–750.
- 142 S. Thatipally, R. A. O. Dammalapati Venkata Lakshmi Narasimha, R. Ramakrishna Kallam Venkata Siva, A. Gorantla Seeta Rama and S. Chava, *World Pat.*, WO2015040640A2, 2015.
- 143 N. S. Suveges, A. A. Rodriguez, C. C. Diederichs, S. P. de Souza, R. A. C. Leão, L. S. M. Miranda, B. A. C. Horta, S. F. Pedraza, O. V. de Carvalho, K. C. Pais, J. H. C. Terra and R. O. M. A. de Souza, *Eur. J. Org. Chem.*, 2018, 2931–2938.
- 144 E. M. Isin, C. S. Elmore, G. N. Nilsson, R. A. Thompson and L. Weidolf, *Chem. Res. Toxicol.*, 2012, **25**, 532–542.
- 145 N. R. Rivera, J. Moore, D. J. Schenk, H. Wang, D. Hesk and I. Mergelsberg, *Tetrahedron Lett.*, 2016, **57**, 1090–1092.
- 146 G. L. Plosker and S. Noble, *Drugs*, 1999, **58**, 325–345.
- 147 P. R. Brodfuehrer, H. G. Howell, C. Sapino and P. Vemishetti, *Tetrahedron Lett.*, 1994, **35**, 3243–3246.
- 148 T. Suzuki, N. Kasai, R. Yamamoto and N. Minamiura, *Appl. Microbiol. Biotechnol.*, 1993, **40**, 273–278.
- 149 N. Kasai, T. Suzuki and Y. Furukawa, *Chirality*, 1998, **10**, 682–692.
- 150 H. K. Chenault, L. F. Chafin and S. Liehr, *J. Org. Chem.*, 1998, **63**, 4039–4045.
- 151 L. Poppe, L. Novák, M. Kajtár-Peredy and C. Szántay, *Tetrahedron: Asymmetry*, 1993, **4**, 2211–2217.
- 152 A. Geerlof, J. A. Jongejan, T. J. G. M. van Dooren, P. C. Raemakers-Franken, W. J. J. van den Tweel and J. A. Duine, *Enzyme Microb. Technol.*, 1994, **16**, 1059–1063.
- 153 A. Geerlof, J. B. A. Van Tol, J. A. Jongejan and J. A. Duine, *Biosci., Biotechnol., Biochem.*, 1994, **58**, 1028–1036.
- 154 J. M. Palomo, R. L. Segura, G. Fernandez-Lorente, J. M. Guisán and R. Fernández-Lafuente, *Tetrahedron: Asymmetry*, 2004, **15**, 1157–1161.
- 155 M. Pregnotato, M. Terreni, I. E. de Fuentes, A. R. Alcantara Leon, P. Sabuquillo, R. Fernández-Lafuente and J. M. Guisán, *J. Mol. Catal. B: Enzym.*, 2001, **11**, 757–763.
- 156 J. M. Palomo, R. L. Segura, C. Mateo, M. Terreni, J. M. Guisán and R. Fernández-Lafuente, *Tetrahedron: Asymmetry*, 2005, **16**, 869–874.
- 157 Y. Liu, Y. Wang, Y. Jiang, M. Hu, S. Li and Q. Zhai, *Biotechnol. Prog.*, 2015, **31**, 724–729.
- 158 A. A. Agbowuro, W. M. Huston, A. B. Gamble and J. D. A. Tyndall, *Med. Res. Rev.*, 2018, **38**, 1295–1331.
- 159 Y.-P. Xue, C.-H. Cao and Y.-G. Zheng, *Chem. Soc. Rev.*, 2018, **47**, 1516–1561.
- 160 K. F. Croom, S. Dhillon and S. J. Keam, *Drugs*, 2009, **69**, 1107–1140.
- 161 S. Venkatraman, *Trends Pharmacol. Sci.*, 2012, **33**, 289–294.



- 162 A. D. Kwong, R. S. Kauffman, P. Hurter and P. Mueller, *Nat. Biotechnol.*, 2011, **29**, 993–1003.
- 163 A. S. Bommarius, M. Schwarm, K. Stingl, M. Kottenhahn, K. Huthmacher and K. Drauz, *Tetrahedron: Asymmetry*, 1995, **6**, 2851–2888.
- 164 N. J. Turner, J. R. Winterman, R. McCague, J. S. Parratt and S. J. C. Taylor, *Tetrahedron Lett.*, 1995, **36**, 1113–1116.
- 165 S. L. Liu, Q. X. Song, D. Z. Wei, Y. W. Zhang and X. D. Wang, *Prep. Biochem. Biotechnol.*, 2006, **36**, 235–241.
- 166 J.-Z. Jin, D.-L. Chang and J. Zhang, *Appl. Biochem. Biotechnol.*, 2011, **164**, 376–385.
- 167 C. Wandrey and B. Bossow, *Biotechnol. Bioind.*, 1986, **1**, 8–13.
- 168 A. Menzel, H. Werner, J. Altenbuchner and H. Groger, *Eng. Life Sci.*, 2004, **4**, 573–576.
- 169 J. Li, J. Pan, J. Zhang and J.-H. Xu, *J. Mol. Catal. B: Enzym.*, 2014, **105**, 11–17.
- 170 W. Liu, H. Ma, J. Luo, W. Shen, X. Xu, S. Li, Y. Hu and H. Huang, *Biochem. Eng. J.*, 2014, **91**, 204–209.
- 171 W. Jiang and B. Fang, *Sci. Rep.*, 2016, **6**, 30462.
- 172 W. Jiang, D. Sun, J. Lu, Y. Wang, S. Wang, Y. Zhang and B. Fang, *Eng. Life Sci.*, 2016, **16**, 283–289.
- 173 J. Lu, Y. Zhang, D. Sun, W. Jiang, S. Wang and B. Fang, *Appl. Biochem. Biotechnol.*, 2016, **180**, 1180–1195.
- 174 L. Zhu, Z. Wu, J.-M. Jin and S.-Y. Tang, *Appl. Microbiol. Biotechnol.*, 2016, **100**, 5805–5813.
- 175 T. Li, A. B. Kootstra and I. G. Fotheringham, *Org. Process Res. Dev.*, 2002, **6**, 533–538.
- 176 E. Heuson, F. Charmantray, J.-L. Petit, V. de Berardinis and T. Gefflaut, *Adv. Synth. Catal.*, 2019, **361**, 778–785.
- 177 Y.-M. Seo and H. Yun, *J. Microbiol. Biotechnol.*, 2011, **21**, 1049–1052.
- 178 H. Zhou, L. Meng, X. Yin, Y. Liu, G. Xu, J. Wu, M. Wu and L. Yang, *Eur. J. Org. Chem.*, 2019, 6470–6477.
- 179 H. Chen, M. B. Prater, R. Cai, F. Dong, H. Chen and S. D. Minter, *J. Am. Chem. Soc.*, 2020, **142**, 4028–4036.
- 180 A. P. Green and N. J. Turner, *Perspect. Sci.*, 2016, **9**, 42–48.
- 181 R. O. M. A. de Souza, L. S. M. Miranda and U. T. Bornscheuer, *Chem. – Eur. J.*, 2017, **23**, 12040–12063.
- 182 K. Eisler, J. Rudinger and F. Sorm, *Collect. Czech. Chem. Commun.*, 1966, **31**, 4563–4580.
- 183 M. Beller, M. Eckert, H. Geissler, B. Napierski, H.-P. Rebenstock and E. W. Holla, *Chem. – Eur. J.*, 1998, **4**, 935–941.
- 184 M.-X. Wang and S.-J. Lin, *J. Org. Chem.*, 2002, **67**, 6542–6545.
- 185 H. Hong, C. Zheng and G. Lina, *US Pat.*, US20160319312A1, 2016.
- 186 V. Köhler, K. R. Bailey, A. Znabet, J. Raftery, M. Helliwell and N. J. Turner, *Angew. Chem., Int. Ed.*, 2010, **49**, 2182–2184.
- 187 C. J. Dunsmore, R. Carr, T. Fleming and N. J. Turner, *J. Am. Chem. Soc.*, 2006, **128**, 2224–2225.
- 188 A. Znabet, E. Ruijter, F. J. J. de Kanter, V. Köhler, M. Helliwell, N. J. Turner and R. V. A. Orru, *Angew. Chem., Int. Ed.*, 2010, **49**, 5289–5292.
- 189 A. Znabet, M. M. Polak, E. Janssen, F. J. J. de Kanter, N. J. Turner, R. V. A. Orru and E. Ruijter, *Chem. Commun.*, 2010, **46**, 7918–7920.
- 190 T. Li, J. Liang, A. Ambrogelly, T. Brennan, G. Gloor, G. Huisman, J. Lalonde, A. Lekhal, B. Mijts, S. Muley, L. Newman, M. Tobin, G. Wong, A. Zaks and X. Zhang, *J. Am. Chem. Soc.*, 2012, **134**, 6467–6472.
- 191 S. Noble and D. Faulds, *Drugs*, 1996, **52**, 93–112.
- 192 K. McKeage, C. M. Perry and S. J. Keam, *Drugs*, 2009, **69**, 477–503.
- 193 S. Noble and K. L. Goa, *Drugs*, 2000, **60**, 1383–1410.
- 194 T. M. Chapman, G. L. Plosker and C. M. Perry, *Drugs*, 2004, **64**, 2101–2124.
- 195 A. K. Ghosh, H. L. Osswald and G. Prato, *J. Med. Chem.*, 2016, **59**, 5172–5208.
- 196 K. E. B. Parkes, D. J. Bushnell, P. H. Crackett, S. J. Dunsdon, A. C. Freeman, M. P. Gunn, R. A. Hopkins, R. W. Lambert and J. A. Martin, *J. Org. Chem.*, 1994, **59**, 3656–3664.
- 197 K. Fuji, T. Kawabata, Y. Kiryu, Y. Sugiura, T. Taga and Y. Miwa, *Tetrahedron Lett.*, 1990, **31**, 6663–6666.
- 198 K. Fuji, T. Kawabata, Y. Kiryu and Y. Sugiura, *Heterocycles*, 1996, **2**, 701–722.
- 199 R. N. Patel, A. Banerjee, C. G. McNamee, D. B. Brzozowski and L. J. Szarka, *Tetrahedron: Asymmetry*, 1997, **8**, 2547–2552.
- 200 R. N. Patel, L. Chu and R. Mueller, *Tetrahedron: Asymmetry*, 2003, **14**, 3105–3109.
- 201 A. S. de Miranda, R. C. Simon, B. Grischek, G. C. de Paula, B. A. C. Horta, L. S. M. de Miranda, W. Kroutil, C. O. Kappe and R. O. M. A. de Souza, *ChemCatChem*, 2015, **7**, 984–992.
- 202 K. Wu, K. Zheng, L. Xiong, Z. Yang, Z. Jiang, X. Meng and L. Shao, *Appl. Microbiol. Biotechnol.*, 2019, **103**, 4417–4427.
- 203 A. Bardsley-Elliott and G. L. Plosker, *Drugs*, 2000, **59**, 581–620.
- 204 S. W. Kaldor, V. J. Kalish, J. F. Davies, B. V. Shetty, J. E. Fritz, K. Appelt, J. A. Burgess, K. M. Campanale, N. Y. Chirgadze, D. K. Clawson, B. A. Dressman, S. D. Hatch, D. A. Khalil, M. B. Kosa, P. P. Lubbehusen, M. A. Muesing, A. K. Patick, S. H. Reich, K. S. Su and J. H. Tatlock, *J. Med. Chem.*, 1997, **40**, 3979–3985.
- 205 L. Castoldi, L. Ielo, P. Hoyos, M. J. Hernáiz, L. De Luca, A. R. Alcántara, W. Holzer and V. Pace, *Tetrahedron*, 2018, **74**, 2211–2217.
- 206 K. Fukuta and N. Fukuhara, *US Pat.*, US005756319A, 1998.
- 207 T. H. P. Maier, *Nat. Biotechnol.*, 2003, **21**, 422–427.
- 208 T. Inaba, A. G. Birchler, Y. Yamada, S. Sagawa, K. Yokota, K. Ando and I. Uchida, *J. Org. Chem.*, 1998, **63**, 7582–7583.
- 209 T. Inaba, Y. Yamada, H. Abe, S. Sagawa and H. Cho, *J. Org. Chem.*, 2000, **65**, 1623–1628.
- 210 K. F. Albizati, S. Babu, A. Birchler, J. K. Busse, M. Fugett, A. Grubbs, A. Haddach, M. Pagan, B. Potts, T. Remarchuk, D. Rieger, R. Rodriguez, J. Shanley, R. Szendroi, T. Tibbetts, K. Whitten and B. C. Borer, *Tetrahedron Lett.*, 2001, **42**, 6481–6485.
- 211 G. Iacazio, D. Martini, S. Sanchez and B. Faure, *Tetrahedron: Asymmetry*, 2000, **11**, 1313–1321.
- 212 M. Gruttadauria, P. L. Meo, S. Riela, F. Giacalone and R. Noto, *Tetrahedron: Asymmetry*, 2006, **17**, 3128–3134.



- 213 C. U. Ingram, M. Bommer, M. E. B. Smith, P. A. Dalby, J. M. Ward, H. C. Hailes and G. J. Lye, *Biotechnol. Bioeng.*, 2007, **96**, 559–569.
- 214 M. Lorillière, M. De Sousa, F. Bruna, E. Heuson, T. Gefflaut, V. de Berardinis, T. Saravanan, D. Yi, W.-D. Fessner, F. Charmantray and L. Hecquet, *Green Chem.*, 2017, **19**, 425–435.
- 215 L. Rios-Solis, M. Halim, A. Cázares, P. Morris, J. M. Ward, H. C. Hailes, P. A. Dalby, F. Baganz and G. J. Lye, *Biocatal. Biotransform.*, 2011, **29**, 192–203.
- 216 M. F. Villegas-Torres, R. J. Martinez-Torres, A. Cázares-Körner, H. Hailes, F. Baganz and J. Ward, *Enzyme Microb. Technol.*, 2015, **81**, 23–30.
- 217 S. Matosevic, G. J. Lye and F. Baganz, *J. Biotechnol.*, 2011, **155**, 320–329.
- 218 A. Abdul Halim, N. Szita and F. Baganz, *J. Biotechnol.*, 2013, **168**, 567–575.
- 219 P. Gruber, F. Carvalho, M. P. C. Marques, B. O'Sullivan, F. Subrizi, D. Dobrijevic, J. Ward, H. C. Hailes, P. Fernandes, R. Wohlgemuth, F. Baganz and N. Szita, *Biotechnol. Bioeng.*, 2018, **115**, 586–596.
- 220 G. L. Plosker and S. Noble, *Drugs*, 1999, **58**, 1165–1203.
- 221 A. S. Demir, H. Hamamci, F. Doganel and E. Ozgul, *J. Mol. Catal. B: Enzym.*, 2000, **9**, 157–161.
- 222 S. Nakano, Y. Igarashi and H. Nohira, *Tetrahedron: Asymmetry*, 2001, **12**, 59–62.
- 223 N. M. T. Lourenço, S. Barreiros and C. A. M. Afonso, *Green Chem.*, 2007, **9**, 734–736.
- 224 H. Yun, J. Kim, K. Kinnera and B.-G. Kim, *Biotechnol. Bioeng.*, 2006, **93**, 391–395.
- 225 A. G. Myers, J. K. Barbay and B. Zhong, *J. Am. Chem. Soc.*, 2001, **123**, 7207–7219.
- 226 N. Connors, R. Prevoznak, M. Chartrain, J. Reddy, R. Singhvi, Z. Patel, R. Olewinski, P. Salmon, J. Wilson and R. Greasham, *J. Ind. Microbiol. Biotechnol.*, 1997, **18**, 353–359.
- 227 B. C. Buckland, S. W. Drew, N. C. Connors, M. M. Chartrain, C. Lee, P. M. Salmon, K. Gbewonyo, W. Zhou, P. Gailliot, R. Singhvi, R. C. Olewinski, W.-J. Sun, J. Reddy, J. Zhang, B. A. Jackey, C. Taylor, K. E. Goklen, B. Junker and R. L. Greasham, *Metab. Eng.*, 1999, **1**, 63–74.
- 228 S. Stahl, N. Ikemoto, A. King, R. Greasham and M. Chartrain, *J. Biosci. Bioeng.*, 1999, **88**, 495–499.
- 229 C. H. Senanayake, L. M. DiMichele, J. Liu, L. E. Fredenburgh, K. M. Ryan, F. Edward Roberts, R. D. Larsen, T. R. Verhoeven and P. J. Reider, *Tetrahedron Lett.*, 1995, **36**, 7615–7618.
- 230 E. Eichhorn, J.-P. Roduit, N. Shaw, K. Heinzmann and A. Kiener, *Tetrahedron: Asymmetry*, 1997, **8**, 2533–2536.
- 231 M. Baumann, B. H. Hauer and U. T. Bornscheuer, *Tetrahedron: Asymmetry*, 2000, **11**, 4781–4790.
- 232 A. Nobili, M. G. Gall, I. V. Pavlidis, M. L. Thompson, M. Schmidt and U. T. Bornscheuer, *FEBS J.*, 2013, **280**, 3084–3093.
- 233 Z. Sun, R. Lonsdale, A. Ilie, G. Li, J. Zhou and M. T. Reetz, *ACS Catal.*, 2016, **6**, 1598–1605.
- 234 V. K. Tandon, A. M. Van Leusen and H. Wynberg, *J. Org. Chem.*, 1983, **48**, 2767–2769.
- 235 Y. Honda, S. Katayama, M. Kojima, T. Suzuki, N. Kishibata and K. Izawa, *Org. Biomol. Chem.*, 2004, **2**, 2061–2070.
- 236 A. Liese, K. Seelbach and C. Wandrey, *Industrial biotransformations*, John Wiley & Sons, Hoboken, 2006.
- 237 A. Liljebblad and L. T. Kanerva, *Tetrahedron: Asymmetry*, 1999, **10**, 4405–4415.
- 238 K. N. G. Valdehuesa, H. Liu, K. R. M. Ramos, S. J. Park, G. M. Nisola, W.-K. Lee and W.-J. Chung, *Process Biochem.*, 2014, **49**, 25–32.
- 239 W. Niu, M. N. Molefe and J. W. Frost, *J. Am. Chem. Soc.*, 2003, **125**, 12998–12999.
- 240 X. Li, Z. Cai, Y. Li and Y. Zhang, *Sci. Rep.*, 2014, **4**, 5541.
- 241 A. K. Ghosh and Y. Chen, *Tetrahedron Lett.*, 1995, **36**, 505–508.
- 242 R. H. Yu, R. P. Polniaszek, M. W. Becker, C. M. Cook and L. H. L. Yu, *Org. Process Res. Dev.*, 2007, **11**, 972–980.
- 243 W. L. Canoy, B. E. Cooley, J. A. Corona, T. C. Lovelace, A. Millar, A. M. Weber, S. Xie and Y. Zhang, *Org. Lett.*, 2008, **10**, 1103–1106.
- 244 A. K. Ghosh, J. F. Kincaid, D. E. Walters, Y. Chen, N. C. Chaudhuri, W. J. Thompson, C. Culberson, P. M. D. Fitzgerald, H. Y. Lee, S. P. McKee, P. M. Munson, T. T. Duong, P. L. Darke, J. A. Zugay, W. A. Schleif, M. G. Axel, J. Lin and J. R. Huff, *J. Med. Chem.*, 1996, **39**, 3278–3290.
- 245 R. A. C. Leão, R. O. de Lopes, M. A. D. M. Bezerra, M. N. Muniz, B. B. Casanova, S. C. B. Gnoatto, G. Gosmann, L. Kocsis, R. O. M. A. de Souza and L. S. M. de Miranda, *J. Flow Chem.*, 2015, **5**, 216–219.
- 246 Y. L. Khmel'nitsky, P. C. Michels, I. C. Cotterill, M. Eissenstat, V. Sunku, V. R. Veeramani, H. Cittineni, G. R. Kotha, S. R. Talasani, K. K. Ramanathan, V. K. Chitineni and B. R. Venepalli, *Org. Process Res. Dev.*, 2011, **15**, 279–283.
- 247 T. Kanemitsu, M. Inoue, N. Yoshimura, K. Yoneyama, R. Watarai, M. Miyazaki, Y. Odanaka, K. Nagata and T. Itoh, *Eur. J. Org. Chem.*, 2016, 1874–1880.
- 248 A. Sevenich, G.-Q. Liu, A. J. Arduengo, B. F. Gupton and T. Opatz, *J. Org. Chem.*, 2017, **82**, 1218–1223.
- 249 T. Shibasaki, H. Mori, S. Chiba and A. Ozaki, *Appl. Environ. Microbiol.*, 1999, **65**, 4028–4031.
- 250 T. Shibasaki, W. Sakurai, A. Hasegawa, Y. Uosaki, H. Mori, M. Yoshida and A. Ozaki, *Tetrahedron Lett.*, 1999, **40**, 5227–5230.
- 251 T. Shibasaki, H. Mori and A. Ozaki, *Biosci., Biotechnol., Biochem.*, 2000, **64**, 746–750.
- 252 C. Klein and W. Hüttel, *Adv. Synth. Catal.*, 2011, **353**, 1375–1383.
- 253 F. Falcioni, B. Bühler and A. Schmid, *Biotechnol. Bioeng.*, 2015, **112**, 322–330.
- 254 K. Hernández, A. Gómez, J. Joglar, J. Bujons, T. Parella and P. Clapés, *Adv. Synth. Catal.*, 2017, **359**, 2090–2100.
- 255 M. Schurink, S. Wolterink-van Loo, J. van der Oost, T. Sonke and M. C. R. Franssen, *ChemCatChem*, 2014, **6**, 1073–1081.
- 256 G. M. Keating, *Drugs*, 2016, **76**, 617–624.
- 257 Y. N. Lamb, *Drugs*, 2017, **77**, 1797–1804.
- 258 J. G. Taylor, S. Zipfel, K. Ramey, R. Vivian, A. Schrier, K. K. Karki, A. Katana, D. Kato, T. Kobayashi and R. Martinez, *Bioorg. Med. Chem. Lett.*, 2019, **29**, 2428–2436.



- 259 P. M. Scola, L.-Q. Sun, A. X. Wang, J. Chen, N. Sin, B. L. Venables, S.-Y. Sit, Y. Chen, A. Cocuzza and D. M. Bilder, *J. Med. Chem.*, 2014, **57**, 1730–1752.
- 260 J. A. McCauley, C. J. McIntyre, M. T. Rudd, K. T. Nguyen, J. J. Romano, J. W. Butcher, K. F. Gilbert, K. J. Bush, M. K. Holloway and J. Swestock, *J. Med. Chem.*, 2010, **53**, 2443–2463.
- 261 Å. Rosenquist, B. Samuelsson, P.-O. Johansson, M. D. Cummings, O. Lenz, P. Raboisson, K. Simmen, S. Vendeville, H. de Kock and M. Nilsson, *J. Med. Chem.*, 2014, **57**, 1673–1693.
- 262 K. F. McDaniel, Y.-Y. Ku, Y. Sun, H.-J. Chen, J. Shanley, T. Middleton, Y. S. Or and D. Kempf, in *HCV: The Journey from Discovery to a Cure*, ed. M. J. Sofia, Springer, Cham, 2019, vol. I, pp. 389–413.
- 263 D. D. Caspi, R. D. Cink, D. Clyne, M. Diwan, K. M. Engstrom, T. Grieme, J. Mei, R. W. Miller, C. Mitchell, J. G. Napolitano, N. Nere, M. M. Ravn, A. Sheikh, S. Wagaw and H. Zhang, *Tetrahedron*, 2019, **75**, 4271–4286.
- 264 P. L. Beaulieu, J. Gillard, M. D. Bailey, C. Boucher, J.-S. Duceppe, B. Simoneau, X.-J. Wang, L. Zhang, K. Grozinger, I. Houpis, V. Farina, H. Heimroth, T. Krueger and J. Schnaubelt, *J. Org. Chem.*, 2005, **70**, 5869–5879.
- 265 S. Zhu, Y. Shi, X. Zhang and G. Zheng, *Appl. Biochem. Biotechnol.*, 2018, **184**, 500–512.
- 266 D. A. Chaplin, M. E. Fox and S. H. B. Kroll, *Chem. Commun.*, 2014, **50**, 5858–5860.
- 267 C. Fliche, J. Braun and F. C. Le Goffic, *Synth. Commun.*, 1994, **24**, 2873–2876.
- 268 Z. J. Song, D. M. Tellers, M. Journet, J. T. Kuethe, D. Lieberman, G. Humphrey, F. Zhang, Z. Peng, M. S. Waters, D. Zewge, A. Nolting, D. Zhao, R. A. Reamer, P. G. Dormer, K. M. Belyk, I. W. Davies, P. N. Devine and D. M. Tschaen, *J. Org. Chem.*, 2011, **76**, 7804–7815.
- 269 R. D. Cink, K. A. Lukin, R. D. Bishop, G. Zhao, M. J. Pelc, T. B. Towne, B. D. Gates, M. M. Ravn, D. R. Hill, C. Ding, S. C. Cullen, J. Mei, M. R. Leanna, J. Henle, J. G. Napolitano, N. K. Nere, S. Chen, A. Sheikh and J. M. Kallemeyn, *Org. Process Res. Dev.*, 2020, **24**, 183–200.
- 270 R. D. Cink, K. A. Lukin, M. R. Leanna, M. J. Pelc, T. B. Towne, D. S. Welch, K. M. Engstrom, M. M. Ravn, R. D. Bishop and G. Zhao, *US Pat.*, US9809576B1, 2017.
- 271 M. J. Abrahamson, A. B. Kielbus, W. T. Riordan, D. R. Hill, S. R. Chemburkar, R. E. Reddy, T. B. Towne, J. Mei and G. J. Brown, *US Pat.*, US010316338B1, 2019.
- 272 X.-J. Wang, L. Zhang, L. L. Smith-Keenan, I. N. Houpis and V. Farina, *Org. Process Res. Dev.*, 2007, **11**, 60–63.
- 273 N. Nishino, G. M. Shivashimpi, P. B. Soni, M. P. I. Bhuiyan, T. Kato, S. Maeda, T. G. Nishino and M. Yoshida, *Bioorg. Med. Chem.*, 2008, **16**, 437–445.
- 274 M. Rusnak-Müller, O. May, P. J. Hermsen, H. M. M. G. Straatman, W. Skranc, W. H. J. Boesten, D. Heemskerk, B. De Lange and G. Sarakinos, *World Pat.*, WO2008067981A2, 2010.
- 275 M. Nojiri, T. Nishiyama and N. Taoka, *US Pat.*, US009464306B2, 2016.
- 276 J. Park, J. C. Moore and F. Xu, *Org. Process Res. Dev.*, 2016, **20**, 76–80.
- 277 D. P. M. Depré, D. J. Ormerod, A. Horvath, T. S. Moody, M. Brossat, O. Riant, N. Vriamont, S. F. E. Lemaire and S. N. J. Hermant, *US Pat.*, US20180093943A1, 2018.
- 278 D. Banner, M. Ceccarelli Simona, U. W. E. Grether, W. Haap, H. Hilpert, H. Kuehne, H. Mauser, J.-M. Plancher and A. Sanchez Ruben, *World Pat.*, WO2010142650A1, 2010.
- 279 S. U. N. Or Yat, J. U. N. Ma, G. Wang, J. Long and B. I. N. Wang, *World Pat.*, WO2012040167A1, 2012.
- 280 J. Kuethe, Y.-L. Zhong, N. Yasuda, G. Beutner, K. Linn, M. Kim, B. Marcune, S. D. Dreher, G. Humphrey and T. Pei, *Org. Lett.*, 2013, **15**, 4174–4177.
- 281 E. M. Bassan, C. A. Baxter, G. L. Beutner, K. M. Emerson, F. J. Fleitz, S. Johnson, S. Keen, M. M. Kim, J. T. Kuethe, W. R. Leonard, P. R. Mullens, D. J. Muzzio, C. Roberge and N. Yasuda, *Org. Process Res. Dev.*, 2012, **16**, 87–95.
- 282 T. Kim, A. M. Kassim, A. Botejue, C. Zhang, J. Forte, D. Rozzell, M. A. Huffman, P. N. Devine and J. A. McIntosh, *ChemBioChem*, 2019, **20**, 1129–1132.
- 283 C. Hicks and R. M. Gulick, *Clin. Infect. Dis.*, 2009, **48**, 931–939.
- 284 M. Breuer, K. Ditrich, T. Habicher, B. Hauer, M. Keßeler, R. Stürmer and T. Zelinski, *Angew. Chem., Int. Ed.*, 2004, **43**, 788–824.
- 285 C. S. Fuchs, R. C. Simon, W. Riethorst, F. Zepeck and W. Kroutil, *Bioorg. Med. Chem.*, 2014, **22**, 5558–5562.
- 286 J.-D. Zhang, J.-W. Zhao, L.-L. Gao, H.-H. Chang, W.-L. Wei and J.-H. Xu, *J. Biotechnol.*, 2019, **290**, 24–32.
- 287 J.-D. Zhang, X.-X. Yang, Q. Jia, J.-W. Zhao, L.-L. Gao, W.-C. Gao, H.-H. Chang, W.-L. Wei and J.-H. Xu, *Catal. Sci. Technol.*, 2019, **9**, 70–74.
- 288 F.-F. Chen, G.-W. Zheng, L. Liu, H. Li, Q. Chen, F.-L. Li, C.-X. Li and J.-H. Xu, *ACS Catal.*, 2018, **8**, 2622–2628.
- 289 F.-F. Chen, S. C. Cosgrove, W. R. Birmingham, J. Mangas-Sanchez, J. Citoler, M. P. Thompson, G.-W. Zheng, J.-H. Xu and N. J. Turner, *ACS Catal.*, 2019, **9**, 11813–11818.
- 290 P. Flores-Sánchez, J. Escalante and E. Castillo, *Tetrahedron: Asymmetry*, 2005, **16**, 629–634.
- 291 T. Heck, D. Seebach, S. Osswald, M. K. J. ter Wiel, H.-P. E. Kohler and B. Geueke, *ChemBioChem*, 2009, **10**, 1558–1561.
- 292 H. Rangel, M. Carrillo-Morales, J. M. Galindo, E. Castillo, A. Obregón-Zúñiga, E. Juaristi and J. Escalante, *Tetrahedron: Asymmetry*, 2015, **26**, 325–332.
- 293 H. Mäenpää, L. T. Kanerva and A. Liljebblad, *ChemCatChem*, 2016, **8**, 1226–1232.
- 294 D. Koszelewski, I. Lavandera, D. Clay, D. Rozzell and W. Kroutil, *Adv. Synth. Catal.*, 2008, **350**, 2761–2766.
- 295 F. G. Mutti, C. S. Fuchs, D. Pressnitz, J. H. Sattler and W. Kroutil, *Adv. Synth. Catal.*, 2011, **353**, 3227–3233.
- 296 C. K. Savile, J. M. Janey, E. C. Mundorff, J. C. Moore, S. Tam, W. R. Jarvis, J. C. Colbeck, A. Krebber, F. J. Fleitz, J. Brands, P. N. Devine, G. W. Huisman and G. J. Hughes, *Science*, 2010, **329**, 305–309.
- 297 X.-L. Tang, N.-N. Zhang, G.-Y. Ye and Y.-G. Zheng, *J. Biotechnol.*, 2019, **295**, 49–54.
- 298 X. Gao, X. Zhang, N. Zhu, Y. Mou, H. Zhang, X. Liu and P. Wei, *Appl. Microbiol. Biotechnol.*, 2020, **104**, 3959–3969.



- 299 R. Li, H. J. Wijma, L. Song, Y. Cui, M. Otzen, Y. E. Tian, J. Du, T. Li, D. Niu, Y. Chen, J. Feng, J. Han, H. Chen, Y. Tao, D. B. Janssen and B. Wu, *Nat. Chem. Biol.*, 2018, **14**, 664–670.
- 300 Y. Asano, I. Kira and K. Yokozeki, *Biomol. Eng.*, 2005, **22**, 95–101.
- 301 A. Vogel, R. Schmiedel, U. Hofmann, K. Gruber and K. Zangger, *ChemCatChem*, 2014, **6**, 965–968.
- 302 M. J. Mulvihill, J. L. Gage and M. J. Miller, *J. Org. Chem.*, 1998, **63**, 3357–3363.
- 303 J. C. Barrow, K. L. Glass, H. G. Selnick, R. M. Freidinger, R. S. L. Chang, S. S. O'Malley and C. Woyden, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 1917–1920.
- 304 J. A. Englund, R. E. Champlin, P. R. Wyde, H. Kantarjian, R. L. Atmar, J. Tarrand, H. Yousuf, H. Regnery, A. I. Klimov and N. J. Cox, *Clin. Infect. Dis.*, 1998, **26**, 1418–1424.
- 305 R. J. Jackson, K. L. Cooper, P. Tappenden, A. Rees, E. L. Simpson, R. C. Read and K. G. Nicholson, *J. Infect.*, 2011, **62**, 14–25.
- 306 M. Von Itzstein, *Nat. Rev. Drug Discovery*, 2007, **6**, 967–974.
- 307 M. R. Richards, M. G. Brant, M. J. Boulanger, C. W. Cairo and J. E. Wulff, *MedChemComm*, 2014, **5**, 1483–1488.
- 308 J. C. Rohloff, K. M. Kent, M. J. Postich, M. W. Becker, H. H. Chapman, D. E. Kelly, W. Lew, M. S. Louie, L. R. McGee, E. J. Prisbe, L. M. Schultze, R. H. Yu and L. Zhang, *J. Org. Chem.*, 1998, **63**, 4545–4550.
- 309 S. Abrecht, P. Harrington, H. Iding, M. Karpf, R. Trussardi, B. Wirz and U. Zutter, *Chimia*, 2004, **58**, 621–629.
- 310 M. Krämer, J. Bongaerts, R. Bovenberg, S. Kremer, U. Müller, S. Orf, M. Wubbolts and L. Raeven, *Metab. Eng.*, 2003, **5**, 277–283.
- 311 S. Ghosh, Y. Chisti and U. C. Banerjee, *Biotechnol. Adv.*, 2012, **30**, 1425–1431.
- 312 K. M. Draths, D. R. Knop and J. W. Frost, *J. Am. Chem. Soc.*, 1999, **121**, 1603–1604.
- 313 D. R. Knop, K. M. Draths, S. S. Chandran, J. L. Barker, R. von Daeniken, W. Weber and J. W. Frost, *J. Am. Chem. Soc.*, 2001, **123**, 10173–10182.
- 314 S. S. Chandran, J. Yi, K. M. Draths, R. V. Daeniken, W. Weber and J. W. Frost, *Biotechnol. Prog.*, 2003, **19**, 808–814.
- 315 O. Adachi, Y. Ano, H. Toyama and K. Matsushita, *Biosci., Biotechnol., Biochem.*, 2006, **70**, 2579–2582.
- 316 J. O. Ahn, H.-W. Lee, R. Saha, M. S. Park, J.-K. Jung and D.-Y. Lee, *J. Microbiol. Biotechnol.*, 2008, **18**, 1773–1784.
- 317 A. Escalante, R. Calderón, A. Valdivia, R. de Anda, G. Hernández, O. T. Ramírez, G. Gosset and F. Bolívar, *Microb. Cell Fact.*, 2010, **9**, 21.
- 318 A. Rodriguez, J. A. Martínez, J. L. Báez-Viveros, N. Flores, G. Hernández-Chávez, O. T. Ramírez, G. Gosset and F. Bolivar, *Microb. Cell Fact.*, 2013, **12**, 86.
- 319 J. A. Martínez, F. Bolívar and A. Escalante, *Front. Bioeng. Biotechnol.*, 2015, **3**.
- 320 M. Karpf and R. Trussardi, *US Pat.*, US20060047002A1, 2006.
- 321 J. Guo and J. W. Frost, *Org. Lett.*, 2004, **6**, 1585–1588.
- 322 D. T. Gibson, J. R. Koch, C. L. Schuld and R. E. Kallio, *Biochemistry*, 1968, **7**, 3795–3802.
- 323 D. R. Boyd, M. V. Hand, N. D. Sharma, J. Chima, H. Dalton and G. N. Sheldrake, *J. Chem. Soc., Chem. Commun.*, 1991, 1630–1632, DOI: 10.1039/C39910001630.
- 324 B. Sullivan, I. Carrera, M. Drouin and T. Hudlicky, *Angew. Chem., Int. Ed.*, 2009, **48**, 4229–4231.
- 325 L. Werner, A. Machara and T. Hudlicky, *Adv. Synth. Catal.*, 2010, **352**, 195–200.
- 326 M. Matveenko, A. C. Willis and M. G. Banwell, *Tetrahedron Lett.*, 2008, **49**, 7018–7020.
- 327 J.-J. Shie, J.-M. Fang and C.-H. Wong, *Angew. Chem., Int. Ed.*, 2008, **47**, 5788–5791.
- 328 U. Zutter, H. Iding, P. Spurr and B. Wirz, *J. Org. Chem.*, 2008, **73**, 4895–4902.
- 329 S. Silva and C. D. Maycock, *Org. Chem. Front.*, 2017, **4**, 236–240.
- 330 H. Li, S.-J. Shen, C.-L. Zhu and H. Xu, *J. Am. Chem. Soc.*, 2018, **140**, 10619–10626.
- 331 M. von Itzstein, W.-Y. Wu and B. Jin, *Carbohydr. Res.*, 1994, **259**, 301–305.
- 332 M. Chandler, M. J. Bamford, R. Conroy, B. Lamont, B. Patel, V. K. Patel, I. P. Steeples, R. Storer, N. G. Weir, M. Wright and C. Williamson, *J. Chem. Soc., Perkin Trans. 1*, 1995, 1173–1180, DOI: 10.1039/P19950001173.
- 333 B. R. Lundgren and C. N. Boddy, *Org. Biomol. Chem.*, 2007, **5**, 1903–1909.
- 334 J. Kang, P. Gu, Y. Wang, Y. Li, F. Yang, Q. Wang and Q. Qi, *Metab. Eng.*, 2012, **14**, 623–629.
- 335 M. E. Horsman, B. R. Lundgren and C. N. Boddy, *Chem. Eng. Commun.*, 2016, **203**, 1326–1335.
- 336 D. G. Comb and S. Roseman, *J. Am. Chem. Soc.*, 1958, **80**, 497–499.
- 337 C. Augé, S. David and C. Gautheron, *Tetrahedron Lett.*, 1984, **25**, 4663–4664.
- 338 M. J. Kim, W. J. Hennen, H. M. Sweers and C. H. Wong, *J. Am. Chem. Soc.*, 1988, **110**, 6481–6486.
- 339 C. Augé, C. Gautheron, S. David, A. Malleron, B. Cavayé and B. Bouxom, *Tetrahedron*, 1990, **46**, 201–214.
- 340 M. D. Bednarski, H. K. Chenault, E. S. Simon and G. M. Whitesides, *J. Am. Chem. Soc.*, 1987, **109**, 1283–1285.
- 341 U. Kragl, D. Gygas, O. Ghisalpa and C. Wandrey, *Angew. Chem., Int. Ed. Engl.*, 1991, **30**, 827–828.
- 342 S. Blayer, J. M. Woodley, M. D. Lilly and M. J. Dawson, *Biotechnol. Prog.*, 1996, **12**, 758–763.
- 343 M. Mahmoudian, D. Noble, C. S. Drake, R. F. Middleton, D. S. Montgomery, J. E. Piercey, D. Ramlakhan, M. Todd and M. J. Dawson, *Enzyme Microb. Technol.*, 1997, **20**, 393–400.
- 344 J.-O. Lee, J.-K. Yi, S.-G. Lee, S. Takahashi and B.-G. Kim, *Enzyme Microb. Technol.*, 2004, **35**, 121–125.
- 345 Y. Zhang, F. Tao, M. Du, C. Ma, J. Qiu, L. Gu, X. He and P. Xu, *Appl. Microbiol. Biotechnol.*, 2010, **86**, 481–489.
- 346 F. Tao, Y. Zhang, C. Ma and P. Xu, *Sci. Rep.*, 2011, **1**, 142.
- 347 I. Maru, J. Ohnishi, Y. Ohta and Y. Tsukada, *Carbohydr. Res.*, 1998, **306**, 575–578.
- 348 X. Chen, J. Zhou, L. Zhang, Z. Pu, L. Liu, W. Shen and Y. Fan, *Metab. Eng.*, 2018, **47**, 374–382.



- 349 P. Xu, J. H. Qiu, Y. N. Zhang, J. Chen, P. G. Wang, B. Yan, J. Song, R. M. Xi, Z. X. Deng and C. Q. Ma, *Adv. Synth. Catal.*, 2007, **349**, 1614–1618.
- 350 H. Ikematsu and N. Kawai, *Expert Rev. Anti-Infect. Ther.*, 2011, **9**, 851–857.
- 351 T. Honda, T. Masuda, S. Yoshida, M. Arai, Y. Kobayashi and M. Yamashita, *Bioorg. Med. Chem. Lett.*, 2002, **12**, 1921–1924.
- 352 Y. S. Babu, P. Chand, S. Bantia, P. Kotian, A. Dehghani, Y. El-Kattan, T.-H. Lin, T. L. Hutchison, A. J. Elliott, C. D. Parker, S. L. Ananth, L. L. Horn, G. W. Laver and J. A. Montgomery, *J. Med. Chem.*, 2000, **43**, 3482–3486.
- 353 J. O. Link, J. G. Taylor, L. Xu, M. Mitchell, H. Guo, H. Liu, D. Kato, T. Kirschberg, J. Sun, N. Squires, J. Parrish, T. Keller, Z.-Y. Yang, C. Yang, M. Matles, Y. Wang, K. Wang, G. Cheng, Y. Tian, E. Mogalian, E. Mondou, M. Cornpropst, J. Perry and M. C. Desai, *J. Med. Chem.*, 2014, **57**, 2033–2046.
- 354 R. W. Scott, J. P. Vitale, K. S. Matthews, M. G. Teresk, A. Formella and J. W. Evans, *World Pat.*, WO2013184702A1, 2015.
- 355 S. Dazhao, S. Qiu, H. Shuaijie, W. Canhui, Z. Mingchen, Y. Youzhe, X. Kailong and G. Peng, *PRC Pat.*, CN105461606B, 2018.
- 356 C. M. Perry, *Drugs*, 2010, **70**, 1189–1213.
- 357 S. J. Haycock-Lewandowski, A. Wilder and J. Åhman, *Org. Process Res. Dev.*, 2008, **12**, 1094–1103.
- 358 V. A. Soloshonok, N. A. Fokina, A. V. Rybakova, I. P. Shishkina, S. V. Galushko, A. E. Sorochinsky, V. P. Kukhar, M. V. Savchenko and V. K. Svedas, *Tetrahedron: Asymmetry*, 1995, **6**, 1601–1610.
- 359 S. J. Faulconbridge, K. E. Holt, L. Garcia Sevillano, C. J. Lock, P. D. Tiffin, N. Tremayne and S. Winter, *Tetrahedron Lett.*, 2000, **41**, 2679–2681.
- 360 S. Gedey, A. Liljebblad, L. Lázár, F. Fülöp and L. T. Kanerva, *Tetrahedron: Asymmetry*, 2001, **12**, 105–110.
- 361 H. Gröger, H. Trauthwein, S. Buchholz, K. Drauz, C. Sacherer, S. Godfrin and H. Werner, *Org. Biomol. Chem.*, 2004, **2**, 1977–1978.
- 362 M. O'Neill, B. Hauer, N. Schneider and N. J. Turner, *ACS Catal.*, 2011, **1**, 1014–1016.
- 363 H. Gröger, O. May, H. Hüsken, S. Georgeon, K. Drauz and K. Landfester, *Angew. Chem., Int. Ed.*, 2006, **45**, 1645–1648.
- 364 M. Shakeri, K. Engström, A. G. Sandström and J.-E. Bäckvall, *ChemCatChem*, 2010, **2**, 534–538.
- 365 K. Engström, M. Shakeri and J.-E. Bäckvall, *Eur. J. Org. Chem.*, 2011, 1827–1830.
- 366 E. Forró, T. Paál, G. Tasnádi and F. Fülöp, *Adv. Synth. Catal.*, 2006, **348**, 917–923.
- 367 B. Wu, W. Szymanski, S. De Wildeman, G. J. Poelarends, B. L. Feringa and D. B. Janssen, *Adv. Synth. Catal.*, 2010, **352**, 1409–1412.
- 368 S. Bartsch, G. G. Wybenga, M. Jansen, M. M. Heberling, B. Wu, B. W. Dijkstra and D. B. Janssen, *ChemCatChem*, 2013, **5**, 1797–1802.
- 369 X. Feng, J. Guo, R. Zhang, W. Liu, Y. Cao, M. Xian and H. Liu, *ACS Omega*, 2020, **5**, 7745–7750.
- 370 S. Mathew, S. P. Nadarajan, T. Chung, H. H. Park and H. Yun, *Enzyme Microb. Technol.*, 2016, **87–88**, 52–60.
- 371 G.-H. Kim, H. Jeon, T. P. Khobragade, M. D. Patil, S. Sung, S. Yoon, Y. Won, S. Sarak and H. Yun, *ChemCatChem*, 2019, **11**, 1437–1440.
- 372 S. Mathew, S. P. Nadarajan, U. Sundaramoorthy, H. Jeon, T. Chung and H. Yun, *Biotechnol. Lett.*, 2017, **39**, 535–543.
- 373 D. Zhang, X. Chen, R. Zhang, P. Yao, Q. Wu and D. Zhu, *ACS Catal.*, 2015, **5**, 2220–2224.
- 374 O. Buß, M. Voss, A. Delavault, P. Gorenflo, C. Syldatk, U. Bornscheuer and J. Rudat, *Molecules*, 2018, **23**, 1211.
- 375 N. W. Fadnavis, K. R. Radhika and A. Vedamayee Devi, *Tetrahedron: Asymmetry*, 2006, **17**, 240–244.
- 376 O. Torre, V. Gotor-Fernández and V. Gotor, *Tetrahedron: Asymmetry*, 2006, **17**, 860–866.
- 377 K. Beutner, A. Friedman-Kien, N. Artman, M. Conant, M. Illeman, R. Thisted and D. King, *Lancet*, 1989, **333**, 831–834.
- 378 D. B. Berkowitz, S. Choi and J.-H. Maeng, *J. Org. Chem.*, 2000, **65**, 847–860.
- 379 W. Lau and E. S. Sattely, *Science*, 2015, **349**, 1224–1228.
- 380 M. Lazzarotto, L. Hammerer, M. Hetmann, A. Borg, L. Schmermund, L. Steiner, P. Hartmann, F. Belaj, W. Kroutil, K. Gruber and M. Fuchs, *Angew. Chem., Int. Ed.*, 2019, **58**, 8226–8230.
- 381 J. Li, X. Zhang and H. Renata, *Angew. Chem., Int. Ed.*, 2019, **58**, 11657–11660.
- 382 D. Stadler and T. Bach, *Angew. Chem., Int. Ed.*, 2008, **47**, 7557–7559.
- 383 J. S. Orman and C. M. Perry, *Drugs*, 2008, **68**, 1435–1463.
- 384 K. S. Fors, J. R. Gage, R. F. Heier, R. C. Kelly, W. R. Perrault and N. Wicnienski, *J. Org. Chem.*, 1998, **63**, 7348–7356.
- 385 S. M. Vrouenraets, F. W. Wit, J. V. Tongeren and J. M. Lange, *Expert Opin. Pharmacother.*, 2007, **8**, 851–871.
- 386 A. S. Thompson, E. G. Corley, M. F. Huntington and E. J. J. Grabowski, *Tetrahedron Lett.*, 1995, **36**, 8937–8940.
- 387 T. Junhua and L. Yongtang, *PRC Pat.*, CN104805148B, 2019.
- 388 S. Diab, D. T. McQuade, B. F. Gupton and D. I. Gerogiorgis, *Org. Process Res. Dev.*, 2019, **23**, 320–333.
- 389 L.-Q. Jin, Y.-F. Li, Z.-Q. Liu, Y.-G. Zheng and Y.-C. Shen, *New Biotechnol.*, 2011, **28**, 610–615.
- 390 L.-Q. Jin, Z.-Q. Liu, J.-M. Xu, R.-C. Zheng, Y.-G. Zheng and Y.-C. Shen, *Catal. Commun.*, 2013, **38**, 6–9.
- 391 D. T. Leung and S. L. Sacks, *Expert Opin. Pharmacother.*, 2004, **5**, 2567–2571.
- 392 T. Yu, Y. J. Zhou, L. Wenning, Q. Liu, A. Krivoruchko, V. Siewers, J. Nielsen and F. David, *Nat. Commun.*, 2017, **8**, 15587.
- 393 S. Shi, Y. Chen, V. Siewers and J. Nielsen, *mBio*, 2014, **5**, e01130–01114.
- 394 C. De Savi, D. L. Hughes and L. Kvaerno, *Org. Process Res. Dev.*, 2020, **24**, 940–976.
- 395 B. A. Ahidjo, M. W. C. Loe, Y. L. Ng, C. K. Mok and J. J. H. Chu, *ACS Infect. Dis.*, 2020, **6**, 1624–1634.
- 396 V. Farina and J. D. Brown, *Angew. Chem., Int. Ed.*, 2006, **45**, 7330–7334.



- 397 Y. S. Hong and E. J. Corey, *J. Am. Chem. Soc.*, 2006, **128**, 6310–6311.
- 398 H. Ishikawa, T. Suzuki, H. Orita, T. Uchimarui and Y. Hayashi, *Chem. – Eur. J.*, 2010, **16**, 12616–12626.
- 399 T. K. Warren, R. Jordan, M. K. Lo, A. S. Ray, R. L. Mackman, V. Soloveva, D. Siegel, M. Perron, R. Bannister, H. C. Hui, N. Larson, R. Strickley, J. Wells, K. S. Stuthman, S. A. Van Tongeren, N. L. Garza, G. Donnelly, A. C. Shurtleff, C. J. Retterer, D. Gharaibeh, R. Zamani, T. Kenny, B. P. Eaton, E. Grimes, L. S. Welch, L. Gomba, C. L. Wilhelmsen, D. K. Nichols, J. E. Nuss, E. R. Nagle, J. R. Kugelman, G. Palacios, E. Doerffler, S. Neville, E. Carra, M. O. Clarke, L. Zhang, W. Lew, B. Ross, Q. Wang, K. Chun, L. Wolfe, D. Babusis, Y. Park, K. M. Stray, I. Trancheva, J. Y. Feng, O. Barauskas, Y. Xu, P. Wong, M. R. Braun, M. Flint, L. K. McMullan, S.-S. Chen, R. Fearn, S. Swaminathan, D. L. Mayers, C. F. Spiropoulou, W. A. Lee, S. T. Nichol, T. Cihlar and S. Bavari, *Nature*, 2016, **531**, 381–385.
- 400 J. Wise, *BMJ*, 2020, **369**, m2610.
- 401 Food and Drug Administration, Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment, <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment>, accessed July 2020.
- 402 M. L. Agostini, E. L. Andres, A. C. Sims, R. L. Graham, T. P. Sheahan, X. Lu, E. C. Smith, J. B. Case, J. Y. Feng, R. Jordan, A. S. Ray, T. Cihlar, D. Siegel, R. L. Mackman, M. O. Clarke, R. S. Baric and M. R. Denison, *mBio*, 2018, **9**, e00221.
- 403 D. Siegel, H. C. Hui, E. Doerffler, M. O. Clarke, K. Chun, L. Zhang, S. Neville, E. Carra, W. Lew, B. Ross, Q. Wang, L. Wolfe, R. Jordan, V. Soloveva, J. Knox, J. Perry, M. Perron, K. M. Stray, O. Barauskas, J. Y. Feng, Y. Xu, G. Lee, A. L. Rheingold, A. S. Ray, R. Bannister, R. Strickley, S. Swaminathan, W. A. Lee, S. Bavari, T. Cihlar, M. K. Lo, T. K. Warren and R. L. Mackman, *J. Med. Chem.*, 2017, **60**, 1648–1661.
- 404 P. Sedmera, P. Halada, E. Kubátová, D. Haltrich, V. Píkrýlová and J. Volc, *J. Mol. Catal. B: Enzym.*, 2006, **41**, 32–42.
- 405 K. Napora, T. M. Wrodnigg, P. Kosmus, M. Thonhofer, K. Robins and M. Winkler, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 3393–3395.
- 406 S. Gao, A. Radadiya, W. Li, H. Liu, W. Zhu, V. de Crécy-Lagard, N. G. J. Richards and J. H. Naismith, *Chem. Commun.*, 2020, **56**, 7617–7620.
- 407 H. Griengl, H. Schwab and M. Fechter, *Trends Biotechnol.*, 2000, **18**, 252–256.
- 408 P. Gautret, J.-C. Lagier, P. Parola, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V. E. Vieira and H. T. Dupont, *Int. J. Antimicrob. Agents*, 2020, 105949.
- 409 J. M. Molina, C. Delaugerre, J. Le Goff, B. Mela-Lima, D. Ponscarne, L. Goldwirt and N. de Castro, *Med. Mal. Infect.*, 2020, **50**, 30085–30088.
- 410 I. D'Acquarica and I. Agranat, *Drug Discovery Today*, 2020, **25**, 1121–1123.
- 411 G. Lentini, M. M. Cavalluzzi and S. Habtemariam, *Molecules*, 2020, **25**, 1834.
- 412 M. Nechab, N. Azzi, N. Vanthuyne, M. Bertrand, S. Gastaldi and G. Gil, *J. Org. Chem.*, 2007, **72**, 6918–6923.
- 413 S. Escoubet, S. Gastaldi, N. Vanthuyne, G. Gil, D. Siri and M. P. Bertrand, *J. Org. Chem.*, 2006, **71**, 7288–7292.
- 414 F. Poulhès, N. Vanthuyne, M. P. Bertrand, S. Gastaldi and G. Gil, *J. Org. Chem.*, 2011, **76**, 7281–7286.
- 415 P. Gautret, J.-C. Lagier, P. Parola, L. Meddeb, J. Sevestre, M. Mailhe, B. Doudier, C. Aubry, S. Amrane and P. Seng, *Travel Med. Infect. Di.*, 2020, 101663.
- 416 R. R. Wilkening, R. W. Ratcliffe, G. A. Doss, K. F. Bartizal, A. C. Graham and C. M. Herbert, *Bioorg. Med. Chem. Lett.*, 1993, **3**, 1287–1292.
- 417 A. L. Demain and J. L. Adrio, in *Natural Compounds as Drugs*, ed. F. Petersen and R. Amstutz, Birkhäuser Basel, Basel, 1st edn, 2008, vol. I, pp. 251–289, DOI: 10.1007/978-3-7643-8117-2_7.
- 418 C. Olano, F. Lombó, C. Méndez and J. A. Salas, *Metab. Eng.*, 2008, **10**, 281–292.
- 419 E. Rodriguez, Z. Hu, S. Ou, Y. Volchegursky, C. R. Hutchinson and R. McDaniel, *J. Ind. Microbiol. Biotechnol.*, 2003, **30**, 480–488.
- 420 Y. Chen, W. Deng, J. Wu, J. Qian, J. Chu, Y. Zhuang, S. Zhang and W. Liu, *Appl. Environ. Microbiol.*, 2008, **74**, 1820–1828.
- 421 R. Pieper, G. Luo, D. E. Cane and C. Khosla, *Nature*, 1995, **378**, 263–266.
- 422 A. R. Reeves, I. A. Brikun, W. H. Cernota, B. I. Leach, M. C. Gonzalez and J. Mark Weber, *Metab. Eng.*, 2007, **9**, 293–303.
- 423 J. Lau, C. Tran, P. Licari and J. Galazzo, *J. Biotechnol.*, 2004, **110**, 95–103.
- 424 X. Gao, P. Wang and Y. Tang, *Appl. Microbiol. Biotechnol.*, 2010, **88**, 1233–1242.
- 425 H. Zhang, Y. Wang, J. Wu, K. Skalina and B. A. Pfeifer, *Chem. Biol.*, 2010, **17**, 1232–1240.
- 426 M. Jiang and B. A. Pfeifer, *Metab. Eng.*, 2013, **19**, 42–49.
- 427 P. Horby, W. S. Lim, J. Emberson, M. Mafham, J. Bell, L. Linsell, N. Staplin, C. Brightling, A. Ustianowski, E. Elmahi, B. Prudon, C. Green, T. Felton, D. Chadwick, K. Rege, C. Fegan, L. C. Chappell, S. N. Faust, T. Jaki, K. Jeffery, A. Montgomery, K. Rowan, E. Juszczak, J. K. Baillie, R. Haynes and M. J. Landray, *N. Engl. J. Med.*, 2020, DOI: 10.1056/NEJMoa2021436.
- 428 M. V. Donova and O. V. Egorova, *Appl. Microbiol. Biotechnol.*, 2012, **94**, 1423–1447.
- 429 S. B. Mahato and S. Garai, *Steroids*, 1997, **62**, 332–345.
- 430 J.-L. Barredo and I. Herráiz, *Microbial steroids: Methods and protocols*, Springer, Cham, 2017.
- 431 Yan, F. Y. Hua, P. Y. Liang, H. Xiong, L. M. Hua, L. Hui and Z. H. Ming, *PRC Pat.*, CN106520896A, 2016.
- 432 H. A. Gerber, *US Pat.*, US3086032A, 1963.
- 433 H. L. Holland, D. H. Nguyen and N. M. Pearson, *Steroids*, 1995, **60**, 646–649.
- 434 A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia,



- <https://ClinicalTrials.gov/show/NCT04261270>, accessed June, 2020.
- 435 Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection, <https://ClinicalTrials.gov/show/NCT04291729>, accessed June, 2020.
- 436 Y. Cao, J. Wei, L. Zou, T. Jiang, G. Wang, L. Chen, L. Huang, F. Meng, L. Huang, N. Wang, X. Zhou, H. Luo, Z. Mao, X. Chen, J. Xie, J. Liu, H. Cheng, J. Zhao, G. Huang, W. Wang and J. Zhou, *J. Allergy Clin. Immunol.*, 2020, **146**, 137–146.
- 437 J. Stebbing, A. Phelan, I. Griffin, C. Tucker, O. Oechsle, D. Smith and P. Richardson, *Lancet Infect. Dis.*, 2020, **20**, 400–402.
- 438 W. Yong, L. Ligang, X. Jie, Y. Shiqiong, L. Qian and K. Litao, *PRC Pat.*, CN104496904B, 2017.
- 439 J. M. Woodley, *Curr. Opin. Green Sustainable Chem.*, 2020, **21**, 22–26.
- 440 M. Legraverend, *Tetrahedron*, 2008, **64**, 8585–8603.
- 441 M. Radi, S. Schenone and M. Botta, *Org. Biomol. Chem.*, 2009, **7**, 2841–2847.
- 442 M. Mahfoudh, R. Abderrahim, E. Leclerc and J.-M. Campagne, *Eur. J. Org. Chem.*, 2017, 2856–2865.
- 443 J. L. Galman, I. Slabu, F. Parmeggiani and N. J. Turner, *Chem. Commun.*, 2018, **54**, 11316–11319.
- 444 A. Al-Shameri, N. Borlinghaus, L. Weinmann, P. N. Scheller, B. M. Nestl and L. Lauterbach, *Green Chem.*, 2019, **21**, 1396–1400.
- 445 B. R. K. Menon, J. Latham, M. S. Dunstan, E. Brandenburger, U. Klemstein, D. Leys, C. Karthikeyan, M. F. Greaney, S. A. Shepherd and J. Micklefield, *Org. Biomol. Chem.*, 2016, **14**, 9354–9361.
- 446 C. Schnepel and N. Sewald, *Chem. – Eur. J.*, 2017, **23**, 12064–12086.
- 447 R. Médici, J. I. Garaycochea, L. A. Dettorre, A. M. Iribarren and E. S. Lewkowicz, *Biotechnol. Lett.*, 2011, **33**, 1999–2003.
- 448 J. Fang, D. Hait, M. Head-Gordon and M. C. Y. Chang, *Angew. Chem., Int. Ed.*, 2019, **58**, 11841–11845.
- 449 J. H. Schrittwieser, S. Velikogne, M. Hall and W. Kroutil, *Chem. Rev.*, 2018, **118**, 270–348.
- 450 M. Winkler, *Curr. Opin. Chem. Biol.*, 2018, **43**, 23–29.
- 451 G. A. Aleku, S. P. France, H. Man, J. Mangas-Sanchez, S. L. Montgomery, M. Sharma, F. Leipold, S. Hussain, G. Grogan and N. J. Turner, *Nat. Chem.*, 2017, **9**, 961.
- 452 M. Schober, C. MacDermaid, A. A. Ollis, S. Chang, D. Khan, J. Hosford, J. Latham, L. A. F. Ihnken, M. J. B. Brown, D. Fuerst, M. J. Sanganee and G.-D. Roiban, *Nat. Catal.*, 2019, **2**, 909–915.
- 453 A. Bornadel, S. Bisagni, A. Pushpanath, S. L. Montgomery, N. J. Turner and B. Dominguez, *Org. Process Res. Dev.*, 2019, **23**, 1262–1268.
- 454 L. Xu, H. Liu, B. P. Murray, C. Callebaut, M. S. Lee, A. Hong, R. G. Strickley, L. K. Tsai, K. M. Stray, Y. Wang, G. R. Rhodes and M. C. Desai, *ACS Med. Chem. Lett.*, 2010, **1**, 209–213.
- 455 M. C. Desai, H. Liu and L. Xu, *US Pat.*, US9891239B2, 2018.
- 456 L. Xie, K. Chen, H. Cui, N. Wan, B. Cui, W. Han and Y. Chen, *ChemBioChem*, 2020, **21**, 1820–1825.
- 457 A. Li, C. G. Acevedo-Rocha, L. D'Amore, J. Chen, Y. Peng, M. Garcia-Borràs, C. Gao, J. Zhu, H. Rickerby, S. Osuna, J. Zhou and M. T. Reetz, *Angew. Chem., Int. Ed.*, 2020, **59**, 2–9.
- 458 Z.-J. Jia, S. Gao and F. H. Arnold, *J. Am. Chem. Soc.*, 2020, **142**, 10279–10283.
- 459 S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, D. Johnson, R. Lalonde, A. Japour, S. Brun and E. Sun, *N. Engl. J. Med.*, 2002, **346**, 2039–2046.
- 460 B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, L. Ruan, B. Song, Y. Cai, M. Wei, X. Li, J. Xia, N. Chen, J. Xiang, T. Yu, T. Bai, X. Xie, L. Zhang, C. Li, Y. Yuan, H. Chen, H. Li, H. Huang, S. Tu, F. Gong, Y. Liu, Y. Wei, C. Dong, F. Zhou, X. Gu, J. Xu, Z. Liu, Y. Zhang, H. Li, L. Shang, K. Wang, K. Li, X. Zhou, X. Dong, Z. Qu, S. Lu, X. Hu, S. Ruan, S. Luo, J. Wu, L. Peng, F. Cheng, L. Pan, J. Zou, C. Jia, J. Wang, X. Liu, S. Wang, X. Wu, Q. Ge, J. He, H. Zhan, F. Qiu, L. Guo, C. Huang, T. Jaki, F. G. Hayden, P. W. Horby, D. Zhang and C. Wang, *N. Engl. J. Med.*, 2020, **382**, 1787–1799.
- 461 D. Menche, F. Arikan, J. Li and S. Rudolph, *Org. Lett.*, 2007, **9**, 267–270.
- 462 H. Land, F. Ruggieri, A. Szekrenyi, W.-D. Fessner and P. Berglund, *Adv. Synth. Catal.*, 2020, **362**, 812–821.
- 463 E. Massolo, M. Pirola and M. Benaglia, *Eur. J. Org. Chem.*, 2020, 4641–4651.
- 464 M. T. Sabatini, L. T. Boulton, H. F. Sneddon and T. D. Sheppard, *Nat. Catal.*, 2019, **2**, 10–17.
- 465 M. J. García, F. Rebolledo and V. Gotor, *Tetrahedron*, 1994, **50**, 6935–6940.
- 466 R. N. Lima, C. S. dos Anjos, E. V. M. Orozco and A. L. M. Porto, *Mol. Catal.*, 2019, **466**, 75–105.
- 467 M. Koreishi, K. Tani, Y. Ise, H. Imanaka, K. Imamura and K. Nakanishi, *Biosci., Biotechnol., Biochem.*, 2007, **71**, 1582–1586.
- 468 M. R. Petchey, B. Rowlinson, R. C. Lloyd, I. J. S. Fairlamb and G. Grogan, *ACS Catal.*, 2020, **10**, 4659–4663.
- 469 M. R. Petchey and G. Grogan, *Adv. Synth. Catal.*, 2019, **361**, 3895–3914.
- 470 B. M. Dorr and D. E. Fuerst, *Curr. Opin. Chem. Biol.*, 2018, **43**, 127–133.
- 471 T. Ikemoto and Y. Watanabe, *US Pat.*, US7951977B2, 2011.
- 472 G. L. Moore, R. W. Stringham, D. S. Teager and T.-Y. Yue, *Org. Process Res. Dev.*, 2017, **21**, 98–106.
- 473 Y. Hayashi, T. Aikawa, Y. Shimasaki, H. Okamoto, Y. Tomioka, T. Miki, M. Takeda and T. Ikemoto, *Org. Process Res. Dev.*, 2016, **20**, 1615–1620.
- 474 A. K. Ghosh, J. Li and R. S. Perali, *Synthesis*, 2006, 3015–3018.
- 475 B. F. Fisher, H. M. Snodgrass, K. A. Jones, M. C. Andorfer and J. C. Lewis, *ACS Cent. Sci.*, 2019, **5**, 1844–1856.
- 476 C. K. Prier and B. Kosjek, *Curr. Opin. Chem. Biol.*, 2019, **49**, 105–112.
- 477 M.-C. Sigmund and G. J. Poelarends, *Nat. Catal.*, 2020, **3**, 690–702.
- 478 S. Chakrabarty, Y. Wang, J. C. Perkins and A. R. H. Narayan, *Chem. Soc. Rev.*, 2020, **49**, 8137–8155.
- 479 N. D. Fessner, *ChemCatChem*, 2019, **11**, 2226–2242.



- 480 I. Kaluzna, T. Schmitges, H. Straatman, D. van Tegelen, M. Müller, M. Schürmann and D. Mink, *Org. Process Res. Dev.*, 2016, **20**, 814–819.
- 481 S. C. Hammer, G. Kubik, E. Watkins, S. Huang, H. Minges and F. H. Arnold, *Science*, 2017, **358**, 215–218.
- 482 T. Hayashi, M. Ligibel, E. Sager, M. Voss, J. Hunziker, K. Schroer, R. Snajdrova and R. Buller, *Angew. Chem., Int. Ed.*, 2019, **58**, 18535–18539.
- 483 F. Rigoldi, S. Donini, A. Redaelli, E. Parisini and A. Gautieri, *APL Bioeng.*, 2018, **2**, 011501.
- 484 B. V. Adalbjörnsson, H. S. Toogood, A. Fryszkowska, C. R. Pudney, T. A. Jowitt, D. Leys and N. S. Scrutton, *ChemBioChem*, 2010, **11**, 197–207.
- 485 A. O. Magnusson, A. Szekrenyi, H.-J. Joosten, J. Finnigan, S. Charnock and W.-D. Fessner, *FEBS J.*, 2019, **286**, 184–204.
- 486 F. S. Aalbers, M. J. Fürst, S. Roviada, M. Trajkovic, J. R. G. Castellanos, S. Bartsch, A. Vogel, A. Mattevi and M. W. Fraaije, *eLife*, 2020, **9**, e54639.
- 487 M. D. Truppo, *ACS Med. Chem. Lett.*, 2017, **8**, 476–480.
- 488 D. A. Holland-Moritz, M. K. Wismer, B. F. Mann, I. Farasat, P. Devine, E. D. Guetschow, I. Mangion, C. J. Welch, J. C. Moore, S. Sun and R. T. Kennedy, *Angew. Chem., Int. Ed.*, 2020, **59**, 4470–4477.
- 489 A. Debon, M. Pott, R. Obexer, A. P. Green, L. Friedrich, A. D. Griffiths and D. Hilvert, *Nat. Catal.*, 2019, **2**, 740–747.
- 490 S. Mazurenko, Z. Prokop and J. Damborsky, *ACS Catal.*, 2020, **10**, 1210–1223.
- 491 Y. V. Sheludko and W.-D. Fessner, *Curr. Opin. Struct. Biol.*, 2020, **63**, 123–133.
- 492 W.-D. Fessner, *New Biotechnol.*, 2015, **32**, 658–664.

